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ABSTRACT 
This thesis concerns the design and synthesis of compounds relevant to a new 
strategy for the synthesis of anti-cancer prodrugs. The focus of this strategy is 
Diels-Alder chemistry leading to oxygen or sulfur-bridged polycyclic adducts. 
Bridge cleavage of such adducts can result in the formation of polycyclic, 
aromatic compounds, a structure characteristic of anti-cancer drugs which act via 
intercalation. 
Part A describes the design of a model system for the synthesis of Diels-Alder 
adducts as prodrugs. A range of isobenzofurans, along with a range of 
fumaramide and N-aryl maleimide derivatives, were synthesised, and these were 
reacted together in Diels-Alder fashion. The resulting adducts were bridge 
cleaved. 
Part B describes the introduction of functional groups into Diels-Alder adducts. 
The functional groups investigated included alkylating and hydrogen-bonding 
substituents, introduced via N-aryl maleimide based dienophiles. A range of 
isobenzothiophenes was also synthesised, and these were used to generate sulfur-
bridged Diels-Alder adducts, with the resulting increase in stability proving 
advantageous in some instances. A variety of functionalised adducts and their 
bridge cleaved derivatives were prepared. The biological properties of some 
showed promise as leads for the development of anti-cancer compounds. 
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Chapter 1 Approaches to Cancer Chemotherapy 
Chapter 1 
PPROACHESTO ANCER 
HEMOT RAPY 
1 .. 1 Introduction 
This thesis concerns the design and synthesis of potential anti-cancer 
compounds, which may offer advantages over existing compounds. The 
introductory chapter describes cancer and the limitations of conventional forms of 
anti-cancer treatment. Novel approaches to potential anti-cancer prodrugs which 
selectively target tumour cells are discussed. DNA intercalation and its relevance 
to anti-cancer treatment is overviewed. This is followed by a description of the 
new class of potential prodrugs which are investigated in this thesis, along with 
the general strategy employed for their synthesis using Diels-Alder chemistry. 
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1.2 Cancer 
Cancer accounts for about 1 in 5 deaths in Western countries. 1 The term 
cancer covers a wide range of diseases which are characterised by uncontrolled 
cell replication. Cell growth is regulated carefully in human and other 
mammalian cells, but mutations in DNA can result in a breakdown in this 
regulation. The body of cells formed by uncontrolled replication is termed a 
tumour. A tumour can be either benign or malignant. In its benign form, a 
tumour is localised and relatively non-dangerous to the host. A malignant 
tumour, however, invades surrounding healthy tissue and cells which break off 
from it can be carried around the body to set up secondary sites of cancerous 
growth. This latter condition, termed metastasis, is often fatal to the host. 
Cancer can currently be treated in several ways, notably surgery, radiotherapy, 
and chemotherapy. Surgery involves the physical removal of the tumour before it 
has begun to metastasise. Radiotherapy involves the bombardment of the tumour 
with ionising radiation leading to cancer cell death. Chemotherapy involves using 
chemicals to induce cancer cell death. These treatments are often combined. 
1.3 Cancer Chemotherapy 
Drugs are currently used at some stage during the treatment of most cancer 
patients.2 Chemotherapy is the treatment of choice for most metastatic cancers. 
Cure rates of 50% or greater have been achieved using combination chemotherapy 
for such cancers as diffuse histiocytic lymphoma, Hodgkin's disease, acute 
lymphocytic leukemia, Wilm's tumour, and childhood sarcomas. Testicular 
carcinoma has a cure rate of over 75% and, by using a combination of the drugs 
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methotrexate and actinomycin D, gestational choriocarcinoma has a cure rate 
greater than 90%. 
The objective of cancer chemotherapy is to reduce the tumour cell population 
to zero. In practice however, this is extremely difficult to achieve. Frequently 
chemotherapy results in prolonging patients' lives rather than effecting permanent 
cures. This can be achieved by successfully inducing remission of the tumour, 
followed by regimens of maintenance therapy, which employs the prolonged use 
of moderately toxic drugs to curb cancer regrowth. With respect to solid tumours 
however, such maintenance therapy is rarely effective and hence seldom used. 
Cancer chemotherapy is used effectively however, to prevent or delay tumour 
recurrence in patients who have .had primary tumours surgically removed. Such 
patients are at a high risk of recurrence and chemotherapy regimens have 
successfully extended the survival of patients with cancers such as breast cancer, 
colon cancer, and osteosarcoma. 
1.4 Limitations of Conventional Cancer 
Chemotherapy 
There can be no question though that, in spite of their benefits, conventional 
cancer treatments have severe limitations. For example bowel cancer is the third 
most common cancer worldwide, and yet there is no effective chemotherapy 
available for this disease.3 Although it can be cured by surgery in its early stages, 
bowel cancer often goes undetected until intervention is no longer any use, and 
about half of all patients die. 
Additionally, both cancer radiotherapy and chemotherapy are limited by severe 
side-effects. The major drawback with conventional cancer chemotherapy is that 
it is rarely cancer specific but is rather specific to rapidly dividing cells. Such 
13 
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rapidly dividing cells are not limited to cancer but are also characteristic of 
normal human cells in the gut, skin epithelium, bone marrow, hair, and mouth 
mucosa. This is the basis of many common side-effects of cancer chemotherapy, 
such as vomiting, nausea, hair loss, skin irritation, and mucous membrane 
irritation. A long term side-effect may be bone marrow depression. 
Other limitations of conventional cancer chemotherapy are drug resistance and 
the presence in solid tumours of a significant portion of slowly dividing cells 
which are unaffected by conventional drugs. Drug resistance occurs when a 
certain portion of the tumour is resistant to a particular drug. This resistant 
section of the tumour will not be killed by the drug and may result in a drug-
resistant secondary tumour. To a certain extent the limitation of drug resistance 
can be overcome by using combination chemotherapy, where drugs with different 
mechanisms of action are combined. The presence of slowly dividing cells in 
solid tumours however presents a different challenge. 
Many human cancers are slow growing solid tumours. 4 This presents the 
challenge of finding and exploiting biochemical differences other than a high rate 
of cell division. One example of such a difference is hypoxia. Solid tumours are 
characterised by the presence of hypoxic, or oxygen-deprived, cells. 5,6 As a solid 
tumour grows, the cells face a challenge in inducing the development of 
additional blood supply. As a consequence a significant proportion of the tumour 
cells are an appreciable distance from any blood vessels. At more than 150!J,m 
from a blood vessel the concentration of oxygen falls to the point where cells 
further away than this suffer oxygen deprivation. In fact such oxygen-starved, or 
hypoxic, cells often surround a region where cells have actually died from lack of 
oxygen. Hypoxia in tumours can also be caused by the spasmodic blocking of 
blood vessels due to the high tluid pressure present in tumours. 
14 
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Unlike rapidly replicating cancer cells, often targeted by anti-cancer drugs, 
hypoxic cells are starved of oxygen and nutrients and hence very slow to replicate. 
This means they are not susceptible to most conventional anti-cancer drugs. It 
also gives them increased resistance to cancer radiotherapy, due to the need for 
molecular oxygen in the inactivation process. The added danger of hypoxic 
cancer cells however, is that once the rapidly replicating cancer cells around them 
have been killed off by anti-proliferative cancer drugs, the blood supply IS 
eventually restored and the tumour is able to commence growing again. 
1.5 Prodrug Approaches to the Treatment of 
Solid Tumours 
The characteristics of solid tumours, which present an obstacle to conventional 
cancer chemotherapy, can potentially be used to advantage in cancer treatment, as 
they differentiate the tumour from normal human cells. One approach to 
selectively target solid tumours is the use of prodrugs. 
A prodrug is the precursor to a drug. It has lower toxicity than the drug itself, 
and is designed to be activated to the drug at the site of the disease, and only at 
that site, in this case the solid tumour. This means that it is a localised form of 
cancer treatment, and might have little effect on other parts of the body. As a 
prodrug is always moving down a concentration gradient, it has the additional 
feature of increased efficiency of delivery to the target site. 
In order to be suitable as an anti-cancer treatment, a tumour cell selective 
prodrug must incorporate several key features. It must convert rapidly and 
selectively to the active drug in the conditions of a solid tumour. It must be of 
low or zero toxicity. It must be stable to normal metabolism. It must be able to 
effectively reach the target cells. 
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The activated drug itself should also incorporate several key features. It must 
be of high toxicity. It should have a relatively long half-life. It should be able to 
diffuse to neighbouring tumour cells. 
Prodrugs can be activated by many methods. For example, some cells of a 
solid tumour can be targeted by exploiting their hypoxia. Since such cells are 
oxygen deficient, reduction can be used to activate the prodrug. Reductions 
which are reversible when oxygen is present in a cell may become irreversible 
under oxygen-deficient conditions. So the activating process best suited for this 
chemistry involves a normally reversible redox component, to avoid activation in 
normal cells. Nitracrine 1.1, shown in Fig. 1.5.1, is one such hypoxia-selective 
prodrug. 7 
1.1 
Fig. 1.5.1 Nitracrine 
Nitracrine 1.1 is thought to be activated in oxygen-deficient conditions by 
reduction of the nitro group to an amino group. In this form the compound is 
potentially a potent DNA intercalating agent and also able to form cross links by 
nucleophilic attack of the amine group. When tested clinically, nitracrine was 
found to be extremely hypoxia-selective against cultured tumour cells. However 
in vivo its activity was not marked. This was thought to be due to its low 
diffusion rate, caused by high DNA binding affinity, and its metabolism in the 
body. 
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There are a range of possible ways of activating a prodrug selectively at a 
tumour site. This thesis documents synthetic chemistry pertinent to developing a 
class of prodrugs which could be activated to DNA intercalating agents. These 
methodologies can be developed to incorporate a variety of triggers activated by a 
range of biochemical processes. An overview of DNA intercalation and its 
relevance to anti-cancer therapy is therefore presented now. 
1.6 Intercalators as Anti-cancer Agents 
Intercalation involves the insertion of a chromophoric, or planar, part of a 
molecule between two stacked DNA base pairs. S While the primary and 
secondary structure of the DNA remain completely intact in this process, the 
tertiary structure, or helix, is altered. The DNA helix is partially lengthened and 
as a consequence is also slightly unwound in relation to the original structure. 
Intercalation thus results in the average separation between two stacked base pairs 
essentially doubling, increasing from an original 3.4A to approximately 7-SA. 
As would be expected, this alteration in DNA topology has a profound effect 
on its biochemistry. Enzymatic blockade and reading errors in the replication 
process disturb the matrix function considerably. There are a variety of 
mechanisms by which intercalators can act. For example intercalation can result 
in DNA damage via interference with the action of the enzyme topoisomerase II, 
which promotes DNA strand breakage and resealing. An alteration in the 3-
dimensional structure of DNA can arrest the cycle of topoisomerase II action at 
the point of DNA cleavage. By this means, or by a variety of other processes, 
intercalation of the planar part of a molecule into DNA can result in DNA 
damage. 
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There are several forces which determine an intercalator's DNA binding 
affinity. These include favourable Van der Waal's Forces between the 
intercalating agent and the base pairs of DNA, along with favourable electrostatic 
and hydrogen bonding interactions between the substituents on the intercalating 
agent and the DNA. 
In some instances it has been shown that there is a relationship between an 
intercalator's binding affinity to DNA and its in vitro as well as in vivo anti-cancer 
activity.9 For example, some potent intercalators appear to form stable ternary 
complexes with DNA and topoisomerase II, which interferes substantially with 
DNA resealing. In these cases the resulting breaks in the DNA have been directly 
correlated with cytotoxity.1 0 However, due to the variety of mechanisms by 
which intercalators can act, anti-cancer activity is often only tenuously related to 
DNA binding strength. 
The intercalating portion of an intercalator is generally made up of at least three 
coplanar, fused rings, which are often aromatic. For optimal intercalation, the 
planar portion of the molecule, also known as its chromophore, must possess a 
minimum surface area of 28A2. In practice this means 3 to 4 fused, coplanar 
rings. A prerequisite for intercalating agents with significant cytotoxic properties 
appears to be not just the presence of a coplanar system but also the presence of 
one or more substituents capable of interacting with DNA and affecting its 
biochemistry . 
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Fig. 1.6.1 Actinomycin D 
One example of a non-topoisomerase II acting intercalator, which has potent 
anti-cancer properties, is actinomycin D 1.2, which is shown in Fig. 1.6.1. 11 ,12 
Actinomycin D 1.2 is known to be a strong DNA-binding drug. It is a powerful 
inhibitor of RNA and protein synthesis. 13 Muller and Crothers proposed a model 
for DNA intercalation of actinomycin D in which its chromophore lies 
intercalated between base pairs with the peptide lactone rings lying in the minor 
groove.14 When cyclic peptides such as these lie in the grooves of DNA they can 
affect the activity of polymerase enzymes. This model was based on 
spectroscopic and hydrodynamic data and has been backed up by x-ray 
crystallographic studies. Actinomycin D has been shown to accumulate in tissue 
by means of passive diffusion. 15 As a consequence the efficiency of actinomycin 
D, as an anti-cancer drug, is dependent on the ability of the cell to accumulate the 
drug, and its activity varies for different tumours.1 6, 17,18 Actinomycin D has 
proved itself a powerful cytotoxic drug for the treatment of gestational 
choriocarcinoma, Wilm's tumour, neuroblastoma, childhood rhabdomyosarcoma, 
and Ewing sarcoma. 
The variety of mechanisms by which intercalators can act make them a 
promising target for anti-cancer prodrugs. They can also be linked into a variety 
of activation strategies. 
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1.7 General Strategy for the Synthesis of Novel 
Anti -cancer Prodrugs 
The main feature of a DNA intercalating agent is its chromophore, the planar 
section usually being composed of 3 or 4 fused coplanar rings. The planarity can 
be destroyed however by the incorporation of a bridge across one of the rings. 
We envisioned such a bridged, non-planar compound as an ideal prodrug target, 
with low cytotoxicity and low DNA binding affinity. Activation of such a 
prodrug 1.3 to a corresponding planar form 1.4, as illustrated conceptually in Fig. 
1. 7.1, could result in an intercalator with both high toxicity and high DNA 
binding affinity. 
1.3 1.4 
Fig. 1.7.1 
From a retrosynthetic viewpoint, Diels-Alder cycloaddition chemistry provides 
a convenient route to the synthesis of bridged compounds such as 1.3. 
C(+~II_ 
U [ (J 1 
Fig. 1.7.2 
--0 
The Diels-Alder reaction, as illustrated in Fig. 1.7.2, was so named after its two 
discoverers Otto Diels and Kurt Alder, and earned them the Nobel prize in 
chemistry in 1950. It is a 4+2 cycloaddition reaction between a diene and a 
20 
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dienophile which generally occurs in a pericyclic fashion, proceeding through a 
cyclic transition state. 19 
The use of the Diels-Alder cycloaddition reaction to form the kind of bridged 
prodrug we envisioned is illustrated in Fig. 1.7.3. 
1 
HlIR3 
~ 1.6 
H R4 
1.7 1.8 
Fig. 1.7.3 
Here an isobenzofuran (X=O), or an isobenzothiophene (X=S) as the diene 1.5 
is reacted in Diels-Alder fashion with a dienophile 1.6. There is the potential for 
two isomers, 1.7 and 1.8, to be formed in such a cycloaddition, corresponding to 
the endo and exo configurations. These adducts contain an oxygen or sulfur 
bridge which should be relatively stable, but cleavable under particular 
conditions. As can be seen, various substituents can be incorporated into the 
reaction (R 1, R2, R3, and R4), giving it great flexibility. For instance R3 and R4 
can potentially be linked together, forming an additional ring. 
Both isomers will form a compound of the type 1.9 if the bridge is opened as 
shown in Fig. 1.7.4. The loss of XH2 from 1.9 results in the planar aromatic 
product 1.10. 
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~' cQ' ~R' 'II ~G H 'II~ ~ -XH2 ,,'I, ~ ~ ,.\ ~ H '\ ~ " RH "\ ~ ~ R4 HX 'R24 R4 R2 R2 
1.7,1.8 1.9 1.10 
Fig. 1.7.4 
In vitro, such a ring opening can be performed by using acidic catalysis. 
However, if the substituent Rl is carefully chosen, then there is the potential for 
cleavage of the SRI bond to act as the trigger for aromatisation in vivo (cf. Section 
4.9). In this way, generation of an intercalating agent can be linked to a tumour 
selective process, and tumour cells may be selectively targeted. 
1.8 Summary 
The primary synthetic goal of this thesis is the synthesis of potential non-planar 
prodrugs utilising Diels-Alder chemistry, along with the corresponding ring-
opened planar products. Part A deals with an investigation of model Diels-Alder 
chemistry. Part B deals with the development of these models into potential anti-
cancer compounds. It is hoped that such compounds may provide the basis for 
new strategies of cancer chemotherapy. 
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DIELS .. ALDER APPROACHES 
TO ANTI-CANCER PRODRUGS 
art A: 
Model I vesti ations 
I11troduction 
Part A describes an investigation into the Diels-Alder chemistry of 
isobenzofurans with a range of dienophiles. This investigation was 
focused on the design of a model system for the synthesis of Diels-
Alder adducts as prodrugs for anti-cancer agents. Chapter 2 describes 
the synthesis of a range of appropriate diene precursors. Chapter 3 
examines the synthesis of a range of dienophiles, along with the 
synthesis of polycyclic aromatic compounds which are models for the 
activated prodrugs. Chapter 4 then describes an investigation into the 
Diels-Alder chemistry of the resulting dienes and dienophiles. A 
description of the bridge cleavage of the resulting adducts is also 
presented. 
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2 
DIENE PRECURSORS 
2.1 Introduction 
Our strategy for the synthesis of prodrugs was based around the formation of 
stable bridged adducts from Diels-Alder reactions. Two components are required 
for Diels-Alder reactions: a diene and a dienophile. 
The required diene is a system containing two double bonds separated by a 
'single' bond. However, because such a system is conjugated the 1t electron 
density is spread across aU four atoms. In order to partake in a Diels-Alder 
reaction a diene must be able to adopt a s-cis conformation, that is a cis-like 
conformation around the central bond. This is due to the pericyclic nature of the 
reaction, which involves a cyclic transition state. Only in the s-cis conformation 
are the terminal carbon atoms of the diene system close enough together to react 
through such a cyclic transition state and form a new ring (Fig 2.1.1). 
( 
S-ClS s-trans 
Fig. 2.1.1 
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The dienes under scrutiny in this work are all rigidly fixed in the correct s-cis 
geometry by their cyclic nature, being derivatives of isobenzofuran 2.1, or 
isobenzothiophene 2.2, which are shown in Fig. 2.1.2. In terms of relative 
aromaticity isobenzothiophenes are less aromatic in character than benzene, while 
isobenzofurans have even less aromatic character. Isobenzofurans are known to 
be highly reactive dienes in Diels-Alder cyc1oaddition reactions. 
Isobenzothiophenes are likely to be less reactive as dienes in such reactions. 
2.1 2.2 
Fig. 2.1.2 
The dienes were all prepared from precursors of the general structure 2.3 as 
shown in Fig. 2.1.3. 
/~S I X 
--'1( ~ 
R H 
x= 0, orS 
R= alkyl, or aryl group 
2.3 
Fig. 2.1.3 
These precursors were one of two main types: furanthiones (X=O) and 
thiophenethiones (X=S). This chapter deals with the synthesis of furanthiones and 
the synthesis of thiophenethiones is discussed in Chapter 7. 
Three classes of furanthiones were used as diene precursors. The 
isobenzofuranthiones (Section 2.2), naphthofuranthiones (Section 2.3), and 
quinofuranthiones (Section 2.4). 
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2.2 Isobenzofuranthiones 
The simplest of the isobenzofuranthiones synthesised was 1 (3H)-
isobenzofuranthione 2.5. This was made by thiation of 1(3H)-isobenzofuranone 
2.4, also known as phthalide, by Lawesson's reagent as shown in Fig. 2.2.1.20 
o s 
toluene! L1 eGo CCo Lawesson's reagent 
2.4 2.5 
Fig. 2.2.1 
Lawesson's reagent, shown in Fig. 2.2.2, is 2,4-bis-(p-methoxyphenyl)-1,3-
dithia-2,4-diphosphetane-2,4-dithione. It is commonly used to convert carbonyl 
groups to thiones.21 Another reagent which has been used successfully to 
perform thiations is phosphorous pentasulfide, but this has been used more 
commonly for exchanging the oxygen atom of a furan ring for a sulfur atom.22 
H3CO~,~~~~t-O-OCH3 
- s 
Fig. 2.2.2 Lawesson's Reagent 
A phenyl-substituted deri vative of 2.5, 3-phenyl-l(3H)-isobenzofuranthione, 
was of particular interest as the presence of a phenyl ring at this position has been 
shown by Cava et al. to stabilise both furans and thiophenes relative to the non-
substituted cases.23 ,24 Thus the isobenzofuran derived from 3-phenyl-l(3H)-
isobenzofuranthione would be expected to be relatively stable. 
26 
Chapter Two Diene Precursors 
The synthesis of 3-phenyl-l(3H)-isobenzofuranthione 2.9 is outlined in Fig. 
2.2.3. Firstly isobenzofuran-I,3-dione 2.6 was ring-opened and arylated using 
aluminium chloride and benzene to give 2-benzoylbenzoic acid 2.7.25 2-
Benzoylbenzoic acid 2.7 was then cyc1ised using zinc and glacial acetic acid to 
give 3-phenyl-l(3H)-isobenzofuranone 2.8.26 Lawesson's reagent was again used 
to give 3-phenyl-l(3H)-isobenzofuranthione 2.9. 
o 
~o Ale's! benzene 
2.6 0 
glacial acetic acid 
o s 
toluene! ~ ~o tXo Lawesson's reagent 
2.8 Ph 2.9 Ph 
Fig. 2.2.3 
A different approach was used to synthesise the 3-methyl and 3-ethyl 
derivatives of isobenzofuranthione. These were prepared via the intermediate 3-
hydroxy-l(3H)-isobenzofuranone 2.11 as shown in Fig. 2.2.4. 1(3H)-
Isobenzofuranone 2.4 was first melted and bromine was bubbled through it on a 
carbon dioxide carrier gas to give the brominated product 3-bromo-l-
isobenzofuranone 2.10.27 Hydrolysis of 2.10 in water gave 3-hydroxy-l(3H)-
isobenzofuranone 2.11.28 
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cCo 
2.4 
Diene Precursors 
o 
~o 
Br 
2.10 
Fig. 2.2.4 
o 
__ H2_0_I_Ll_....... ~o 
OH 
2.11 
3-Hydroxy-l(3H)-isobenzofuranone 2.11 exists as an equilibrium mixture of 
both its ring-closed 2.11a and ring-opened 2.11b tautomers as shown in Fig. 2.2.5. 
The aldehyde component reacts with a range of Grignard reagents, as 
demonstrated by Rodrigo.29 
o 
~o 
H OH 
2.11a 
Fig. 2.2.5 
o¢~H 
° 2.11b 
Grignard reactions are nucleophilic addition reactions, but, unlike similar 
additions such as the nucleophilic addition of water, they are generally 
irreversible. Grignard reagents act as powerful nuc1eophiles due to the strong 
polarisation of the carbon-magnesium bond, with a high electron density on the 
carbon. Acid-base complexation of the magnesium ion with the carbonyl oxygen 
atom of the starting material first serves to make the carbonyl group a better 
electrophile as shown in Fig. 2.2.6.30 Nucleophilic addition to 2.11b then 
produces a tetrahedral intermediate 2.12. Protonation of the intermediate by 
aqueous acid gives the neutral alcohol 2.13. 
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C¢~8 ----...... ct~8 2.12 
(9 "--e e R oeeMgX 
RMgX 
2.11b ~ -
H30+~ 0 
~OH ~H 
R OH 
2.13 
Fig. 2.2.6 Proposed mechanism of the Grignard reaction 
The alcohols formed in this manner from 2.11, with either methyl or ethyl 
substitution at the 3-position, were then dehydrated to give the corresponding 
ring-closed products 2.14a and 2.14b as shown in 2.2.7. Both these products 
were yellow oils which were purified by radial silica chromatography. 
0 0 S CC;o 1) RMgX CC;o Lawesson's Reagent CC;o ~ • 
2) H30+ toluene/ /::,. 
OH R R 
2.11 2.14a,b 2.15a,b 
a R= CH3 
b R= CH2CH3 
Fig. 2.2.7 
Reaction of 2.14a and 2.14b with Lawesson's reagent was found to give the 
corresponding isobenzofuranthiones 2.15a and 2.15b, which were also yellow 
oils. These were now available for use as diene precursors. 
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2.3 Naptho[2,3-c]furan-l-thiones 
Naphthalene-2,3-dicarboxylic anhydride was used as the starting material 
the synthesis of naphthofuranthiones. The synthesis of naphthalene-2 
dicarboxylic anhydride itself was carried out in 3 steps as outlined in Fig. 2.3.1. 
CC
CH
' 
Br21 fjj uv CCCHBr2 
.. 1/;/ 
4 CH3 CHBr2 
2.16 2.17 
maleic anhydride 
Nal/DMF 
0 
roC02H AC201 tl CC;<o /;/ 4 C02H 4 /;/ 
2.18 2.19 0 
Fig. 2.3.1 
Firstly, a standard bromination of 2-xylene 2.16 under ultraviolet light led to 
the formation of 1,2-bis(dibromomethyl)benzene 2.17)1 1,2-bis-
(Dibromomethyl)-benzene 2.17 has been shown to be capable of undergoing a 
concerted elimination reaction, forming the highly reactive 2-quinodimethane 
derivative 2.20 when reacted with sodium iodide as shown in Fig. 2.3.2.32 
30 
e~ 
I Br 
OCcHBr ~ h ~ CHBr 
I 
Br 
2.17 
Fig. 2.3.2 
H 
I 
,. 
~C-Br 
~C-H 
I 
Br 
2.20 
This feature was exploited and the intermediate 2.20, an excellent diene, was 
immediately trapped with the dienophile. maleic anhydride in a Diels-Alder 
reaction to give naphthalene-2,3-dicarboxylic acid 2.18 as the Diels-Alder 
adduct. 3 3 Conversion of 2.18 to naphthalene-2,3-dicarboxy lie anhydride 2.19, by 
refluxing with acetic anhydride proved facile and this step proceeded in 
quantitative yield. 
To make the diene precursor 1 ,3-dihydronaptho[2,3-c Jfuran-l-thione 2.22, 
naphthalene-2,3-dicarboxylic anhydride 2.19 was first reduced to 1,3-
dihydronaphtho[2,3-c ]furan-l-one 2.21 as shown in Fig. 2.3.1. 
2.19 2.21 Lawesson's reagent 
toluene/ d 
s 
~o 
2.22 
Fig. 2.3.1 
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This reduction was performed using sodium borohydride, a commonly used 
reagent for reduction of cyclic anhydrides to lactones.34 Thiation of 2.21 with 
Lawesson's reagent gave 1 ,3-dihydronaptho[2,3-c ]furan-l-thione 2.22. 
To introduce a phenyl group at the 3-position of the napthofuranthione, and 
hence potentially add stability to the subsequent diene, a method analogous to the 
synthesis of 3-phenyl-l(3H)-isobenzofuranthione 2.9 was employed (cf. Fig. 
2.2.3). 
As shown in Fig. 2.3.2, firstly naphthalene-2,3-dicarboxylic anhydride 2.19 
was ring-opened and arylated using aluminium chloride and benzene to give the 
acid 2.23; this was then reduced and cyclised in situ using zinc and glacial acetic 
acid to give 3-phenyl-l (3H)-isonaphtho[2,3-c ]furan-l-one 2.24.25 ,26 Reaction of 
2.24 with Lawesson's reagent gave the desired product 3-phenyl-l (3H)-
isonaphtho[2,3-c ]furan-l-thione 2.25. 
o 
~.~ 0' 
2.24 Ph 
o 
AICI31 benzene ~OH 
~Ph 
2.23 0 
glacial acetic acid 
Lawesson's reagent 
" 
toluenel A 
2.3.2 
s 
~o 
2.25 Ph 
By this chemistry, 1 ,3-dihydronaptho[2,3-c ]furan-l-thione 2.22 and 3-phenyl-
1 (3H)-isonaphtho[2,3-c]furan-l-thione 2.25 were available for use as diene 
precursors. 
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2.4 Quino[2,3-c ]furan-l-thione 
It has been noted that the presence of one or more nitrogen atoms in the 
chromophore of an intercalating agent often increases its binding affinity to DNA. 
Many intercalators of this nature are known, for example 6H-pyrido[4,3-
b]carbazole 2.26 and the ellipticine derivative 2.27 which are shown in Fig. 
2.4.1. 8 
H3CO 
2.26 2.27 
Fig. 2.4.1 
The increased DNA affinity of such heterocyclic intercalators is attributed to 
favourable electrostatic and hydrogen bonding interactions between the protonated 
nitrogen atom of the chromophore and the DNA. 
Quino[2,3-c ]furan-l-thione, with a nitrogen atom substituted into the coplanar 
ring system of the furanthione, proved to be the most challenging of the 
furanthiones to synthesise. In order to introduce the nitrogen atom into the ring 
system, 2-nitrobenzaldehyde 2.28 was used as the starting material. Reduction of 
the nitro group using ferrous sulfate and ammonia solution gave 
amino benzaldehyde 2.29 which was separated out of the reaction mixture by 
steam distillation.35 This reaction sequence is outlined in Fig. 2.4.2. 
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2.28 2.29 
NaOHI ethanol 
ethyl acetoacetate 
2.30 
Fig. 2.4.2 
A variation of the Friedlander synthesis was then employed to cyc1ise 2-
amino benzaldehyde 2.29 with ethyl acetoacetate to give 2.30.36 
The Friedlander synthesis is an acid or base catalysed reaction between a 2-
amino substituted aromatic aldehyde or ketone with an appropriately substituted 
aldehyde, ketone, or other carbonyl containing compound with a reactive (X-
methylene group. It involves condensation followed by cyc1odehydration. 
Quinoline formation was carried out effectively by stirring the reactants in ethanol 
at room temperature with a catalytic amount of sodium hydroxide 
present. 37 ,38,39,40 
The next step necessary was the conversion of 2.30 to the corresponding N-
oxide 2.31 using 3-chloroperbenzoic acid. 
The first quinoline N -oxide was prepared by Meisenheimer in 1926 by 
oxidation of quinoline with perbenzoic acid.41 Ochiai et al. later established the 
necessity of an acid in this kind of oxidation as well as the conditions which have 
been most commonly used since.42 Usually a mixture of glacial acetic with 30% 
hydrogen peroxide is satisfactory, however for lower temperature reactions 3-
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chloroperbenzoic acid has been used effectively, and this is the reagent we 
chose.43 ,44,45 A possible mechanism of N-oxide formation by oxidation of a 
quinoline is shown in Fig. 2.4.3 . 
. . 
Cn 
0-0 
I \ 
H c=o 
I 
R R 
Fig. 2.4.3 Possible mechanism of N-oxide fonnation 
The reaction of an alkyl-substituted quinoline N-oxide with acetic anhydride 
has been shown to result in deoxygenation of the quinoline nitrogen and 
acetoxylation of the alkyl group.46 This characteristic reaction of N-oxides was 
used to synthesise 2.32 from 2.31, as shown in Fig. 2.4.4. 
35 
Chapter Two Diene Precursors 
cone. Hel 
Lawesson's reagent 
.. 
toluene/ ~ 
Fig. 2.4.4 
Cyclisation of 2.32 to the lactone quino[2,3-c]furan-l-one 2.33 was performed 
with concentrated hydrochloric acid.47 Thiation of 2.33 using Lawesson's reagent 
gave the desired diene precursor quino[2,3-c]furan-l-thione 2.34, although in 
lower yield than that obtained for 1 ,3-dihydronaptho[2,3-c ]furan-l-thione 2.22. 
This was now available for use as a diene precursor. 
2.5 Summary 
Using known chemistry a range of furanthione diene precursors, both bicyc1ic 
and tricylic, was synthesised. These were: isobenzofuranthione, along with its 3-
phenyl, 3-methyl, and 3-ethyl substituted derivatives; naphthofuranthione, along 
with its 3-phenyl substituted derivative; and a heterocyclic quinofuranthione. The 
conversion of these diene precursors to dienes and their subsequent trapping with 
dienophiles to form Diels-Alder adducts will be described in Chapter 4. 
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Chapter 3 
OPHILES 
3.1 Introduction 
The alkene component of a Diels-Alder cycloaddition reaction is called a 
dienophile, meaning 'diene lover'. The cycloaddition is most efficient when the 
dienophile has complementary electronic properties to the diene. For a normal 
electron-demand Diels-Alder reaction, which has an electron-rich diene, this 
means that the reaction occurs optimally if the dienophile is substituted by an 
electron withdrawing group.19 Hence the reaction is biased towards those 
dienophiles where the double bond is next to a substituent which withdraws 
electron density. For an inverse electron-demand Diels-Alder reaction the 
situation is reversed. 
Many different classes of compounds have been used as dienophiles in Diels-
Alder chemistry. For our purposes, the choice of dienophile was crucial, as it 
would determine to a large extent the effectiveness of our final planar aromatic 
compounds as intercalators. We were interested in incorporating a range of 
functional groups into these aromatic compounds via the dienophile, in particular 
nitrogen based substituents. 
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This chapter describes the dienophiles used in Part 1 of this thesis and, where 
appropriate, their synthesis. Section 3.2 describes those simple dienophiles used 
initially, which were related to dimethyl fumarate and dimethyl 
acetylenedicarboxylate. Section 3.3 describes the synthesis of N-aryl maleimides. 
Section 3.4 describes the extension of the N-aryl maleimide synthesis to 
polycyclic compounds related to the products of the proposed Diels-Alder 
chemistry. 
3.2 Fumarate and Acetylene Based Dienophiles 
Dimethyl fumarate 3.1and dimethyl acetylenedicarboxylate 3.2 are commonly 
used dienophiles and are readily available reagents (Fig. 3.2.1). 
3.1 3.2 
Fig. 3.2.1 
Amide analogues of fumaric acid were generated as illustrated in the reaction 
scheme shown in Fig. 3.2.2. Fumaric acid 3.3 was first chlorinated using 
phosphorous pentachloride to give the highly reactive fumaroyl dichloride 3.4.48 
Reaction of 3.4 with n-butylamine and N,N-dimethylethylene diamine gave the 
products 3.5 and 3.6 respectively. 49 
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PC Is COCI F 
CIOC 
3.4 
n-butylamine N,N-dimethylethylenediamine 
CONHC 4Hg F C4HgHNOC 
3.5 
Fig. 3.2.2 
The two diamides 3.5 and 3.6, along with dimethyl fumarate and dimethyl 
acetylenedicarboxylate, were used as dienophiles in Diels-Alder reactions which 
are described in Chapter 4. 
3.3 N-Aryl maleimides 
N-Phenyl maleimide is well-known as an excellent dienophile. In addition, it 
offers the possibility of incorporating useful functionality into the Diels-Alder 
adducts via substitution on the phenyl ring. 
N-Phenyl maleimide is synthesised in a two stage process from maleic 
anhydride and aniline as shown in Fig 3.3.1, which also serves to illustrate the 
synthesis of N-aryl maleimides in generaL 50 
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Fig. 3.3.1 Two stage synthesis of N-aryl maleimides 
In the first step nucleophilic attack on the maleic anhydride by the nitrogen of 
aniline results in the formation of an unsymmetrical intermediate. Dehydration of 
this intermediate by heating gently with acetic anhydride results in the 
symmetrical product N-phenyl maleimide. N-Phenyl maleimide is easily 
identified with proton NMR by its characteristic singlet at 6.85ppm, 
corresponding to its two olefinic protons. In fact, the presence of a singlet in this 
region is characteristic of all N-aryl maleimides. 
An analogous procedure was followed to produce nitro-substituted N-aryl 
maleimides, with 2-nitroaniline and 3-nitroaniline respectively used as starting 
materials. This led to the synthesis of 3.7 and 3.8 as shown in Fig. 3.3.2. 
.. ~N~ 2-nitroaniline 
o 3.7 
3-nitroaniline 
Fig. 3.3.2 
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It was envisioned that appropriate substitution of N-aryl maleimides could lead 
to Diels-Alder adducts with stronger binding affinity to DNA. One possible route 
to such compounds was via amide bond formation from amine substituted N-aryl 
maleimide starting materials. 
An attempt was therefore made to reduce the nitro-substituted derivative 3.8 to 
the corresponding amino-substituted compound 3.9 as shown in Fig. 3.3.3. 
o N02 
~N-{ ~m_m_m ___ _ 
o 
3.8 3.9 
Fig. 3.3.3. 
Common reagents which have been used for the reduction of a nitro group 
include tin and hydrochloric acid, iron and acetic acid, and catalytic 
agents. 51 ,52,53,54,55 In view of possible side-reactions we chose to evaluate tin 
and hydrochloric acid. Several attempts to perform this reduction however, using 
both the meta-substituted 3.8, and the artha-substituted 3.7, were unsuccessful, 
with the maleimide ring being opened in the reaction. 
A different approach to synthesise amide substituted N-aryl maleimides was 
therefore used. In this approach, outlined in Fig. 3.3.4, the maleimide ring was 
incorporated in the final step, after any necessary reductions. 
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Fig. 3.3.4 
3-Nitroaniline 3.10 was first refluxed with acetic anhydride to give the 
acetylated product 3.11. Potentially, any acyl substituent could be added in this 
step, allowing a wide range of functional groups to be incorporated into 
subsequent Diels-Alder adducts. 
The next step again required reduction of the nitro group. The procedure using 
tin and hydrochloric acid proved unsuitable once more. So catalytic 
hydrogenation was chosen. Nitro groups have been shown to be one of the most 
easily reduced groups by catalytic hydrogenation. 56 Catalysts which have been 
successfully employed for the reduction of aromatic nitro groups include platinum 
oxide, Raney nickel, and palladium on carbon. 52 
We performed the reduction of 3.11 to 3.12 by dissolving 3.11 in methanol, 
and using 5% palladium-on-carbon as the catalyst for hydrogenation. The amine 
3.12 thus formed was then reacted with maleic anhydride followed by acetic 
anhydride, to give the desired product 3.13.50 
The corresponding ortho-substituted compound 3.14 was synthesised in an 
analogous manner, starting with 2-nitroaniline (Fig. 3.3.5). 
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o 
3.14 
Fig. 3.3.5 
The two compounds thus synthesised, N-(3-acetylaminophenyl)maleimide 3.13 
and N-(2-acetylaminophenyl)maleimide 3.14 were now available for use as 
dienophiles in Diels-Alder chemistry. This chemistry is described in Chapter 4. 
3.4 Planar Aromatic Models 
3.4.1 Introduction 
Section 3.3 described the successful syntheses of N-aryl maleimides. Diels-
Alder adducts resulting from the use of N-substituted maleimides as the 
dienophiles will produce polycyclic aromatic derivatives containing a cyclic 
imide structure. The chemistry used to generate maleimides can also be used to 
generate analogous polycyclic structures directly. This section describes the 
syntheses of planar aromatic models, as a preliminary survey to see whether any 
class of N-substituted imide might offer interesting biological opportunities above 
those offered by simple N-aryl imides. A range of N-substituted imides was 
therefore prepared. 
The synthesis of N-substituted imides can be carried out in several ways, the 
two most favoured being a two-step synthesis, as in the preparation of N-phenyl 
maleimide, with nucleophilic attack in the first step being followed by cyclisation 
in the second, or a single step synthesis in which both processes take place in the 
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same reaction vessel, such as in the reported synthesis of 3-isopropyl-N-
(benzyloxy)succinimide. 50,57 The latter route was chosen for our purposes and 
the reaction conditions tested by the insertion of N,N-dimethylethylene diamine 
into isobenzofuran-l,3-dione 2.6 as shown in Fig. 3.4.1. 
o 
eGo 
o 2.6 
N,N-dimethylethylene diamine 
.. 
Mtoluene 
Fig. 3.4.1 
In this method the anhydride? isobenzofuran-l,3-dione 2.6 in this case, is 
brought to reflux in toluene and the amine added and further refluxed. This 
reaction proceeded cleanly to give 3.15 in 90% yield. 
Our work was directed at the synthesis of polycyclic systems, so quinoline-2,3-
dicarboxylic anhydride and naphthalene-2,3-dicarboxylic anhydride were chosen 
as the starting anhydrides. Section 3.4.2 describes the attempted synthesis of 
quinoline-2,3-dicarboxylic anhydride. Section 3.4.3 describes the synthesis of 
polycyclic N-substituted imide derivatives from naphthalene-2,3-dicarboxylic 
anhydride. 
3.4.2 Quinoline-2,3-dicarboxylic anhydride 
As noted in Section 2.4 the presence of a nitrogen atom in the chromophore of 
an intercalating agent often increases its binding affinity to DNA. Quinoline-2,3-
dicarboxylic anhydride was therefore targeted as a useful starting material for the 
synthesis of N-substituted imides. Our attempted method of synthesising 
quinoline-2,3-dicarboxylic anhydride is outlined in Fig. 3.4.2. 
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ethyl acetatel Na ?i q ----------------~C2H5/0~~O~C2H5 
EtOH/NaOH CHO 
~NH2 
U 2.29 
cone. HCI 
Fig. 3.4.2 
o 3.17 
... 
In the first step diethyl oxalate 3.16 was reacted with ethyl acetate and sodium 
metal to give the sodium salt of diethyl oxaloacetate 3.17. This was recrystallised 
and converted to its neutral form by addition of hydrochloric acid and extraction 
with ether. The Friedlander synthesis was then used to react 3.17 with 2-
aminobenzaldehyde 2.29, prepared freshly from 2-nitrobenzaldehyde 2.28 (cf. 
Fig. 2.4.2), forming the diethyl derivative of 2,3-quinoline dicarboxylic acid 
3.18.36,58 The conditions of the Friedlander synthesis were the same as those 
used successfully in Section 2.4, namely stirring the reactants in ethanol at room 
temperature with a catalytic amount of sodium hydroxide present. 
With 3.18 thus synthesised, quinoline-2,3-dicarboxylic acid 3.19 itself was 
prepared by removal of the ethyl substituents with concentrated hydrochloric 
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acid. However the proposed final step of synthesising quinoline-2,3-dicarboxylic 
anhydride 3.20 from the diacid 3.19 was unsuccessful. Reflux of 3.19 with acetic 
anhydride was found to result in thermal decomposition, with decarboxylation 
resulting in formation of 3-quinoline carboxylic acid 3.21.59,60 
3.4.3 Derivatives of NaphthaleneN 2,3-dicarboxylic anhydride 
The synthesis of naphthalene-2,3-dicarboxylic anhydride 2.19 is described in 
Section 2.3. The preparation of a range of polycyclic N-substituted imides from 
2.19 is summarised in 3.4.3. 
o 
~o 
2.19 0 
oc<":::: 0 I N-X d d 
o 
3.22 X= CH2CH2N(CH3)2 
3.23 X= CH 2CN 
3.24 X= Cs H4N 
3.25 X= CaHs 
Fig. 3.4.3 
The amines were selected so as to incorporate a variety of functionalities and 
thereby explore the effects of various substituents on the properties of the 
polycyclic imides relative to the N-phenyl case 3.25. Studies of intercalation have 
shown that the cytotoxity of an intercalating agent often depends not only on the 
presence of a coplanar aromatic ring system, but also on the presence of a 
substituent capable of interacting with and affecting DNA biochemistry.8 Thus 
3.22, 3.23, and 3.24 all incorporate a heteroatom, nitrogen, separate from the 
chromophore itself, with the aim of enhancing favourable interactions between 
the DNA and the intercalator. For example the dimethylamine moiety of 3.22, 
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which can be protonated, has been shown able to produce favourable electrostatic 
interactions with phosphate groups on the DNA backbone, if positioned correctly 
in relation to the DNA.61 Similarly cyano and pyridinyl groups, such as those 
incorporated into 3.23 and 3.24 respectively, are capable of hydrogen bonding 
interactions with the backbone of DNA. 
The polycyclic N-substituted imides thus synthesised were tested for biological 
activity in the P388 anti-tumour assay (cf. Appendix). The N-phenyl substituted 
imide 3.25 showed mild anti-cancer activity, giving an ID50 value of 4.39!lg/mL. 
However, none of the other compounds synthesised were found to have enhanced 
biological activity relative to the N-phenyl case. They were, therefore, not 
pursued further. 
3.5 Summary 
The initial dienophiles used in this thesis were dimethyl 
acetylenedicarboxylate, dimethyl fumarate, and amide derivatives of fumaric acid. 
A convenient route was developed for the synthesis of a range of N-aryl 
maleimide dienophiles, with the potential for introducing further functionality (cf. 
Chapter 5). A range of polycyclic N-substituted imides was synthesised as 
preliminary models of bridge-cleaved Diels-Alder adducts. These did not appear 
to offer any biological opportunities above those offered by N-aryl imides. 
The Diels-Alder chemistry of the dienophiles synthesised in this chapter will 
be described in Chapter 4. 
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Chapter 
XYGEN-BRIDGED DIELS-
ALDER ADDUCTS 
4.1 Isobenzofurans 
In 1964 the brief existence of isobenzofuran 4.1 was conclusively demonstrated 
(Fig. 4.1.1).62 Since then many isobenzofurans have been synthesised. Most 
isobenzofurans, like 4.1, are too unstable to be isolated in the conventional 
sense.29 Aryl substituents on the furanoid ring have a stabilising effect on the 
system, as do electron withdrawing groups; thus 1,3-diphenyl isobenzofuran 4.2 is 
a commercially available materiaL 63 Isobenzofurans with a single aryl substituent 
however, are not stable enough for routine isolation. It is for this reason that 
isobenzofurans are generally prepared and reacted in situ. 
4.1 
Fig. 4.1.1 
Ph 
4.2 
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Isobenzofurans are highly reactive dienes in Diels-Alder cycloadditions. 
Routes that have been used to synthesise isobenzofurans for subsequent trapping 
with dienophiles vary and include flash vacuum pyrolysis of dihydro-substituted 
furan precursors, the acid catalysed reaction of acetals, thermal cycloreversion, 
and lithium diisopropylamide (LDA) induced l,4-elimination of acetals.64,65,66 
In order to synthesise sulfur substituted isobenzofurans we chose a synthetic 
route analogous to that Iwao et al. reported in pioneering the synthesis of 
silyloxyisobenzofurans from isobenzofuranones (Fig. 4.1.2).67,68 They described 
deprotonation of isobenzofuranones 4.3 by LDA to generate 3-
lithioisobenzofuranones, sily lation of the resulting ambident anions led to 1-
silyloxyisobenzofurans 4.4, due to. silicon's much stronger affinity for oxygen than 
for carbon.69 The silyloxyisobenzofurans so generated were trapped with simple 
dienophiles, such as dimethyl fumarate, to give bridged Diels-Alder adducts. 
o C<O 1) LDA 2) TBDMSCI 
Ph 
4.3 4.4 
Fig. 4.1.2 
Bailey et al. have shown that such an approach can be successfully adapted to 
the synthesis of sulfur-substituted isobenzofurans.67 This strategy involved 
preparing anions by the deprotonation of isobenzofuranthiones with LDA, 
followed by alkylation on the sulfur atom. Section 4.2 will describe the general 
method which was followed in this thesis to generate such sulfur-substituted 
isobenzofurans in situ. 
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4 .. 2 General Method for the Preparation of 
Isobenzofuran Dienes 
The first step in the conversion of diene precursors to their corresponding 
dienes is deprotonation using lithium diisopropylamide (LDA, 4.6, Fig. 4.2.1). 
LDA is an exceedingly powerful base, since diisopropylamine has a pKa of 40. It 
is soluble in organic solvents such as tetrahydrofuran (THF), yet it is too bulky to 
act as an effective nucleophile. 
THFI GOG 
4.5 4.6 
Fig. 4.2.1 Preparation of LDA. 
As shown in Fig. 4.2.2, deprotonation of a isobenzofuranone 4.7 with LDA 
leads to formation of the diene system 4.8 as an anion. Alkylation on sulfur is 
then achieved using an appropriate alkylating agent, such as methyl iodide, to give 
the sulfur-substituted isobenzofuran 4.9, ready for use in a Diels-Alder 
cycloaddition reaction. This reaction sequence is sensitive to water and must be 
done in an anhydrous environment. 
4.8 4.9 
Fig. 4.2.2 
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The sulfur-substituted isobenzofurans thus formed were reacted immediately 
with a dienophile in situ, and no attempt was made to isolate them. The advantage 
of this approach was a 'one-pot' synthesis in which all the reactions involved in 
converting the diene precursors to Diels-Alder adducts were performed together. 
4.3 Overview 
This section provides an overview of the chemistry presented in this chapter. 
The reactions described can be grouped into two categories: the formation of 
Diels-Alder adducts, and the bridge cleavage of these adducts and their subsequent 
chemistry. 
SR" R':oq -;?' :;;.-
R' ~ ::::--.. 0 
R 
EWG 4.10 
II 
EWG 
SR" SR" 
R'xxtr
EWG 
I 0 I 
R' ~ EWG 
R':c$EWG I 0 
R' ~ EWG 
R R 
4.11 4.12 
Fig. 4.3.1 Adduct formation 
Fig. 4.3.1 outlines Diels-Alder adduct formation, with the diene 4.10 reacting 
with an alkyne or alkene dienophile to give the Diels-Alder adducts 4.11 and 4.12 
respectively. The four major variable substituents present in these reaction 
sequences are R, R', R", and EWG. 
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SR" 
R':o$tEWG I 0 I 
R' b EWG 
R 
4.11 R=H 
SB" 
R'~EWG 
R'~EWG 
OH 
4.13 
SRI! 
R'xxfcEWG I 0 
R' b EWG 
R 
J 
4.12 
SR" 
R'~EWG 
R'~EWG 
HO R 
4.14 
SB" 
R'~EWG 
R'~EWG 
R 
4.15 
Fig. 4.3.2 Bridge cleavage and subsequent chemistry 
Fig. 4.3.2 outlines some possible bridge cleavages and subsequent chemistry of 
these Diels-Alder adducts. Bridge cleavage can be induced by either acid 
catalysis, or cleavage of SRI! (in which case R"=H). If R=H, bridge cleavage of 
4.11 leads to the aromatic product 4.13. Bridge cleavage of 4.12 leads to the 
intermediate product 4.14, which can follow either of two pathways to 
aromatisation: loss of H20 to give 4.15, or loss of HR to give 4.13 in the case 
where R is a leaving group. 
This chapter describes an investigation into the effects of varying the 
substituents R, R', R", and EWG. Sections 4.4 to 4.6 describe the effects of 
varying R, which has an influence on both the stability of the diene 4.10 and the 
pathways open to aromatisation. Initially, Sections 4.4 and 4.5 describe the Diels-
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Alder chemistry of a range of simple l-methylsufanyl-isobenzofurans with simple 
dienophiles, in particular dimethyl fumarate, dimethyl acetylenedicarboxylate, and 
N-phenyl male imide. Section 4.6 then describes an example of Diels-Alder 
chemistry when R is a leaving group. 
Section 4.7 is focused on studies in which R' is varied, extending the ring 
system. R' influences both the stability of the diene 4.10, and the biological 
properties of the final aromatic product. 
Section 4.8 describes investigations into the effects of varying the electron 
withdrawing groups (EWG) of the dienophile. The choice of EWG influences the 
reactivity of the dienophile, and is also a potential way of introducing useful 
functionality into the final drug. . 
Section 4.9 introduces studies aimed at evaluating the possibility of adding a 
trigger to the prodrug. Incorporation of a suitable R" substituent, which could lead 
to remote activation of the drug, is described. 
4.4 Diels-Alder Chemistry of I-Methylsulfanyl-
isobenzofuran 
This section describes the Diels-Alder chemistry of l-methylsulfanyl-
isobenzofuran, i.e. the case where the R substituent is hydrogen, with simple 
dienophiles. These studies focused on dimethyl fumarate, dimethyl 
acetylenedicarboxylate, and N-phenyl maleimide. It also describes the chemistry 
of the resulting Diels-Alder adducts. 
The first Diels-Alder reaction under consideration is that with the alkyne 
dienophi Ie dimethyl acety lenedicarboxy late. 1-Methy lsulfany l-isobenzofuran 4.16 
was prepared in situ as described in Section 4.2, and reacted with dimethyl 
acetylenedicarboxylate as shown in Fig. 4.4.1. 
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4.16 
Fig. 4.4.1 
Two products of interest were observed in this reaction; the Diels-Alder adduct 
itself 4.17, in 25% yield, and the naphthalene product 4.18, in 10% yield, formed 
via bridge cleavage of 4.17. This result was in accord with the results of Bailey et 
al .. 67 These two products could easily be identified and distinguished using mass 
spectrometry techniques, with the Diels-Alder adduct 4.17 giving rise to ions 
corresponding to retro-Diels-Alder fragmentation. Bridge cleavage of 4.17 to 
4.18, an acid-catalysed process, likely occurred during the isolation procedure, 
which involved radial silica chromatography. 
An analogous Diels-Alder reaction was carried out using the alkene dienophile 
dimethyl fumarate, as shown in Fig. 4.4.2. 
r 
SCH1 ~o j H3C02C~CO"cH3 
4.16 ~
Fig. 4.4.2 
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In this case only bridged adducts were observed: 4.19 and 4.20, which are 
stereo isomers of each other, isolated in a combined yield of 57%. No attempt was 
made to separate the isomers, and assignment of the stereochemistry, as shown in 
Fig. 4.4.2, was made by analogy with work done by Bailey et al.. 67 In the 1 H 
NMR spectra, the major isomer 4.19 gave rise to characteristic doublets, 
corresponding to the protons a to the esters, at 3.21 and 3.79ppm, compared to 
corresponding doul5lefs at 3.10 and 4.15ppm for the minor isomer 4.20. The mass 
spectrum of this mixture included a peak· at 308 mass units corresponding to the 
parent ion, as well as peaks corresponding to retro Diels-Alder fragmentation. 
Bridge cleavage of the isomeric mixture of 4.19 and 4.20 was achieved by 
reaction with trifluoroacetic acid (TFA) as outlined in Fig. 4.4.3. 
This resulted in the formation of two isomeric products: 4.21a and 4.21b, 
isolated in a combined yield of 82%. The mass spectrum of 4.21 also included a 
peak at 308 mass units corresponding to the parent ion, as well as a peak at 290 
mass units corresponding to the loss of water. Notably, there were no peaks 
corresponding to retro Diels-Alder fragmentation, in accordance with bridge 
cleavage. 
SCH3 
cq~ ~ C02CH3 ~ ·"co CH H 2 3 
OH 
4.19,4.20 4.21a,b 
Fig. 4.4.3 
The mechanism of such an acid-catalysed bridge cleavage is thought to be 
initiated by protonation of the bridge oxygen atom as shown in Fig 4.4.4. 
Subsequent elimination leads to the observed products 4.21a and 4.21b.29,70 
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4.19,4.20 
Fig. 4.4.4 Proposed mechanism of bridge cleavage. 
Such acid-catalysed bridge cleavage mimics the first stage of the proposed in 
vivo prodrug activation pathway. Although not observed in this case, further loss 
of H20 to give the corresponding planar aromatic compound was frequently 
observed in subsequent bridge cleavage reactions. 
The third sirhple dienophile reacted with I-methylsulfanyl-isobenzofuran 4.16 
was N-phenyl maleimide, as shown in Fig. 4.4.5. 
In this instance, none of the desired product 4.22 was isolated This is likely 
due to the relative instability of I-methylsulfanyl-isobenzofuran 4.16 under the 
reaction conditions. This relatively low stability makes 4.16 unsuitable for more 
complex Diels-Alder chemistry. The following section will describe the use of 
substitution at the 3-position of methylsulfanyl-isobenzofurans to enhance diene 
stability. 
---------------------~ 
4.16 
Fig. 4.4.5 
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Substitution at the 3 Position 
Section 4.4 illustrated possible limitations in the Diels-Alder chemistry of 
isobenzofurans lacking a substituent at the 3-position. It is known that 3-alkyl-
and 3-aryl-substituted dienes undergo Diels-Alder chemistry with dienophiles 
such as dimethyl fumarate more efficiently.63 We were mainly interested in 
Diels-Alder chemistry involving N-aryl maleimides as the dienophile, which had 
failed with un substituted case. Therefore this section describes the Diels-Alder 
chemistry of 3-alkyl and 3-aryl substituted dienes, along with the chemistry of the 
resulting adducts. 
I-Methylsulfanyl-3-phenyl-isobenzofuran 4.23, I-methy Isulfanyl-3-methyl-
isobenzofuran 4.24, and I-methylsulfanyl-3-ethyl-isobenzofuran 4.25 were used 
as the dienes in a series of Diels-Alder reactions with N-phenyl maleimide as the 
dienophile, as outlined in Fig. 4.5.1. 
o 
~N-o 
4.23 R=Ph 
4.24 R=Me 
4.25 R=Et 
o 
+ 
4.26 R=Ph 
4.27 R=Me 
4.28 R=Et 
SCH30 ~~ > 4.29 R=Ph 
RHo 
Fig. 4.5.1 
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With the phenyl-substituted diene, two products were isolated, 4.26 and 4.29. 
The major isomer 4.26 was isolated in 48% yield and the minor isomer 4.29 in 1 % 
yield. Based on analogy with related Diels-Alder adducts, which have been well 
characterised by x-ray crystallographic and 1 H NMR spectroscopic studies, the 
major product was identified as the endo isomer and the minor product as the exo 
isomer. 67 A notable feature in the 1 H NMR spectra of bridged Diels-Alder 
adducts such as these is the presence of two doublet resonances corresponding to 
the bridgehead protons. For the endo isomer 4.26 these two resonances were at 
3.91 and 4.13ppm, while for the exo isomer 4.29 they were at 3.34 and 3.59ppm. 
The presence of a phenyl group at the 3-position of the isobenzofuran had a 
beneficial effect on the reaction qf the isobenzofuran with N-phenyl maleimide. 
However, being a large, bulky group it could sterically hinder intercalation into 
DNA. So the question of whether smaller groups, such as small alkyl groups, 
could also have such a positive effect was explored in the case of the methyl- and 
ethyl-substituted dienes. 
The Diels-Alder reactions of I-methylsulfanyl-3-methyl-isobenzofuran 4.24, 
and I-methylsulfanyl-3-ethyl-isobenzofuran 4.25 with N-phenyl male imide gave 
the Diels-Alder adducts 4.27 and 4.28 respectively. In both instances only one 
stereoisomer was observed as the product, which was identified, by analogy with 
the phenyl substituted case, as the endo isomer. The methyl-substituted adduct 
4.27 contained doublets in the 1 H NMR spectrum corresponding to the bridgehead 
protons at 3.67 and 3.82ppm, while for the ethyl-substituted adduct 4.28, doublets 
were at 3.72 and 3.79ppm. 
In the case of the methyl-substituted adduct 4.27, the assignment of an endo 
configuration was confirmed by X-ray crystallographic studies (cf. Appendix). 
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SCH30 
cGtN-{ > . 
RHO ~ SCH30 
4.26 R=Ph ~~ ~ 
4.27 R=Me I // N~ 
4.28 R=Et HO H 
R 0 
4.29 R=Ph "" SCH3 0 
4.30 R=Me ~ox 
4.31 R=Et I ~ ~ ~ 
// // N~ 
Fig. 4.5.2 
R 0 
4.32 R=Ph 
4.33 R=Me 
4.34 R=Et 
The bridge cleavage and aromatisation reactions of the Diels-Alder adducts 
4.26,4.27, and 4.28 are outlined in Fig. 4.5.2. It was expected that reaction of the 
phenyl-substituted endo adduct, 4.26, with TFA would lead not only to bridge 
cleavage, but also directly to the aromatisation product 4.32, through spontaneous 
dehydration. However in fact, the intermediate product 4.29 was observed, easily 
identifiable by 1 H NMR spectroscopy due to the loss of the two doublets at 3.91 
and 4.13ppm, along with the observation of a new singlet resonance at 4.22ppm 
corresponding to the remaining lone hydrogen of the ring junction. When 
purification of 4.29 was attempted by radial silica chromatography it was found to 
decompose on the silica to the originally expected product 4.32, as identified by 
the loss of the 4.22ppm singlet from the 1 H spectrum. Interestingly, the 
intermediate and final products were indistinguishable by mass spectrometry, with 
a peak at 395 mass units corresponding to loss of water in 4.29, and the parent ion 
in 4.32. 
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A similar sequence was observed in the aromatisation of the methyl-substituted 
adduct 4.27. Reaction with led to the intermediate product 4.30. However in 
this instance 4.30 was purified successfully by radial silica chromatography 
without evident dehydration. Subsequent dissolution in acetonitrile and addition 
of concentrated hydrochloric acid resulted in aromatisation, giving the desired 
product 4.33. 
In the light of the above observations, the ethyl substituted adduct 4.28 was 
aromatised by a more direct route. This involved treatment of 4.28 directly with 
concentrated hydrochloric acid to give the aromatised product 4.34. 
Diels-Alder reactions of this type were observed to work more efficiently when 
an alkyl or aryl group was introduced at the 3-position of the isobenzofuran. 
Diels-Alder adducts so formed were able to be converted, through acid-catalysed 
bridge cleavage and dehydration, to their corresponding planar, aromatic forms. 
An example of incorporating a leaving group at the 3-position of these 
isobenzofurans is described in the following section. 
4.6 'R' as a Leaving Group 
The introduction of a leaving group into such Diels-Alder adducts offers the 
possibility of an alternative route to aromatisation.29 The phenylsulfanyl group 
was chosen as the leaving group for this study. Fig. 4.6.1 shows how this was 
incorporated into a Diels-Alder adduct via the isobenzofuran diene. 
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1} XS LDA 
2} PhSCI 
3} Mel 
Fig. 4.6.1 
The in situ preparation of the isobenzofuran 4.35 from its precursor 2.5 was 
carried out in the presence of an excess of LDA. This deprotonates the thione at 
the 3 position and lithiates the furan ring. Reaction with phenylsulfenyl chloride 
followed by alkylation thus gave rise to the disulfanyl-substituted isobenzofuran 
4.35. This was immediately trapped with dimethyl fumarate in Diels-Alder 
fashion to give the adduct 4.36 in one isomeric form, identified as the 9-exo-l (}.. 
endo isomer by analogy with related adducts.67 This adduct was characterised in 
its mass spectrum by a peak at 416 mass units corresponding to the parent ion, as 
well as a peak at 307 mass units corresponding to the loss of the phenylsulfanyl 
group. 
However, the modifications made to this reaction sequence resulted in lowering 
the yield of the Diels-Alder adduct from 57%, in the 3-hydrogen-substituted case, 
to below 1%. This substantial drop in efficiency makes the route unsuitable for 
more complex Diels-Alder chemistry and so these studies were not pursued 
further. 
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4 .. 7 Extending the Ring System 
Optimum intercalation of an intercalating agent requires the presence of three 
or more fused coplanar rings. The Diels-Alder adducts and their corresponding 
aromatised products considered thus far have been designed with a tricyclic 
chromophore in mind. This section explores the possibility of varying the R' 
substituent so as to extend the system to four rings (cf. Fig. 4.3.1). 
The isonaphthofuranthiones 2.22 and 2.25 were treated with LDA and methyl 
iodide, as shown in Fig. 4.7 .1~ to prepare the tricyclic dienes, 4.37 and 4.38 
respectively, in situ. 
S 
~o 
R 
2.22 R=H 
2.25 R=Ph 
1) LDA 
--- - ........ 
2) CH31 
, 
a '''', 
4.37 R=H 
4.38 R=Ph 
GN-{ )""'" SCH30 
H o 
Fig. 4.7.1 
4.39 R=H 
4.40 R=Ph 
N-Q 
Since the isonaphthofurans 4.37 and 4.38 are less aromatic in nature than the 
corresponding isobenzofurans, they would be expected to be more reactive than 
the corresponding isobenzofurans. Attempts to trap 4.37 or 4.38 with the 
dienophile N-phenyl maleimide however, were unsuccessful. Neither of the 
desired Diels-Alder adducts, 4.39 or 4.40 respectively, could be isolated. 
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A similar result was observed when the quinoline-containing furanthione 2.34 
was used as the starting material as outlined in Fig. 4.7.2. 
1) LDA 
2.34 4.41 
o , 
~-i ~/'/ 
o ",'" ' 
N-i > 
o 
Fig. 4.7.2 
I 
I 
I 
I 
: dimethyl fumarate 
I 
Attempts were made to trap the intermediate 4.41 with N-phenyl maleimide 
and dimethyl fumarate. However, again, neither of the desired Diels-Alder 
adducts, 4.42 or 4.43 respectively, were isolated. 
Consideration of these results caused us to refocus on adducts which would 
lead to a tricyclic chromophore. 
4.8 Modification of the Dienophile 
The survey of isobenzofurans and derivatives described in previous sections 
has shown the viability of their Diels-Alder chemistry with simple dienophiles. 
Attention is now focused on modification of the dienophi1e, particularly the 
possibility of incorporating nitrogen-based substituents. Nitrogen-based 
substituents may allow tuning of the biological activity of the products. Variations 
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in the dienophile were explored by adding functionality into the Diels-Alder 
adducts via the electron withdrawing groups (EWG). This section initially 
discusses the Diels-Alder reactions of fumaramides (4.8.1). The Diels-Alder 
reactions of N-aryl maleimides, and the chemistry of the resulting adducts, are 
then described (4.8.2). 
4.8.1 Fumaramides 
The first class of nitrogen-enriched dienophiles investigated was amide 
derivatives of fumaric acid. Chapter 3 described the synthesis of two such 
compounds; the fumaramides 3.5 and 3.6. 
The Diels-Alder reactions of 1-methylsulfanyl-isobenzofuran 4.16, and 1-
methylsulfanyl-3-phenyl-isobenzofuran 4.23 with 3.5 are shown in Fig. 4.8.1. 
[ O<:H3 ] _C_4H_9_H_N_O_C_~_~ __ C_O_N_H_C_4H_9_ 
4.16 R=H 
4.23 R=Ph 
Fig. 4.8.1 
R 
4.44 R=H 
4.45 R=Ph 
This resulted in the formation of the Diels-Alder adducts 4.44 and 4.45 
respectively, each of which was isolated in one isomeric form only, identified by 
analogy with related adducts.67 Adduct 4.44 was isolated in 20% yield, and 4.45 
in 25% yield. Both adducts gave rise to a characteristic pair of doublets in the 1 H 
NMR spectra; at 2.75 and 2.94ppm for 4.44, and 3.36 and 3.66ppm for 4.45. The 
mass spectra for these compounds showed peaks corresponding to the parent ions, 
at 389 mass units for 4.44, and 466 mass units for 4.45. 
64 
Chapter 4 Oxygen-Bridged Diels-Alder Adducts 
I-Methylsulfanyl-isobenzofuran 4.16, and I-methylsulfanyl-3-phenyl-
isobenzofuran 4.23 were likewise reacted in Diels-Alder fashion with the 
dienophile 3.6 as shown in Fig. 4.8.2. In neither of these cases could the expected 
Diels-Alder adducts, 4.46 or 4.47, be isolated. 
(H3CbN(H2CbHNOC ~CONH(CH2bN(CHs)2 
, 3.6 
4.16 R=H 
4.23 R==Ph 
Fig. 4.8.2 
There was a lack of success in introducing further functionality into such 
amides and so these studies were not pursued further. 
4.8.2 N-Aryl maleimides 
N-Phenyl maleimide had proved to be a very effective dienophile for reaction 
with 3-substituted isobenzofurans. The possibility of using N-aryl maleimides to 
introduce additional functionality into our Diels-Alder adducts was thus explored 
further. In particular we were interested in introducing a range of nitrogen-based 
substituents at the artha and 11'leta positions of the phenyl ring. Substituents at 
these positions can provide the base for functional groups to interact with the 
grooves of DNA (cf. Fig. 5.1.1). 
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An exploratory Diels-Alder reaction, performed using a nitro-derivative of N-
phenyl maleimide, is shown in Fig. 4.8.3. I-Methylsulfanyl-3-phenyl-
isobenzofuran 4.23 was here trapped with N-(3-nitrophenyl) maleimide 3.23 to 
give the adduct 4.48. Only the endo stereoisomer was isolated. The 1H NMR 
spectrum of 4.48 contained resonances at 4.00 and 4.25ppm, corresponding to the 
bridgehead protons. Its mass spectrum was characterised by a peak at 458 mass 
units, corresponding to the parent ion, and a peak at 412 mass units, corresponding 
to loss of the nitro group. 
4.23 
Fig. 4.8.3 
The successful formation of 4.48 is encouraging for the synthesis of substituted 
Diels-Alder adducts. It would be possible to modify the nitro-substituent of 4.48 
to generate functional groups capable of binding in the groove of DNA. Instead 
though, we decided to explore Diels-Alder reactions with alternative 
functionalised N-aryl maleimides, as they open up a more convergent strategy for 
the synthesis of complex Diels-Alder adducts. This avenue of research was 
evaluated by introducing amide substituents to the N-phenyl maleimide skeleton, 
at either the ortho or meta position. 
The ortho-substituted N-phenyl maleimide derivative 3.29 was prepared as 
described as in Chapter 3 and used to trap both I-methylsulfanyl-3-phenyl-
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isobenzofuran 4.23 and l-methylsulfanyl-3-methyl-isobenzofuran 4.24 as shown 
in Fig. 4.8.4. In each case, isomeric pairs of products, 4.49,4.51 and 4.50,4.52 
respectively, were obtained (cf. Fig. 4.8.6). 
4.23 R=Ph 
4.24 R=Me 
4.49 R=Ph 
4.50 R=Me 
4.51 R=Ph 
4.52 R=Me 
Fig. 4.8.4 
o 
SCH }-CH3 
3 0 HN oitN~ > 
RHO 
o 
+ SCH3 }-CH3 
.~HN 0+hN~ > 
RHo 
Likewise, the meta-substituted N-phenyl maleimide derivative 3.28 was used to 
trap both I-methylsulfanyl-3-phenyl-isobenzofuran 4.23 and I-methylsulfanyl-3-
methyl-isobenzofuran 4.24 as shown in Fig. 4.8.5. Once again, isomeric pairs of 
products, 4.53,4.55 and 4.54, 4.56 respectively, were obtained (cf. Fig. 4.8.6). 
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4.23 R""Ph 
4.24 R=Me o 
3.28 H c-f(° 
4.53 R=Ph ~N 'MNH 
4.54R:::Me ~ 
RHO 0 
+ SCH H3C-f( ~30 NH 4.55 R=Ph I ~ 0 ~::: N---\) 4.56 R=Me // RHO 
Fig. 4.8.5 
The mass spectra for this series of ortho and meta acetamido-substituted Diels-
Alder adducts were characterised by the presence of a parent ion, at 470 mass 
units in the case of 3-phenyl-substitution and 408 mass units in the case of 3-
methyl-substitution, along with an ion at 42 mass units lower, corresponding to 
loss of the acyl group. Their 1 H NMR spectra were characterised by a pair of 
doublet resonances at around 4ppm corresponding to the two bridgehead protons. 
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Diels-Alder Adducts 
Fig. 4.8.6 
Isomeric Ratio 
(Combined % Yield) 
2.4: 1 
(64%) 
24: 1 
(27%) 
43: 1 
(13%) 
11 : 1 
(14%) 
Fig. 4.8.6 shows the isomeric ratios obtained for this series of reactions, along 
with the combined percentage yields for both isomers. In each case the endo 
isomer predominated over the exo, although the diastereoselectivity showed 
substantial variation. 
4.8.3 Bridge Cleavage 
The acetamido-substituted Diels-Alder adducts described in Section 4.8.2 were 
bridge cleaved and aromatised directly, by dissolving in acetonitrile, adding 
concentrated hydrochloric acid, and stirring at room temperature. 
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Fig. 4.8.7 
Bridge cleavage of the ortho-substituted adducts is shown in Fig. 4.8.7. In the 
phenyl case, which was stirred for two days, only one product was observed: the 
expected aromatic product 4.57. However, upon the extended acid treatment 
required in the methyl case (five days), two products were observed, the expected 
aromatic product 4.58 and the additional aromatic compound 4.59, where the 
amide had been hydrolysed to give an amine. The 1 H NMR spectrum of 4.58 
contained a resonance at 2.08ppm corresponding to the acetamido-methyl group. 
This resonance was absent in the IH NMR spectrum of 4.59. The mass spectrum 
of 4.58 was characterised by a peak at 390 mass units, corresponding to the parent 
ion, and another peak at 348 mass units, corresponding to loss of the acetyl group. 
In the case of 4.59, the mass spectrum also contained a peak at 348 mass units, in 
this case corresponding to the parent ion. 
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Fig. 4.8.8 
R:::Ph 
R=Me 
R=Ph 
R=Me 
In the meta-substituted cases, amide hydrolysis competed with aromatisation in 
each case, as shown in Fig, 4.8.8 .. The pairs of products were: 4.60 and 4.62 for 
the phenyl case, and 4.61 and 4.63 for the methyl case. These corresponded to the 
expected aromatic product and the amine derivative, formed via amide hydrolysis. 
The 1 H NMR spectra of the acetamido-substituted products, 4.60 and 4.61, each 
contained a resonance corresponding to the acetamido methyl group, at 2.15 and 
2.18ppm respectively. These resonances were absent in the corresponding IH 
NMR spectra of 4.62 and 4.63, indicative of amide hydrolysis. The mass spectra 
of 4.60 and 4.61 contained peaks corresponding to the parent ions, at 452 and 390 
mass units respectively, along with peaks at 410 and 348 mass units respectively, 
corresponding to loss of the acetyl group. The mass spectra of 4.62 and 4.63 also 
contained peaks at 410 and 348 mass units respectively, in this case corresponding 
to the parent ions. 
This work has demonstrated the viability of synthesising Diels-Alder adducts 
from amide derivatives of N-phenyl maleimide. Extension of this work into more 
highly functionalised derivatives is covered in Chapter 5. 
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4.9 Addition of a Trigger 
Having established that functional groups could be introduced into Diels-Alder 
adducts, it was decided to evaluate whether aromatisation could be triggered 
remotely by incorporation of a suitable sulfur-based substituent. This section, 
therefore, explores the possibility of adding a trigger to our Diels-Alder adducts by 
variation of R" (cf. Fig. 4.3.1). The term 'trigger' refers, in this case, to a chemical 
moiety which can induce bridge cleavage. 
An example of such a trigger would be a group which allowed the non-planar 
bridged adduct to be selectively converted to the corresponding planar form in the 
reducing conditions of an hypoxic tumour cell. One such bioreductive trigger is 
shown in Fig. 4.9.1. 
4.64 4.65 
Fig. 4.9.1 
Cleavage.. HS~ 
R 
4.66 
Reduction of the nitro moiety in the prodrug 4.64 to an amine moiety in 4.65 
leads to cleavage of the sulfur-carbon bond to give 4.66 as shown, with subsequent 
conversion of the compound to its active dntg form. 
The model trigger chosen for this work was an analogue of this process. A 
benzyl acetate moiety was introduced into the Diels-Alder adduct via 4-
chlorometh y I phen y I acetate. 
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H3C)= 
srO-o 0 G/0~ 
c¢r~ _e_st_er_c_le_av_a_ge_ c¢ri 
R R 
SH 
~X ~i 
R 
Fig. 4.9.2 Proposed mode of activation 
The basic mode of activation proposed for this class of compound is outlined in 
Fig. 4.9.2. Cleavage of the ester leads to cleavage of the carbon-sulfur bond 
through a quinomethide intermediate. The thiolate anion thus produced is 
unstable and collapses to give the active planar aromatic compound.? 1 
0 
OH OH O)lCH3 ¢ LiBH4 ~ acetyl chloride ~ .. CHO OH CI 
4.67 4.68 4.69 
Fig. 4.9.3 
4-Chloromethylphenyl acetate 4.69 was synthesised as the precursor to such a 
trigger, as shown in Fig. 4.9.3. Reduction of 4-hydroxybenzaldehyde 4.67 using 
lithium borohydride gave 4-hydroxybenzyl alcohol 4.68.29 Reaction with acetyl 
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chloride converted 4.68 to 4-chloromethylphenyl acetate 4.69, which was purified 
by distillation under reduced pressure. 72 
s 
cQ 1) LOA I = 0 ---------/'/ 2) 4-chloromethylphenyl acetate 
Ph 
2.9 4.70 
Fig. 4.9.4 
This triggering moiety was introduced into a Diels-Alder adduct as shown in 
Fig. 4.9.4. 3-Phenyl-l(3H)-isobenzofuranthione 2.9 was deprotonated with LDA 
and alkylated with 4-chloromethylphenyl acetate to generate the isobenzofuran 
4.70. This was trapped in situ with N-phenyl maleimide to give the desired Diels-
Alder adduct 4.71, as a single diastereoisomer. This was identified as the endo 
isomer by analogy with related adducts. The lH NMR spectrum of 4.71 showed 
characteristic doublet resonances at 3.96 and 4.l6ppm corresponding to the 
bridgehead protons. It also contained a characteristic singlet resonance at 
2.30ppm, corresponding to the methyl group. The mass spectrum of 4.71 was 
characterised by a peak at 547 mass units, corresponding to the parent ion. 
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H3
C>= 
s,-Q--o ° 
~ -0 NaHCO,l II ~-o N '" -~ -------~N ~ II 
Ph H 0 Ph 0 
4.71 4.72 
Fig. 4.9.5 
Bridge cleavage of 4.71 was performed by base hydrolysis as shown in Fig. 
4.9.5. The Diels-Alder adduct 4.71 was refluxed in methanol with sodium 
bicarbonate. This resulted in cleavage of the bridge and subsequent dehydration to 
give the aromatic product 4.72. No intennediate product was observed. The 1H 
NMR spectrum of 4.72 was characterised by the absence of the two bridgehead 
proton doublet resonances, at 3.96 and 4.16ppm, found for 4.71. The singlet 
resonance at 2.30ppm, characteristic of 4.71, was also absent. The mass spectrum 
of 4.72 was characterised by a peak at 381 mass units, corresponding to the parent 
ion. 
It was thus demonstrated that remote activation of such a system can lead to 
aromatisation, as required for our prodrug strategy. 
4.10 Summary 
A wide range of Diels-Alder chemistry was described in this chapter. 1-
Methylsulfanyl isobenzofuran was reacted with a range of simple dienophiles, in 
particular dimethyl fumarate, dimethyl acetylenedicarboxylate, and N-phenyl 
maleimide. This isobenzofuran proved unsuitable for use with N-aryl maleimides, 
the dienophiles under particular scrutiny in this thesis. Therefore the Diels-Alder 
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chemistry of 3-substituted isobenzofurans with N-phenyl maleimide was explored, 
resulting successfully in a range of adducts. The introduction of a leaving group 
into such adducts was also demonstrated, offering the possibility of an additional 
pathway to aromatisation. When the ring system of the diene was extended, no 
Diels-Alder adducts could be isolated. 
The Diels-Alder chemistry of functionalised dienophiles was also described. 
Diels-Alder adducts were successfully synthesised from the reaction of 
fumaramides with isobenzofurans. It was demonstrated that functionality could be 
introduced into Diels-Alder ad ducts via substituents on the phenyl ring of N-aryl 
maleimides. It was also demonstrated that aromatisation of Diels-Alder adducts 
could be triggered remotely by the introduction of a suitable sulfur-based 
substituent. 
76 
DIELS-ALDER APPROACHES 
TO ANTI·CANCER PRODRUGS 
art A: 
Model Investigations 
Conclusion 
A model system for the synthesis of Diels-Alder adducts as 
prodrugs for anti-cancer agents was successfully developed by the 
systematic variation of adduct substituents. This system was 
successful for a range of isobenzofurans, and was flexible, allowing 
the introduction of a range of functionality via the dienophile. 
However, in some cases the limited stability of the oxygen bridge 
presented difficulties. There was also the need to introduce biological 
functionality into these adducts. Part B addresses these issues. 
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TO ANTI-CANCER PRODRUGS 
art B: 
o ards Biologically 
ctive rodrugs 
Introduction 
Based on the model system developed in Part A, Part B describes 
the extension of this system towards biologically active prodrugs for 
anti-cancer agents. Chapter 5 describes the introduction of biological 
functionality into Diels-Alder adducts via the dienophile. Chapter 6 
describes the introduction of a sulfur bridge into such adducts. 
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Chapter 
OXYGEN-B DGED DIELS-
ALDER ADDUCTS 2 
5.1 Introduction 
This chapter concerns the synthesis of dienophiles with functionality that could 
promote binding to DNA, either reversibly or irreversibly. The evaluation of the 
Diels-Alder reactivity of these dienophiles with isobenzofurans is then described. 
For a prodrug of an intercalator to be efficiently transported throughout the 
body and permeate a solid tumour via diffusion, a low DNA binding affinity is 
important. This is counterbalanced with the need for the drug itself to have a high 
DNA binding affinity, thereby increasing its toxicity. The compounds in this 
chapter were designed to address both these factors. Our basic design concept was 
to incorporate further functionality into the model systems developed in Part A, 
leading to non-planar prodrugs with low DNA binding affinity, but where 
aromatised derivatives have the potential for high DNA binding affinity. 
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DNA Nucleophllic Sites 
~ Nu'"'''' ""'" """,X Tail 
NUIIIIIII ...... H-) / 
DI\lA base pairs---- ***************************** o 
Intercalated 
Chromophore 
***************************** 
Fig. 5.1.1 
Fig. 5.1.1 illustrates this concept, showing diagramatically the intercalation of a 
planar chromophore between base-pairs of DNA. At the same time the 'tail' of the 
intercalating agent is able to stabilise the intercalation through hydrogen-bonding, 
or alkylation, with nucleophilic sites in a groove of the DNA. DNA is rich in 
nucleophilic sites, such as the phosphate backbone or heteroatoms in the DNA 
base pairs. 
Examples of functional groups (X) which could participate in hydrogen-
bonding are shown in Fig. 5.1.2. The presence of ammonium substituents is 
important for the action of many intercalating agents. 
G HNO I~ 
Fig. 5.1.2 
In N-aryl maleimides, the ortho and meta positions are both sites at which 
appropriately oriented electrophilic moieties could be incorporated via an amide 
bond. A schematic analysis of the geometries of these options is presented in Fig. 
5.1.3. 
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R )=0 
I\lu"" ''''H-N +~) 
altho substituted 
Fig. 5.1.3 
R 
Nu"" ""H-N' 
+\ >=0 
meta substituted 
Here it can be seen that a protonated nitrogen centre pointing back towards the 
DNA strand, and therefore potentially able to participate in hydrogen-bonding, can 
result from direct linkage of the amine at the ortho position, or via a carboxyl 
group at the meta position. These considerations were taken into account in the 
design and synthesis of the compounds presented in this chapter. 
Intercalation with a nucleophilic site on DNA can be either non-covalent, as in 
the case of hydrogen-bonding, or covalent, as in the case of alkylating agents. 
5.2 Addition of an Alkylating Group 
In anti-tumour chemistry, the term 'alkylating agent' refers to a drug whose 
mode of action is the covalent bonding of an alkyl group to cellular molecules,?3 
Such alkylating agents have played a vital role in the progress of cancer 
chemotherapy. In fact the nitrogen mustards were the first non-hormonal agents to 
show significant anti-tumour activity in humans,?4,75,76 Fig. 5.2.1 shows the 
general structure of the nitrogen mustards. 
~CI 
R-N 
~CI 
Fig. 5.2.1 
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The proposed mechanism of alkylation by the nitrogen mustards is shown in 
Fig. 5.2.2. 
,CH2CH2CI R ,CH2CH2CI R2NH ,CH2CH2CI 
R-N ----- 'I'lCB -------" R-I'l 
'CH2CH2CI D 'CH2CH2NHR2 
R3NH 
,CH2CH2NHR3 \7 
R-N ..... ----- R-NCB 
'CH2CH2NHR2 'CH2CH2NHR2 
Fig. 5.2.2 
The processis triggered by the' initial loss of chloride, which results in the ~-
carbon reacting with the internal nitrogen atom, forming a cyclic, highly reactive 
aziridinium moiety. Such a moiety can react with a nucleophilic centre in DNA, 
resulting in alkylation. In the case of the nitrogen mustards, this process can be 
repeated, resulting in DNA cross-linking. 
We wished to incorporate the potential for alkylation into our N-aryl maleimide 
based dienophile system, via an amide linker. Acylation of 2-nitroaniline 5.1 with 
chloroacetyl chloride and bromoacetyl bromide was carried out as shown in Fig. 
5.2.3, to give 5.2 and 5.3 respectively. 
5.1 
Fig. 5.2.3 
5.2 X=CI 
5.3 X=Br 
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Fig. 5.2.4 shows the similar reactions which were repeated starting with 3-
nitroaniline 5.4 to give the products 5.5 and 5.6. All these acylation reactions 
proceeded smoothly and in quantitative yield. 
(Yf\IH2 Y ----
N02 
5.4 
Fig. 5.2.4 
H (YNI("'X yo 
N02 
5.5 X=CI 
5.6 X=Br 
Reduction of the nitro groups to amino groups proved complicated. This was 
attempted via hydrogenation, catalysed by palladium-on-carbon. This had been 
found to be effective for other nitrobenzene derivatives. In the bromo-substituted 
cases, 5.3 and 5.6, these reducing conditions were found to result in loss of the 
bromo-substituent. In the case of 5.5 also, with a meta-substituted chloro-
substituent, the desired product was not isolated. In this case two products were 
isolated. Each of these had undergone reductive cleavage of the carbon-halogen 
bond. They differed in that one product, 3.11, retained an intact nitro group, 
whereas the other, 3.12, was an amine. This reaction is shown in Fig. 5.2.5. 
H 
(Y~ NrfCI Y 0 H2/ Pd-on-C 
N02 
5.5 
Fig. 5.2.5 
H 
(YNi(CH3 yo 
1\102 3.11 
H 
(YNi(CH3 yo 
NH2 3.12 
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The observed products, 3.11 and 3.12, were easily identified as both 
compounds had been synthesised earlier. This product distribution showed that 
side-chain reduction was more facile than reduction of the nitro group in 5.5. 
Investigations into the meta-substituted cases were discontinued due to the 
complexities of reaction and the fact that this system is not optimally aligned for 
interaction with DNA. 
In the case of the ortho-substituted 5.2 however the hydrogenation proceeded 
smoothly, forming one product only, the desired amine 5.7 as shown in Fig. 5.2.6. 
H 
tCCN~CI __ H_2_I_P_d_-o_n-_c _____ .. 
N02 
5.2 5.7 
Fig. 5.2.6 
As such amine compounds are known to decompose on prolonged storage, 5.7 
was immediately used as the starting material in the reaction with maleic 
anhydride outlined in Fig. 5.2.7. 
0 CI 
H c: >=0 ONIf'CI '~b 0 ~ NH~ 
0 
5.7 5.B 
Fig. 5.2.7 
This reaction, the introduction of an amine into the maleic skeleton, is 
analogous to the synthesis of N-phenyl maleimide as discussed earlier in this 
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thesis. The result was the desired product N - ( 2-
chloroacetylaminophenyl)maleimide 5.8, whose 1 H NMR spectrum had the 
characteristic sharp singlet at 6.94ppm corresponding to the two equivalent 
male imide protons. 
N-(2-chloroacetylaminophenyl)maleimide 5.8 was now available for use as a 
dienophile in further Diels-Alder chemistry. 
5.3 Diels Alder Reactions of N-(2-
chloroacetylaminophenyl)maleimide 
This section describes the incQrporation of a potential alkylating moiety into 
Diels-Alder adducts and the bridge cleavage of the resulting adducts. 
5.3.1 Diels-Alder Reactions 
N-(2-chloroacetylaminophenyl)maleimide 5.8 was used to trap 1 
methylsulfanyl-3-phenyl-isobenzofuran 4.23 and I-methylsulfanyl-3-methyl-
isobenzofuran 4.24 in Diels-Alder reactions as outlined in Fig. 5.3.1. Both of 
these reactions were successful in generating Diels-Alder adducts. In each case 
only a single stereoisomer was isolated, 5.9 and 5.10 respectively. Both of these 
adducts were assigned as endo isomers by comparison with analogous adducts. 
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4.23 R=Ph 
4.24 R=Me 
5.8 0 CI 
SCH30 }--I ~HN 
VmN-{ > 
Fig. 5.3.1 
RHO 
5.9 R=Ph 
5.10 R=Me 
The 1 H NMR spectrum of the 3-phenyl-substituted adduct 5.9 contained a 
characteristic pair of doublets at 4.08ppm and 4.27ppm corresponding to the two 
bridgehead protons. A two proton singlet at 3.73ppm corresponding to the 
chloromethyl group showed that the chloroacetamide portion of the dienophile had 
remained intact in the reaction. This was further confirmed by the mass spectrum 
which included a peak at 520.1 mass units corresponding to the parent ion as well 
as a peak at 473.1 mass units corresponding to loss of the chloromethyl group. 
The pattern of fragmentation around these peaks was consistent with the loss of 
chlorine, showing the characteristic pattern expected due to the two isotopes 35Cl 
and 37CL 
The 3-methyl-substituted adduct 5.10 also gave rise to a characteristic pair of 
doublets in its IH NMR spectrum at 3.10ppm and 3.23ppm corresponding to the 
bridgehead protons. Once more a two proton singlet at 3.83ppm confirmed the 
presence of the chloroacetamide substituent, and a singlet resonance due to the 3-
methyl group was observed at 2.02ppm. The mass spectrum of 5.10 was 
analogous to that for the 3-phenyl-substituted 5.9, containing a parent ion at 442 
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mass units along with a peak at 395 mass units corresponding to loss of the 
chloromethyl group. 
5.3.2 Aromatisation 
The Diels-Alder adducts 5.9 and 5.10 were aromatised by treatment of a 
dichloromethane solution with trifluoroacetic acid (TFA) as shown in Fig. 5.3.2. 
o CI 
SCH3 }-I 
~N~) 
RHo 
5.9 R=Ph 
5.10 R=Me 
Fig. 5.3.2 
0}-lCI 
~-bHN 
.~N ~;) 
R ° 
5.11 R=Ph 
5.12 R=Me 
This resulted in the direct formation of the desired aromatised derivatives 5.11 
and 5.12 respectively, although traces of the intermediate 3-hydroxy substituted 
compounds were also observed. 
The characteristics of these two aromatised products were an absence of the 
doublet pairs which occurred between 3.0 and 4.5ppm in the 1 H NMR spectra of 
the bridged adducts, along with shifts in the aryl proton peaks, and mass spectra 
containing a parent ion along with peaks corresponding to the loss of Cl, CH3C1, 
and CaCHCl fragments. 
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5.3.3 Biological Testing 
In vitro P388 anti-tumour biological testing of these compounds (see 
Appendix) gave interesting results. An effective prodrug requires the potency of 
the prodrug to be low relative to the potency of the drug itself. The 3-phenyl-
substituted adduct 5.9 gave an IDSO value of 1.26)lg/rnL. As expected from steric 
considerations, the 3-methyl-substituted adduct 5.10 gave a lower result, an 
encouraging 0.42)lg/mL. Contrary to expectation however, the corresponding 
bridge-opened planar compounds 5.11 and 5.12 displayed higher IDSO values, 
3.03 and 2.S21lg/rnL respectively. This could indicate that the oxygen-bridged 
adducts are more easily taken up by the tumour cells, and are perhaps being 
bridge-opened to their planar forms in situ. This possibility led to the synthesis 
and anti-tumour testing of more stable sulfur-bridged adducts, as described in 
Chapter 6. 
5.3.4 Summary 
Several Diels-Alder adducts and their aromatised derivatives were synthesised 
with the chloroacetamide functionality introduced at the ortho position of the N-
aryl group. These compounds displayed intriguing anti-tumour activity in vitro. 
5.4 Dienophiles with Hydrogen-Bonding 
Functionality 
We also undertook the synthesis of dienophiles capable of hydrogen-bonding 
with nucleophilic sites in DNA. This required the introduction of hydrogen-
bonding moieties into N-aryl maleimide based dienophiles. A convergent 
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synthetic approach was used, with N-(3-carboxyphenyl) maleimide 5.13 chosen as 
the general starting compound for a series of coupling reactions. 
5.4.1 shows the synthesis of 5.13 from maleic anhydride and 3-amino 
benzoic acid, in a preparation analogous to that for N-phenyl maleirnide. This 
reaction proceeded smoothly, giving 5.13 in 90% yield. 
~o 3-aminobenzoic acid ~ A C02H --------------~ ~N~ 
° ° 5.13 
Fig. 5.4.1 
The synthesis of amide derivatives of 5.13 was accomplished by direct 
coupling of an amine and this carboxylic acid. This coupling was brought about 
by the use of dicyclohexylcarbodiimide (DeC). The proposed general mechanism 
of this reaction is illustrated in Fig. 5.4.2.77 
\i~Q-Q 
o-N=C=N-Q _R_C_O_O_H--.. RtO-C~N-Q 
H-N-H 
12 R 
° II R-C-N-R2 + 
H 
Fig. 5.4.2 Proposed mechanism of Dee coupling reaction 
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The reaction commences with the acylation of DCC by the carboxylic acid, 
thereby activating it for nucleophilic attack. The amine, present also in the 
reaction mixture, attacks as the nucleophile, displacing the DCC and forming a 
peptide bond in the process. The products are N,N'-dicyclohexylurea (DCU) and 
an amide. 
The use of I-hydroxybenzotriazole (HOBt) as a catalyst in the reaction 
generally enhances the efficiency and specificity of the coupling by intercepting 
the acyl urea and forming a highly reactive 0 -acyl-l-hydroxybenzotriazole 
intermediate. 
o C02H ~ ;==( ethanolamine 
~N~ DCC! HOBt 
o 
5.13 
Fig. 5.4.3 
OH 
o ~ 
o JNH 
<N-o-I; 
o 
5.14 
The coupling reaction of 5.13 with ethanolamine using DCC and HOBt is 
outlined in Fig. 5.4.3. This resulted in the formation of the corresponding N-aryl 
maleimide compound 5.14. The 1 H NMR spectrum of 5.14 was characterised by 
a singlet at 6.87ppm corresponding to the two maleimide protons, which indicated 
that the maleimide ring had remained intact in the coupling process. MUltiplet 
resonances at 3.46ppm and 3.63ppm corresponding to the ethanolic moiety 
indicated that the coupling had been successful. 
Compound 5.14 had to be used immediately as a dienophile, as it was found to 
decompose rapidly. The maleimide ring fragmented upon storage, as indicated in 
the 1 H NMR spectrum by the appearance of two doublet resonances, in place of 
the singlet at 6.87ppm. 
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o C02H 
r1<N M N,N-dimethylethylene diamine. ~ ~ DCC! HOSt 
o o 
5.13 5.15 
Fig. 5.4.4 
The next coupling reaction involved the introduction of a dimethylamino-
substituted side chain. This is shown in Fig. 5.4.4. In this reaction the carboxylic 
acid 5.13 was coupled to N,N-dimethylethylene diamine to give as the product N-
3-(2-aza-4-dimeth y lamino-l-oxobutany I )pheny I maleirnide 5.15. This N -ary 1 
maleimide derivative was characterised in the IH NMR spectrum by a singlet at 
6.84ppm corresponding to the two maleimide protons. Once more, relatively 
rapid decomposition involving maleimide ring opening was observed on storage, 
and 5.15 was used immediately in Diels-Alder chemistry. 
In analogy of systems with strong DNA affinity synthesised by Dervan et al., 
this system was further extended by the addition of an extra linking section, as 
shown in 5.4.5.61 3-Aminobenzoic acid 5.16 was first coupled with N,N-
dimethylethylene diamine to give the amine 5.17. In turn this was coupled to N-
(3-carboxyphenyl) maleimide 5.13 to give the N-aryl maleimide 5.18, which 
contained a characteristic maleimide singlet at 6.85ppm in its 1 H NMR spectrum. 
However this N-aryl maleimide was found to decompose very rapidly, and as a 
consequence, it was not used in Diels-Alder chemistry. 
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92 
C02H A- N,N-dimethylethylene diamine V DCC/HOBt ' 
NH2 
5.16 
DCC! HOBt 
5.13 
Fig. 5.4.5 
Once more with the aim of enhancing hydrogen-bonding interactions with 
DNA, a pyridyl moiety was introduced into the system. Fig. 5.4.6 outlines this 
synthesis. 
<
0 -OC02H 2-aminopyridine 
I N \ I: 
\\ II DCC! HOBt 
o 
5.13 5.19 
Fig. 5.4.6 
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N-(3-Carboxyphenyl) male imide 5.13 was coupled to 2-aminopyridine to give 
the N-aryl maleimide 5.19, with a characteristic singlet corresponding to its two 
maleimide protons at 6.93ppm in the 1 H NMR spectrum. As with the related 
compounds already mentioned, 5.19 decomposed on storage and was used 
immediately as a dienophile in subsequent Diels-Alder chemistry. 
5.5 Diels-Alder Chemistry of Functionalised 
Dienophiles 
This section describes the Diels-Alder chemistry of functionalised dienophiles 
detailed in Section 5.4, along with the bridge cleavage and aromatisation of the 
resulting adducts. 
5.5.1 Diels-Alder Reactions 
The dienes 1-methylsulfanyl-3-phenyl-isobenzofuran 4.23 and 1-
methylsulfanyl-3-methyl-isobenzofuran 4.24 were prepared in situ and reacted 
with the freshly synthesised dienophile 5.14 as shown in Fig. 5.5.1. 
These Diels-Alder reactions gave the desired adducts 5.20 and 5.21 
respectively. The 1 H NMR spectrum of the 3-phenyl-substituted adduct 5.20 
included characteristic bridgehead proton doublet resonances at 4.01 and 4.27ppm, 
while those for the 3-methyl-substituted adduct 5.21 were at 3.08 and 3.21ppm. 
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o 5.14 OH 
o ~ SC~3 0 JNH ottN-o-tI 
RHO 
5.20 R=Ph 
5.21 R=Me 
Fig. 5.5.1 
The dienes 1-methylsulfanyl-3-phenyl-isobenzofuran 4.23 and 1-
methylsulfanyl-3-methyl-isobenzofuran 4.24 were also reacted in Diels-Alder 
fashion with the freshly synthesised dienophile 5.15, as shown in Fig. 5.5.2. In 
these instances the desired adducts, 5.22 or 5.23 respectively, could not be 
isolated. 
Fig. 5.5.2 
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In like manner I-methylsulfanyl-3-phenyl-isobenzofuran 4.23 and 1-
methylsulfanyl-3-methyl-isobenzofuran 4.24 were reacted in Diels-A1der fashion 
with the dienophile 5.19, as shown in Fig. 5.5.3. 
[o¢:Hl 0 NO R 0 JI\IH 
4.23 R=Ph rN-o 
4.24 R=Me ~ 
o 5.19 NP~ 
o -~ JNH 
Vft-t-o-jj 
RHo 
Fig. 5.5.3 
5.24 R=Ph 
5.25 R=Me 
These reactions were both stereospecific, leading to the formation of the 
desired adducts 5.24 and 5.25 respectively. Once again the presence of two 
bridgehead proton doublet resonances at around 4ppm in the 1 H spectra were 
indicative of Diels-Alder adduct formation. The mass spectra of these two adducts 
were characterised by the presence of only a very small parent ion peak but of a 
stronger peak corresponding to the loss of a C5H2N fragment. 
5.5.2 Bridge Cleavage 
The bridge cleavage and aromatisation of the Die1s-Alder adducts 5.20 and 
5.21 is shown in Fig. 5.5.4. The adducts were dissolved in dichloromethane and 
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trifluoroacetic acid added, resulting in cleavage of the bridge and formation of the 
aromatised products and 5.28 respectively. 
OH OH 
o ~ 0 ~ SC~3 0 JNH SCH30 JNH ~N-O ---=--=-~N-o-/; 
RHO HO RHO 5.26 R=Ph 
5.21 R=Me 
OH 
5.20 R=Ph I 
o ~ ~ J-NH 
Fig. 5.5.4 
~'A0t-o 
R 0 
5.27 R=Ph 
5.28 R=Me 
In the 3-phenyl case, the intermediate 3-hydroxy compound 5.26 was also 
observed, as evidenced by a singlet resonance at 4.10ppm in the IH NMR 
spectrum. Further stirring with trifluoroacetic acid resulted in the disappearance 
of this singlet, indicating that the 3-hydroxy compound had all been dehydrated to 
the aromatic derivative 5.27. Relative to their oxygen-bridged precursors, the 1 H 
NMR spectra of 5.27 and 5.28 were characterised by a downfield shift in the 
aromatic protons along with disappearance of the bridgehead proton doublet 
resonances. 
96 
Chapter 5 Oxygen-Bridged Diels-Alder Adducts 2 
NP~ 
° -SC~3 0-e-NH 
cxft"= - TFAI CH2CI2 a ° N ~ 0 • 
NP~ 
° -
SCH30-e-NH ~-~N ~o 
R H ° 
5.24 R=Ph 
5.25 R=Me 
R ° 
5.29 R=Ph 
5.30 R=Me 
Fig. 5.5.5 
Similarly the Diels-Alder adducts 5.24 and 5.25 were aromatised as shown in 
Fig. 5.5.5 to give the expected products 5.29 and 5.30 respectively. The mass 
spectrum of the 3-phenyl-substitut~d compound 5.29 contained a weak parent ion 
peak and two stronger peaks corresponding to the loss of C5H2N and C5H5N2 
fragments. The mass spectrum of the 3-methyl-substituted compound 5.30 on the 
other hand, contained a weak parent ion along with peaks corresponding to loss of 
C2H6S and C5H3N fragments. Once again, relative to their oxygen-bridged 
precursors, the 1 H NMR spectra of 5.29 and 5.30 showed a downfield shift in the 
aromatic protons and disappearance of the bridgehead proton doublets. 
5.5.3 Biological Testing 
The hydroxy-substituted adducts, 5.20 and 5.21, displayed moderate activity in 
the P388 biological assay, giving ID50 values of 2.27 and 8. 15 Ilg/mL respectively. 
However as with the alkylating products synthesised previously, the bridge-
opened planar aromatic compounds 5.27 and 5.28 displayed less activity than their 
relative precursors, giving 1D50 values of 34.60 and 51.00llg/mL respectively. 
The oxygen-bridged pyridine-substituted compounds, 5.24 and 5.25, both 
displayed moderate cytotoxic activity, giving 1D50 values of 10.99 and 4.991lg/mL 
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respectively. However once again, the bridge-opened planar aromatic compounds 
5.29 and 5.30 displayed less activity than their relative precursors, giving ID50 
values of >6.25 and 8.11~g/mL respectively. 
5.6 Conclusion 
A range of oxygen-bridged Diels-Alder adducts containing functional groups 
of interest were successfully synthesised. These included the synthesis of adducts 
with alkylating substituents, and adducts with groups capable of hydrogen-
bonding interactions with nucleophiles. These adducts were also successfully 
bridge-opened to give planar aromatic products with potential intercalating ability. 
Biological testing of compounds synthesised in this chapter gave intriguing 
results. Both those compounds containing a hydrogen-bonding functionality in the 
side chain and those containing an alkylating functionality showed significant 
activity. In these series, however, the bridged precursors were found to be more 
cytotoxic than the corresponding aromatic derivatives. This result directed 
attention to the preparation of Diels-Alder adducts with a more stable bridge. To 
this end, Chapter 6 deals with the synthesis of sulfur-bridged Diels-Alder adducts. 
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Chapter 6 
SULFUR-BRIDGED DIELS-
ALDE DDUCTS 
6.1 Introduction 
Stability is an important factor in the Diels-Alder chemistry of isobenzofurans. 
If an isobenzofuran is too unstable then it may decompose before it can be 
trapped by a dienophile. On the other hand if it is very stable it can be isolated, 
but may be less reactive as a diene.23 Another factor under consideration in this 
thesis is the stability of the bridge of Diels-Alder adducts resulting from reaction 
with dienophiles. This bridge must be stable enough to prevent spontaneous 
cleavage under biological conditions, which would lead to toxicity problems. If 
too stable however, then cleavage itself, and thereby activation of the drug, could 
present difficulties. 
The investigation of isobenzothiophene Diels-Alder chemistry presented in this 
chapter was undertaken in response to the search for an appropriate balance. 
Isobenzothiophenes are inherently more stable than the corresponding 
isobenzofurans. Sulfur-bridged Diels-Alder adducts, too, offer more stability than 
their oxygen-bridged counterparts. This chapter describes the evaluation of the 
THE LIBRARY 
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synthesis of such sulfur-bridged Diels-Alder adducts and their subsequent bridge 
cleavage. 
6.2 Isobenzothiophenethiones 
In order to explore the Diels-Alder chemistry of isobenzothiophenes it was 
first necessary to synthesise appropriate precursors. This section describes the 
synthesis of these precursors, isobenzothiophenethiones, which were used to 
generate the corresponding isobenzothiophenes. 
a 
cCo sodium ethoxide ~C02H ~ ~s~ benzyl mercaptan 
2.4 6.1 
polyphosphoric acid 
s 
toluene! ~ cCs Lawesson's reagent 
6.2 6.3 
Fig. 6.2.1 
Fig. 6.2.1 outlines the synthesis of 1 (3H)-isobenzothiophene-I-thione 6.3. 
(Benzylmercaptomethyl)benzoic acid 6.1 was generated by the nucleophilic 
attack of benzyl mercaptan on I (3H)-isobenzofuranone 2.4, and then cyclised to 
1 (3H)-isobenzothiophenone 6.2 using polyphosphoric acid. 78 The generation of 
6.2 from the starting material 2.4 was clearly evidenced by a change in the 
chemical shift of the benzylic protons from 5.35ppm in 2.4 to 4.48ppm in 6.2. 
Thionation using Lawesson's reagent was then performed in a manner analogous 
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to that used to generate isobenzofuranthiones, resulting in the formation of 1 (3H)-
isobenzothiophenethione 6.3 as desired. This was characterised by 1 H NMR 
spectroscopy, with a particularly distinctive singlet resonance observed at 
4.53ppm.79 
The synthesis of 3-phenyl-l(3H)-isobenzothiophene-l-thione 6.5 was 
accomplished in a single step as outlined in Fig. 6.2.2. 2-Benzoylbenzoic acid 6.4 
was thionated with Lawesson's reagent to give 3-phenyl-l(3H)-
isobenzothiophene-l-thione 6.5 directly. 79 
o 
~.I~ OH ~(Ph 
o 
6.4 
Lawesson's reagent (2 equiv.) 
toluene/ A 
Fig. 6.2.2 
s 
cQs 
Ph 
6.5 
The synthesis of 3-methyl-l(3H)-isobenzothiophene-l-thione was carried out 
in an analogous fashion to that of the phenyl-substituted case. This is outlined in 
Fig. 6.2.3. 
Lawesson's reagent (1 equiv.) 
toluene/ A 
Fig. 6.2.3 
6.7 
Treatment of 2-acetylbenzoic acid 6.6 with one equivalent of Lawesson's 
reagent under reflux in toluene gave the desired product 3-methyl-l(3H)-
isobenzothiophene-l-thione 6.7.79 The 1 H NMR spectrum included a doublet 
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resonance at 1.78ppm, and a quartet at 4.93ppm corresponding to the methyl 
group and the benzylic hydrogen respectively. 
The isobenzothiophenethiones 6.3, 6.5, and 6.7 were used to generate dienes 
for appropriate Diels-Alder chemistry. 
6.3 Sulfur .. Bridged Diels-Alder Adducts 
This section describes an investigation of the Diels-Alder chemistry of 
isobenzothiophenes with simple dienophiles, and the bridge cleavage of the 
resulting adducts. Section 6.4 discusses the extension of this Diels-Alder 
chemistry to functionalised dienopbiles. 
6.3.1 Diels-Alder Chemistry 
The synthesis of sulfur-bridged Diels-Alder adducts was initiated by 
evaluating the cycloaddition of I-methylsulfanyl-isobenzothiophene 6.8 with 
dimethyl fumarate, as shown in Fig. 6.3.1. The synthesis of the diene was carried 
out in an analogous fashion to the isobenzofuran syntheses developed earlier. 
s 
cCs 1 LDA 2) CH31 [ SCH31 c:r:s 6.8 
6.9 
Fig. 6.3.1 
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1 (3H)-Isobenzothiophenethione 6.3 was converted to I-methylsulfanyl-
isobenzothiophene 6.8 in situ using LDA and methyl iodide. This was then 
trapped with dimethyl fumarate, to give a mixture of two isomeric adducts, 6.9 
and 6.10, in 9% yield. The mass spectrum of this mixture was characterised by a 
peak corresponding to the parent ion at 324 mass units, along with a peak at 180 
mass units due to retro-Diels-Alder fragmentation. 
In the case of I-methylsulfanyl-isobenzofuran, trapping with N-phenyl 
maleimide was only effective when substituents were present at the 3-position of 
the diene. Such substitution restricts the opportunities for prodrug design and 
activation. We evaluated whether the enhanced stability of I-methylsulfanyl-
isobenzothiophene, relative to I-methylsulfanyl-isobenzofuran, would result in a 
successful Diels-Alder reaction with N-phenyl maleimide. This reaction is 
outlined in Fig. 6.3.2. 
o 
~N-o 
o 
SC~3 0 ~N--{ > 
H 0 
6.8 6.11 
Fig. 6.3.2 
The reaction resulted in the isolation of a single Diels-Alder adduct 6.11, in 
6% yield. This was identified as the endo isomer by its 1 H NMR spectrum, which 
contained a characteristic pair of doublet resonances at 3.25 and 3.57ppm. In 
adducts such as this, with no substitution at the 3-position of the diene, the exo 
isomer is characterised by a singlet resonance and a multiplet resonance 
corresponding to the bridgehead hydrogens, rather than two doublet resonances. 
o 
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~:H' 
~ 
CH3 
6.12 
o 
~N-o 
o 
SCH30 
ccftN-{ > + 
CH3 0 
6.14 
Fig. 6.3.3 
SCH30 
ccftN-{ > 
CH3H 0 
6.13 
The 3-methyl substituted isobenzothiophene 6.12 was likewise generated in 
situ and trapped with N-phenyl maleimide as shown in Fig. 6.3.3. In this case a 
pair of isomeric adducts, 6.13 and 6.14, was isolated, in 7% yield and in a 5 to 1 
ratio. The endo isomer 6.14 was identified as the major isomer by comparison 
with analogous adducts. The 1 H NMR spectrum included two pairs of doublet 
resonances corresponding to the bridgehead protons, at 4.07 and 4.23ppm for 
6.14, and 3.21 and 3.34ppm for 6.13. 
Section 6.3b describes the bridge cleavage of these sulfur-bridged Diels-Alder 
adducts. 
6.3.2 Bridge Cleavage 
The enhanced stability of the sulfur bridge requires a reagent other than TF A 
for bridge cleavage in the model system. The method chosen for bridge cleavage 
of these Diels-Alder adducts was mercuric acetate catalysed hydrolysis. The 
proposed mechanism for such a cleavage is outlined in Fig. 6.3.4. 
104 
Chapter 6 Sulfur-Bridged Diels-Alder Adducts 
6.16 
6.17 
Fig. 6.3.4 Proposed mechanism of bridge cleavage 
The large positively charged mercury ion can associate with the sulfur bridge, 
catalysing bridge cleavage to give 6.15. This may be followed by the loss of 
another hydrogen as shown to give the planar aromatic 6.16. Alternatively, the 
mercury cation may dissociate from the sulfur atom of 6.15, leading to the non-
planar product 6.17. 
o±tSC~3 :: C02CH3 I ""= S . mercuric acetate! MeOH .. h- '('CO CH H 2 3 
6.9,6.10 
Fig. 6.3.5 
Fig. 6.3.5 outlines the bridge cleavage of the isomeric mixture of 6.9 and 6.10 
with mercuric acetate, to give a dihydronaphthalene derivative 6.18. Both the lH 
NMR spectrum and mass spectrum of 6.18 were analogous to those of the 
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hydroxy-substituted product synthesised in previous work on oxygen-bridged 
Diels-Alder adducts. 
The N-phenyl maleimide derived Diels-Alder adduct 6.11 underwent an 
analogous elimination reaction on treatment with mercuric acetate, as shown in 
Fig. 6.3.6. 
SC~3 0 SCH30 ~I ~ -0 mercuric acetate/ MeOH ~I ~ ~ -0 ~N ~ /; .. ~N ~ /; 
H 0 SHH 0 
6.11 6.19 
Fig. 6.3.6 
The product was found to be 6.19, as evidenced in the 1 H NMR spectrum by 
loss of the two bridgehead hydrogen doublet resonances, and a strong shift 
downfield in the resonances of the aromatic protons relative to those of 6.11. A 
new singlet resonance was observed at 3.90ppm corresponding to the remaining 
bridgehead proton. Mass spectroscopy, using both electron impact (El) and fast 
atom bombardment (FAB) techniques, showed a peak corresponding to the parent 
ion at 353 mass units, as well as a peak at 317 mass units, corresponding to its 
aromatic derivative, formed by loss of SH2. 
SCH30 
cctt}-<> 
CH3 0 
mercuric acetate/ MeOH 
6.13,6.14 4.33 
Fig. 6.3.7 
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A different result was observed in the case of the analogous 3-methyl 
substituted Diels-Alder adducts 6.13 and 6.14, as shown in Fig. 6.3.7. In this case 
the product was identified by 1 H NMR as the aromatic derivative 4.33, which had 
been both synthesised and characterised in previous work on oxygen-bridged 
Diels-Alder adducts. This result, along with those of subsequent sulfur-bridge 
cleavage reactions, indicates that when alkyl substituents are present at the 3-
position, bridge cleavage by mercuric acetate catalysed hydrolysis leads to 
aromatisation. This parallels the situation observed in the oxygen-bridged 
adducts. 
6.3.3 Summary 
These Diels-Alder reactions of I-methylsulfanyl-isobenzothiophene and 1-
methylsulfanyl-3-methyl-isobenzothiophene demonstrated the feasibility of 
synthesising sulfur-bridged compounds in line with our model systems. Such 
isobenzothiophenes displayed more stability than their isobenzofuran 
counterparts, resulting in increased yields from Diels-Alder reactions. The sulfur 
bridge present in the Diels-Alder adducts themselves was also found to be more 
stable than analogous oxygen-bridged adducts. Two pathways were observed to 
be followed for bridge cleavage by mercuric acetate, with alkyl substitution at the 
3-position resulting in aromatisation. 
6.4 Functionalised Diels-Alder Adducts 
With the feasibility of synthesising sulfur-bridged Diels-Alder adducts 
demonstrated, we now wished to investigate the introduction of functional groups 
capable of interacting with DNA. This section describes the synthesis of such 
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adducts via functionalised dienophiles and the subsequent bridge cleavage of the 
resulting adducts. 
6.4.1 Introduction of Hydrogen-Bonding Functional Groups 
Electrophilic moieties attached to an intercalator are capable of hydrogen-
bonding interactions with nucleophilic sites in DNA. This section explores the 
introduction of such functionalities into sulfur-bridged Diels-Alder adducts via 
the dienophile. 
In the case of isobenzofurans, Diels-Alder chemistry had proceeded most 
smoothly with phenyl substitution ,at the 3 position, likely due to enhanced diene 
stability. It was hoped that use of the corresponding 3-phenyl substituted 
isobenzothiophene would, likewise, result in successful Diels-Alder reactions 
with functionalised dienophiles. 
Rather than prepare this diene in situ, 1-methylsulfanyl-3-phenyl-
isobenzothiophene 6.20 was sufficiently stable to be isolated and purified prior to 
investigation of its Diels-Alder chemistry.80 3-Phenyl-1(3H)-isobenzothiophene-
I-thione 6.5 was converted to 6.20 as shown in Fig. 6.4.1. 
s C<:H' CC;s 1) LDA 
2) CH31 ~ :::-..... 
Ph Ph 
6.5 6.20 
Fig. 6.4.1 
I-Methylsulfanyl-3-phenyl-isobenzothiophene 6.20 was reacted with the 
hydroxy-substituted dienophile 5.16, as outlined in Fig. 6.4.2. 
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OH 
~:H3 
~ 
6.20 Ph 
o ~ ~N-oNH 
o 5.16 OH 
o ~ SC~3 0 JNH Q:ffiN-o-IJ 
Ph
H 
0 6.21 
Fig. 6.4.2 
This resulted in formation of the desired adduct 6.21. The 1 H NMR spectrum 
of 6.21 included resonances corresponding to the bridgehead protons at 4.45 and 
4.98ppm, downfield relative to the corresponding oxygen-bridged case, which 
had corresponding doublets at 4.01 and 4.27ppm. 
~:H3 
~ 
Ph 
6.20 
H3C, 
N-CH3 
o ~ 
o JNH ~N-o-IJ 
o 5.17 H3C\ 
N-CH3 
o ~ SC~3 0 JNH 
oitN-o-IJ 
Ph H 0 6.22 
Fig. 6.4.3 
Although a less stable dienophile, 5.17 also reacted successfully with 1-
methylsulfanyl-3-phenyl-isobenzothiophene 6.20. The reaction, to give the 
adduct 6.22, is shown in Fig. 6.4.3 The yield of this reaction was low (4%), 
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however it compared favourably with the oxygen-bridged case, where none of the 
desired adduct was isolated in the analogous reaction. 
The Diels-Alder adduct 6.22 itself proved relatively unstable, decomposing 
upon prolonged freezer storage. The mass spectrum of 6.22 exhibited features 
corresponding to retro-Diels-Alder fragmentation, highly characteristic of these 
Diels-Alder adducts. The parent ion peak itself, at 543 mass units, was fairly 
weak, but sufficiently intense to allow high resolution data to be obtained. 
I-Methylsulfanyl-3-phenyl-isobenzothiophene 6.20 was also reacted with the 
pyridinyl-substituted dienophile 5.21, another relatively unstable dienophile, as 
outlined in 6.4.4. 
6.20 
o ~ > 
o JNH 
<N-Q 
o 5.21 N~ 
o ';=1-SC~3 0 JNH ~N-Q-/; 
Ph H 0 6.23 
Fig. 6.4.4 
This resulted successfully in the formation of the desired Diels-Alder adduct 
6.23, once more in 4% yield. As with the other functionalised sulfur-bridged 
adducts, only the endo isomer was isolated, as identified by comparison with 
analogous adducts. Once again, the resonances in the 1 H NMR spectrum 
corresponding to the bridgehead protons were shifted downfield relative to the 
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corresponding oxygen-bridged case 5.24, from 3.96 and 4.20ppm in 5.24 to 4.35 
and 4.98ppm in the case of 6.23. 
6.4.2 Introduction of an Alkylating Group 
As discussed in Section 5.2, alkylating agents are an important class of anti-
tumour agent. This section explores the introduction of an alkylating group into 
sulfur-bridged Diels-Alder adducts. 
An attempt was made to trap the diene I-methylsulfanyl-isobenzothiophene 
6.8 with N-(2-chloroacetamidophenyl)maleimide 5.10 as outlined in Fig. 6.4.5. 
However, none of the desired product 6.24 was isolated. 
Fig. 6.4.5 
A more encouraging result was observed with aryl substitution at the 3-
position of the diene. I-Methylsulfanyl-3-phenyl-isobenzothiophene 6.20 was 
reacted with N-(2-chloroacetamidophenyl)maleimide 5.10 as outlined in Fig. 
6.4.6. 
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~:H3 
~ 
Ph 6.20 
Fig. 6.4.6 
This reaction proceeded smoothly to form the desired sulfur-bridged adduct 
6.25. Only one stereoisomer, the endo product, was observed. The 1 H NMR 
spectl1lm of 6.25 was very similar to its oxygen-bridged analogue 5.9, but with 
many of the resonances shifted downfield. For example, resonances due to the 
bridgehead protons were at 4.04 and 4.27ppm in the oxygen-bridged case 5.9, and 
4.45 and 4.96ppm in the sulfur-bridged case 6.25. 
6.4.3 Bridge Cleavage 
This section describes the bridge cleavage and aromatisation, by mercuric 
acetate catalysed hydrolysis, of the functionalised sulfur-bridged adducts which 
have been described thus far in this chapter. 
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OH 
o ~ SC~3 0 JNH cQtN-o-IJ 
OH Ph H 0 
6.21 o ~ SCH3 0 -c)NH ~-~N ~IJ 
Ph 0 5.27 
Fig. 6.4.7 
The bridge cleavage and aromatisation of the hydroxy-substituted adduct 6.21 
by mercuric acetate treatment is 'shown in Fig. 6.4.7. The desired aromatic 
compound 5.27, synthesised previously from the analogous oxygen-bridged 
adduct 5.20, was observed as the product. 
Fig. 6.4.8 
The sulfur-bridged adduct 6.22 was only available in small quantities. This 
made the study of its aromatlsation a challenge. Nevertheless it was successfully 
achieved as shown in Fig. 6.4.8. In this case the aromatic product 6.26 had not 
been prepared previously. The 1 H NMR spectrum of 6.26 was characterised by 
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the absence of the doublet resonances, at 4.36 and 4.88ppm, associated with the 
two bridgehead protons of its precursor 6.22, along with a relative shift downfie1d 
in the aromatic proton peaks, characteristic of bridge cleavage. No parent ion was 
observed in the mass spectrum, but the peaks observed corresponded to the 
expected fragmentation products of 6.26, including a peak at 479 mass units 
corresponding to loss of the N-methyl groups. 
NO cQtSC~3 0 -0-0 NH-I~SH N ~-~ /'/ mercuric acetatel MeOH 
Ph 0 
6.23 
Fig. 6.4.9 
The pyridinyl-substituted adduct 6.23 was likewise reacted with mercuric 
acetate, as outlined in Fig. 6.4.9, to give the desired aromatic compound 5.29, as 
synthesised previously from the analogous oxygen-bridged case 5.24. 
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o CI 
SCH3 }-J ~HN 0fuN-i ) 
Ph ° 
6.25 
mercuric acetatel MeOH 
Fig. 6.4.10 
0}-JCI 
~HNM 
~N~ 
Ph ° 5.11 
The bridge cleavage and aromatisation of 6.25 is shown in Fig. 6.4.10, 
successfully resulting in the synthesis of 5.11, an identical product to that formed 
previously from aromatisation of the corresponding oxygen-bridged case 5.9. 
Thus, all the sulfur-bridged Diels-Alder adducts were able to be successfully 
bridge cleaved and aromatised by treatment with mercuric acetate. 
6.4.4 Biological Testing 
In the P388 biological activity assay, the hydroxy-substituted Diels-Alder 
adduct 6.21 gave an IDSO value of 0.24~g/mL, surprisingly active compared to its 
aromatised derivative 5.27, which displayed little anti-tumour activity 
(34.60 Jlg/mL). The adduct 6.22 was more promising, giving an IDSO value of 
7.98~g/mL, while its aromatised derivative 6.26 gave a value of 2.86 Jlg/mL. The 
pyridinyl-substituted adduct 6.23 gave an IDSO value of 2.23Jlg/mL, a little more 
activity than the corresponding oxygen-bridged adducts, but still more active than 
its aromatised derivative 5.29 which gave a value of >6.2S~g/mL. 
The chloroacetyl substituted Diels-Alder adduct 6.25, and its aromatised 
derivative 5.11 gave the most promising results. The adduct 6.25 displayed low 
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anti-tumour activity, with an 1DSO value of 38.34Ilg/mL. This contrasted well 
with the two oxygen-bridged analogues, 5.9 and 5.10, previously tested, which 
both displayed relatively high activity. The aromatised derivative 5.11, on the 
other hand, had an ID SO value of 3.03Ilg/mL. This result indicates that 6.25, with 
a 12-fold lower activity than its derivative 5.11, is a promising lead ali a prodrug. 
These studies have shown that in some cases the extra stability of a sulfur-
bridge may offer benefits over an oxygen-bridge, by decreasing the anti-tumour 
activity of the bridged adduct relative to its aromatised derivative. 
6.5 Conclusion 
The enhanced stability of isobenzothiophenes relative to isobenzofurans was 
shown to benefit Diels-Alder chemistry. It was demonstrated that 1-
methylsulfanyl-isobenzothiophene, unsubstituted at the 3-position, could react 
with N-aryl maleimides to give Diels-Alder adducts, whereas no such adducts had 
been isolated in the corresponding isobenzofuran case. However, like the 
corresponding isobenzofurans, Diels-Alder chemistry was observed to occur more 
efficiently with alkyl or aryl substitution at the 3-position of the 
isobenzothiophene. The Diels-Alder chemistry of 1-methylsulfanyl-3-phenyl-
isobenzothiophene in particular was investigated. It was demonstrated that a 
range of hydrogen-bonding functional groups could be introduced into sulfur-
bridged adducts via N-aryl male imide based dienophiles. The introduction of an 
alkylating group into sulfur-bridged adducts via an N-aryl maleimide based 
dienophile was also demonstrated. The aromatised derivative of this adduct 
displayed promising biological activity, providing an interesting lead for the 
development of anti-cancer prodrugs. 
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Conclusion 
It was demonstrated that biological functionality could be 
introduced into Diels-Alder adducts via the dienophile, and that the 
bridge cleavage of such adducts could lead to planar aromatic 
products. The generation of both oxygen-bridged and sulfur-bridged 
adducts was demonstrated; the resulting increase in stability of the 
former proving advantageous in many instances. A variety of 
functionalised adducts were prepared. The introduction of an 
alkylating functionality into a sulfur-bridged Diels-Alder adduct 
offered a promising lead into the synthesis of prodrugs for anti-cancer 
chemotherapy. Such prodrug-based strategies may lead to treatments 
which offer advantages over existing forms of cancer chemotherapy. 
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ha t 
EXPERIMENTAL 
7.1 General 
Radial silica chromatography was performed on 1,2, or 4 mm silica plates. The 
silica was gradient eluted from 0% to 100% of the most polar solvent, and the plates 
washed and reactivated with methanol. 
Melting points (m.p.) were determined on a Reichert Hotstage microscope and 
are uncorrected. 
Elemental microanalyses of crystalline samples were performed at the Chemistry 
Department of the University of Otago, New Zealand. 
Proton nuclear magnetic resonance (1 H NMR) experiments were performed on a 
Varian Unity 300 MHz Fourier transform spectrometer. Peaks are quoted in parts 
per million (ppm, 0) relative to tetramethylsilane (TMS). Multiplicities are quoted 
as singlet (s), broad singlet (br.s.), doublet (d), triplet (t), quartet (q), or multiplet 
(m). Coupling constants (1) are quoted in Hertz (Hz). 
Carbon-13 nuclear magnetic resonance (l3C NMR) experiments were performed 
at MHz on a Varian Unity 300 MHZ or Varian XL 300 MHz Fourier transform 
spectrometer. Peaks are quoted in ppm (0) relative to TMS. 
118 
Chapter 7 Experimental 
1 H NMR spectra were referenced to TMS (O.OOppm), deuterated chloroform 
(CDCI3, 7.24ppm), deuterated methanol (CD30D, 3.30ppm), d6-acetone 
(2.17ppm), deuterium oxide (D20, 4.70ppm), or d6-dimethylsulfoxide (2.60ppm). 
13C NMR were referenced to CDCl3 (77.00ppm). 
Electron impact (EI) and fast atom bombardment (FAB) mass spectra (m/z) 
experiments were performed on a Kratos MS80RFA mass spectrometer. High 
resolution mass results have been compared with expected calculated values. 
Infra-red (IR) experiments were performed on a Shimadzu FTIR-8201PC or a 
Perkin Elmer 1600-FTIR spectrophotometer. The sample was presented as either a 
CDCl3 solution in a 0.1 or 1.0mm NaCI solution cell, as an oil, or as a Nujol® 
mull on NaCl plates. Absorption maxima (vmax) are recorded in wavenumbers 
(cm- I). 
Solvents and reagents used were dried and purified in accordance with the 
recommendations collected in Perrin and Armarego, or as obtained from commercial 
sources.8I 
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7.2 Chapter 2 Experimental 
Preparation of 1(3H)-isobenzofuranthione 2.520 
o 
~o s ~o 
1 (3H)-Isobenzofuranone (l.164g, 8.68mmo1.) and Lawesson's reagent 
(l 4.34mmol.) were refluxed in toluene (25mL) for 17 hours during which 
time the solution turned from yellow to brown. The toluene was removed under 
reduced pressure, and the crude solid taken up in ether and filtered to remove ether 
insoluble components. From this solution a yellow solid precipitated which was 
recrystallised from ether to give l(3H)-isobenzofuranthione as yellow needles 
(590mg, 45%). 
m.p. 106-] 09°C (lit. 106-109°C).20 
1 H NMR (CDCl3) 8 5.59 (s, 2H, OCH2), 7.50-7.52 (m, IH, aryl CH). 
mlz (El) 150 (M+, 100%), 121 (M-CHO+), 89 (M-CHOS+). 
IR Vmax (KBr) 2958, 1315, 1 ,1165,769 ern-I, 
120 
Preparation of 2-benzoylbenzoic acid 2.725 
o C<o 
o 
o 
__ " ~lOH 
~Ph 
o 
Crushed anhydrous aluminium chloride (32.0g, 240mmol.) was added slowly to 
a solution of phthalic anhydride (l6.6g, 109mmol.) in benzene (66mL), causing 
HCI gas to be evolved. The reaction was refluxed until completion. Ice was added 
to the hot brown solution until it turned white, when it was acidified with 
concentrated HCI (30mL) to give a solid which was filtered and washed with ice 
water. This solid was neutralised with sodium carbonate solution (10%, 100mL) 
and impurities removed by boiling with decolourising charcoal (2g). The filtrate 
was acidified with concentrated HCI (l5mL) and the resulting oil crystallised on 
cooling. The crystals were washed with cold water, dissolved in toluene (llOmL) 
and dried (MgS04). The filtrate was concentrated under reduced pressure and 
petroleum ether (20mL) added to induce crystallisation. 2-Benzoylbenzoic acid was 
obtained as glassy white needles (17.7g, 33%). 
m.p. 126-12TC (lit. 128°C).25 
1H NMR (CDC13) (5 7.33-7.40 (m, IH, aryl CH), 7.43 (m, IH, aryl CH), 7.45 
(m, 1H, aryl CH), 7.56-7.79 (m, 2H, aryl CH), 7.66-7.69 (m, IH, aryl CH), 
7.71-7.74 (m, 2H, aryl CH), 8.10 (d, JH, J=7.5Hz, aryl CH). 
m/z 226 (M+), 182, 149 (C8H603+), 105 (C7H60+). 
IR Vmax (KEr) 3024, 1675, 1304, 1256 em-I. 
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Preparation of 3-phenyl-l(3H)-isobenzofuranone 2.826 
o 
~OH 
~Ph 
o 
o 
~o 
Ph 
Anhydrous 2-benzoylbenzoic acid (11.46g, 51mmol.), glacial acetic acid (89ruL, 
1.554mol.), water (23mL), and zinc dust (22.8g, 349mmol.) were refluxed 
together for 2 hours. The hot supernatant was decanted and left overnight during 
which time crystallisation of the crude product occurred. The crystals were 
collected in a Buchner funnel and the remainder of the product precipitated out of 
the filtrate on addition of water. The crude product was then neutralised with a 
solution of saturated sodium bicarbonate and collected in a Buchner funneL This 
was recrystallised from methanol to give 3-phenyl-l(3H)-isobenzofuranone as large 
rectangular white crystals (6.2g, 59%). 
m.p. 114-116"C (lit. 114-116°C).26 
IH NMR (CDC13) (3 6.57 (s, IH, CH), 7.28 (m, 2H, aryl CH), 7.37-7.41 (m, 
4H, aryl CH), 7.61 (m, 1H, aryl CH), 7.73 (m, IH, aryl CH), 7 
J=7.3Hz, aryl CH). 
mlz (El) 210 (M+), 165, 105 (C7H60+). 
IR Vmax (KBr) 3032, 1746, 1068,741 cm- l , 
(d, IH, 
Preparation of 3-phenyl-l(3H)-isobenzofuranthione 2.920 
o 
~o s o:! 
Ph Ph 
3-Phenyl-l (3H)-isobenzofuranone (2.519g, 12.0mmol.) and Lawesson's 
reagent (3g, 7.42mmol.) were refluxed in toluene (30mL) for 17 hours during 
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which time the solution turned from yellow to red/brown. The toluene was 
removed under reduced pressure, and the crude solid taken up in ether and filtered 
to remove the ether-insoluble components. This was recrystallised from ether to 
give 3-phenyl-l(3H)-isobenzofuranthione as yellow plate crystals (1.357g, 50%). 
m.p. 98-100°C (lit. 97-99°C).20 
1 H NMR (CDCI3) 8 6.65 (s, lH, CH), 7.27-7.40 (m, 5H, aryl CH), 7.52-7.69 
(m, 3H, aryl CH), 8.10 (d, lH, aryl CH). 
I71/Z eEl) 226 (M+), 197, 193. 
High Res. C14HlOS0 calc. 226.04523; found 226.0445. 
IR Vmax (KBr) 3030,1316,1264,1164,1099 em-I. 
Preparation of 3·bromo~1(3H)·Isobenzofuranone 2.1027 
o 
cCo 
1 (3H)-lsobenzofuranone (48.8g, 364mmol.) was heated on an oil bath to 140°C 
and dry bromine (l9.5mL, 381mmol.) was bubbled in on a stream of dry carbon 
dioxide at such a rate that no excess bromine vapour was observed. The oil bath 
was maintained at 140-15YC and the carbon dioxide flow was continued for 30 
minutes after all the bromine had been added, which took 10 hours. Excess 
hydrogen bromide was removed by heating at 120°C under reduced pressure. 
Distillation under reduced pressure gave a fore-run of 1 (3H)-isobenzofuranone, 
followed by 3-bromo-l (3H)-isobenzofuranone, as a clear liquid which solidified to 
an off-white solid. This was used in the subsequent hydrolysis without further 
purification (20.5g, 26%). 
m.p. 74-75°C (lit. 7yC).27 
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IH NMR (CDCI3) (3 5.34 (s, lH, CBrH), 7.53 (t, IH, J=7.8Hz, aryl CH), 
7.66 (t, IH, J=7.8Hz, aryl CH), 7.79 (d, IH, 
J=7AHz, aryl CH). 
1/11;:. (El) 214 (M+), 133 (M-Br+), 105,77,50. 
AHz, aryl CH), 7.93 (d, IH, 
Preparation of 3-hydroxy-1(3H)-isobenzofuranone 2.1128 
o 
~o o ~o 
Br OH 
3-Bromo-l(3H)-isobenzofuranone (20.5g, 96mmol.) was covered with water 
(80mL) and stirred and heated on a steam bath until the layer of 3-bromo-l (3H)-
isobenzofuranone had disappeared. 3-Hydroxy-l (3H)-isobenzofuranone solidified 
on cooling (ODC) and was recrystallised from hot water as white crystals (14.3g, 
99%). 
m.p. 93-94°C (lit. 96°C).28 
IH NMR (CDC13) (3 6.65 (s, IH, C(OH)H), 7.64 (m, 2H, aryl CH), 7.72 (d, 
IH, J=7.3Hz, aryl CH), 7.89 (d, IH, .3Hz, aryl CH). 
mlz CEl) 150 (M+), 122 (M-CO+), 105,77,50. 
Preparation of 3-methyl.1(3H)-isobenzofuranone 2.14a29 
o 
~o 
OH 
Magnesium turnings (2.14g, 88mmol.) and methyl iodide (11.2g, 4.9mL, 
77mmo1.) dissolved in dry ether (50mL) were mixed together under nitrogen. 3-
Hydroxy-l (3H)-isobenzofuranone (5g, 33mmol.) dissolved in dry THF (50mL) 
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was added dropwise. After 2 hours the reaction was cooled (O°C) and 10% HCI 
solution (50mL) was added. Stirring at 40°C was continued for 1 hour. The 
solution was extracted with ether and the organic extracts combined and dried 
(MgS04). The solvent was removed under reduced pressure to give 3-methyl-
1 (3H)-isobenzofuranone as a yellow oil which was purified by radial silica 
chromatography (3.3g, 67%). 
1 H NMR (CDC13) 0 1.64 (d, 3H, J::::;6.9Hz, CH3), 5.59 (q, lH, J=6.4Hz, 
CH), 7.47-7.56 (m, 2H, aryl CH), 7.7 Ct, 1H, J=7.8Hz, aryl CH), 7.88 (d, IH, 
J::::;7.8Hz, aryl CH). 
m/z (El) 148.1 (M+), 133.0 (M-CH3 +), 105.0 (M-C2H40+), 77.0 (M-
C3H402+). 
High Res. C12H802 calc. 148.05243; found 148.05231. 
Preparation of 3~methyl-l(3H)~isobenzofuranthione 2.1Sa 
~o s cQo 
CH3 CH3 
3-Methyl-l (3H)-isobenzofuranone (485mg, 3.3mmoL) was dissolved in toluene 
(lOmL). Lawesson's reagent (662mg, 1.7mmoL) was added and the mixture 
refluxed overnight. The toluene was removed under reduced pressure and the 
resultant oil was dissolved in dry ether and filtered through cotton wool 3 times. 
The ether was removed under reduced pressure to give a red oil which was purified 
by radial silica chromatography to give 3-methyl-l(3H)-isobenzofuranthione as a 
yellow oil (309mg, 57%). 
1 H NMR (CDC13) 0 1.72 (d, 3H, J=6.8Hz, CH3), 5.83 (q, IH, J=6.8Hz, 
CH), 7.43 (d, 1 H, J=6.5Hz, aryl CH), 7.52 (t, lH, J=7.8Hz, aryl CH), 7.68 Ct, 
lH, J=6.5Hz, aryl CH), 8.04 (d, lH, J=7.8Hz, aryl CH). 
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Preparation of 3-ethyl-l(3H)-isobenzofuranone 2.14b29 
o 
eGo 
OH 
Magnesium turnings (854mg, 29.3mmol.) and ethyl bromide (l.96mL, 
26.3mmol.) dissolved in dry ether (25mL) were mixed together under nitrogen. 3-
Hydroxy-l (3H)-isobenzofuranone (2g, 11.2mmol.) dissolved in dry THF (25mL) 
was added dropwise. After 2 hours it was cooled to O°C and hydrolysed with 10% 
HCI solution. This reaction mixture was stirred at 40°C for another hour. The 
solution was extracted with ether and the organic extracts combined and dried 
(MgS04). The solvent was removed under reduced pressure to give 3-ethy 1-1 (3H)-
isobenzofuranone as a yellow oil which was purified by radial silica 
chromatography (408mg, 22%). 
lH NMR (CDCI3) 8 1.00 (t, 3H, J=7.4Hz, CH3), 1.84 (m, lH, CH2), 2.13 
(m, IH, CH2), 5.47 (m, lH, CH), 7.47 (d, 1H, aryl CH), 7.53 (t, lH, 
J=7.3Hz, aryl CH), 7.69 (t, lH, J=7.3Hz, aryl CH), 7.69 (t, lH, J=7.3Hz, aryl 
CH), 7.89 (d, lH, J=7.3Hz, aryl CH). 
mlz (EI) 162.1 (M+), 133.0 (M-C2H5+). 
Preparation of 3-ethyl-l(3H)-isobenzofuranthione 2.1Sb 
3-Ethyl-1 (3H)-isobenzofuranone (328mg, 2.0mmol.) was dissolved in toluene 
(IOmL) and Lawesson's reagent (409mg, 1.0mmol.) added. This mixture was 
refluxed overnight in an oil bath. The toluene was removed under reduced pressure 
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and the resultant oil was dissolved in dry ether and filtered through cotton wool. 
This was repeated 3 times. The ether was removed under reduced pressure to give 
a red/brown oil. This was purified by radial silica chromatography to give 3-ethyl-
I (3H)-isobenzofuranthione as a yellow oil (340mg, 94%). 
1 H NMR (CDCI3) 8 1.01 (t, 3H, J=7.3Hz, CH3), 1.91 (m, 1H, CH2), 2.19 
(m, IH, CH2), S.72 (m, IH, CH), 6.99-7.07 (m, 2H, aryl CH), 7.91-8.13 (m, 
2H, aryl CH). 
/11/z (El) 178.1 (M+), 149 (M-C2HS+). 
High Res. ClOHlOSO m/z calc. 178.04S28; found 178.04499. 
Preparation of 1,2-bis.-(dibromomethyl)-benzene 2.1731 
Dry 2-xylene (29.2Sg, 19.48mL, 27Smmol.) was stirred and heated to 120°C. 
A lamp was placed close to the flask so as to admit the maximum amount of light. 
Bromine (17Sg, 1.Imo!.) was added in portions from a dropping funnel to the 
reaction flask at such a rate that the bromine colour was removed as fast as it was 
added. After approximately one-half of the bromine was added the temperature was 
slowly increased to 17SoC for the remainder of the addition. After 12 hours all the 
bromine had been added and the mixture was illuminated and stirred at 170°C for a 
further hour. The mixture was cooled to room temperature and crystallised out 
overnight as a dark solid. This was dissolved in hot, dry chloroform (SOOmL) and 
treated with Norit (2Sg). The mixture was filtered, the Norit washed with hot 
chloroform, and the Norit treatment repeated with another portion (2Sg). The 
filtrate was concentrated under reduced pressure and chilled (OCC), to give a pale 
brown solid which was collected and washed with cold chloroform (SmL). The 
filtrate was concentrated further to obtain further product. Recrystallisation from 
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chloroform gave 1 ,2~bis(dibromomethyl) benzene as off-white crystals (52.85g, 
46%). 
m.p. 112-116°C (lit. 11 lI6°C). 
1 H NMR (CDC13) d 7.14 (s, 2H, CHBfl), 7.38 (m, 2H, aryl CH), 7.67 (m, 
2H, aryl CH). 
m/~ (El) 422 (M+), 341 (M-Br+), 262 (M-Bfl+), 181 (M-Br3+), 102 (M-
B1A+). 
IR Vmax 1315.4,1236.3,1170.7,1137.9 em-I. 
Preparation of naphthalene-2,3-dicarboxylic acid 2.1833 
A mixture of 1,2-bis(dibromomethyl)-benzene (20.0g, 47 Ammo!.), sodium 
iodide (47Ag, 316mmol.), maleic anhydride (14.2g, 145mmol.), and dry DMF 
(l50mL) was stirred at 60-70°C for 5 hours. The reaction mixture was poured into 
water (1.5L) containing sodium bisulfite (20.0g, 192mmol.) and the resulting 
precipitate collected on a Buchner funnel to give naphthalene-2,3-dicarboxylic acid 
as prisms (7.26g, 71 % ). 
m.p. 234-235°C (lit. 238-239°C). 
IH NMR (D20) 87.57 (m, 2H, aryl CH), 7.91 (m, 2H, aryl CH), 8.15 (s, 2H, 
CHCC02)· 
m/z (El) 198 (M-H20+), 154,126. 
1Rvmax (Nujol) 1698,1460,1377,1223, 1140cm- 1. 
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Preparation of naphthalene-2,3-dicarboxylic anhydride 2.19 
Naphthalene-2,3-dicarboxylic acid (7.82g, 36.2mmol.) was refluxed in freshly 
distilled acetic anhydride (50mL, 530mmol.) for 3 hours. The remaining acetic 
anhydride was then removed under reduced pressure to give naphthalene-2,3-
dicarboxy lie anhydride as a white crystalline solid (7.50g, 100%) 
m.p. 241-244°C. 
NMR (CDC13) 8 7.83 (m, 2H, aryl CH), 8.15 (m, 2H, aryl CH), 8.56 (s, 
2H, aryl CH). 
1111::. (El) 198 (M+), 154 (M-C02+), 126,63. 
Res. C8H603 mlz calc. 198.03170; found 198.03170. 
IR vmax (Nujol) 2360,1836,1763,1460,1377,1247,1198 em-I. 
Prepara tion of 1 ,3-dihydronaphtho [2,3-c ]furan-1-one 2.21 
Sodium borohydride (20mg, 0.529mmol.) in dry DMF (lmL) was stirred at OCC 
while naphthalene-2,3-dicarboxylic anhydride (lOOmg, 0.505mmol.) in DMF 
(4mL) was added over 5 minutes. Stirring was continued for one hour at room 
temperature. Hydrochloric acid (6M, 1 mL) was added cautiously, followed by 
water (lOmL) and the mixture extracted with ether. The ether fractions were 
combined, dried (MgS04), and the ether removed under reduced pressure to give 
naphthalide as small white needles (60.8mg, 65%). 
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m.p. 205-206°C. 
1 B NMR (CDCl3) 0 5.50 (s, 2B, CH2), 7.65 (m, 2H, aryl CH), 7.95 (m, 2H, 
aryl CH), 8.06 (d, IH, J=7.4Hz, aryl CH), 8.52 (s, IH, COCCH). 
111/z. (El) 184 (M+), 140 (M-C02+). 
High Res. C12H802 m/z calc. 184.05246; found 184.05253. 
lR Vmax CNujol) 1757, 1690, 1462, 1377, 1300, 1102, 1031,783,746 em-I. 
Preparation of 1,3-dihydronaphtho[2,3-c]furan-l·thione 2.22 
Naphthalene-2,3-dicarboxylic anhydride (60mg, 0.326mmol.) and Lawesson' s 
reagent (66mg, 0.163mmol.) were refluxed in toluene (5mL) for 17 hours. The 
toluene was removed under reduced pressure to give an oil. This was purified by 
radial silica chromatography to give 1 ,3-dihydronaphtho[2,3-c ]furan-1-thione as a 
yellow solid (9.3mg, 14%) 
m.p. 193-194°C. 
1 H NMR (CDC!3) 0 5.75 (s, 2H, CH2), 7.59-7.68 (m, 2B, aryl CH), 7.93 (m, 
2H, aryl CH), 8.09 (d, lH, J=8.3Hz, aryl CH), 8.66 (s, IH, CSCCB). 
m/z (El) 200 (M+), 140 (M-CSO+). 
High Res. C12HgSO m/z calc. 200.02962; found 200.02936. 
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Preparation of 3-benzoylnaphthoic acid 2.23 
Crushed anhydrous aluminium chloride (l9.28g, 145mmol.) was added slowly 
to a solution of 2,3-naphthalic anhydride (10g, 50mmol.) in benzene (40mL) 
causing hydrogen chloride gas to be evolved. The reaction was refluxed until no 
more was evolved. Ice was then added until the solution turned from brown to 
white, whereupon it was acidified with concentrated hydrochloric acid. The 
resulting solid was filtered and washed with cold water. This solid was neutralised 
with sodium carbonate solution (10%, 31.3mL, 0.030mmol.) and the impurities 
were removed by boiling with decolourising charcoal (625mg). The mixture was 
filtered and the filtrate acidified with concentrated hydrochloric acid (5mL) to give 
an oil which crystallised on cooling. The crystals were washed with cold water 
and dried under reduced pressure to give 3-benzoylnaphthoic acid as white crystals 
(9.04g, 65%). 
m.p. 202-204°C, 
mlz (El) 276.1 (M+), 232.1 (M-C02+), 155.0, 105.0. 
High Res. C18H1203 mlz calc. 276.07864; found 276.07917. 
Preparation of 3-phenyl-l (3 H)-isonaph tho[2,3-c ]furan-l-one 2.24 
3-Benzoyl phthaloic acid (9.04g, 33mmol.), zinc dust (18.1 277mmoL), 
glacial acetic acid (18.1g, 301mmol.), and water (20mL) were refluxed together for 
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3 hours. The hot supernatant was decanted and left to crystallise overnight to give 
the crude lactone. The crystals were collected on a Buchner funnel and the 
remainder of the lactone precipitated out of the filtrate on addition of water. The 
crude lactone was then neutralised with a saturated solution of sodium bicarbonate 
and collected on a Buchner funnel. Recrystallisation from ethanol gave 3-phenyl-
1 (3H)-isonaphtho[2,3-c ]furan-l-one as white crystals (1.6g, 19%). 
m.p. 151-152°C. 
Analysis C18H1202 calc. C, 83.06; H, 4.65; found: C, 82.72; H, 4.50. 
IH NMR (CDCl3) (5 6.58 (s, IH, CH), 7.33-7.41 (m, 5H, aryl CH), 7.59-7.66 
(m, 2H, aryl CH), (s, 1H, aryl CH), 7.87 (d, IH, .3Hz, aryl CH), 8.07 
(d, IH, .3Hz, aryl CH), 8.55 (s, IH, aryl CH). 
111/Z (EI) 260 (M+), 216 (M-C02+). 
High Res. Cl 1202 m/z calc. 260.08378; found 260.08378. 
Preparation of 3-phenyl-l(3H)-isonaphtho[2,3-c]furan-l-thione 
2.25 
Ph 
3 -Pheny 1-1 (3H)-isonaphtho [2,3 -c ]furan-l-one (300mg, 1.15mmol.) and 
Lawesson's (300mg, 0.742mmol.) were refluxed in toluene (l5mL) for 17 
hours during which time the solution turned from yellow to brown. The toluene 
was removed under reduced pressure, and the crude solid taken up in ether and 
filtered to remove the ether-insoluble components. This was recrystallised from 
ether to give 3-phenyl-l(3H)-isonaphtho[2,3-c]furan-l-thione as pale yellow 
crystals (144mg, 46%). 
m.p. 142-144°C. 
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IH NMR (CDC13) 8 6.81 (s, 1H, CH), 7.31-7.43 (m, 5H, aryl CH), 7.56-
7.647 (m, 2H, aryl CH), 7.74 (s, IH, aryl CH), 7.86 (d, 1H, J=7.8Hz, aryl CH), 
8.09 (d, 1H, J=7.8Hz, aryl CH), 8.68 (s, IH, aryl CH). 
mlz (El) 276 (M+), 216. 
High Res. C18H12S0 mlz calc. 276.06094; found 276.06108. 
Preparation of 2-aminobenzaldehyde 2.2935 
~CHO ___ _ 
~N02 
'Vater (175mL), ferrous chloride heptahydrate (l05g, 380mmol.), concentrated 
hydrochloric acid (0.5mL), and 2-nitrobenzaldehyde (6g, 40mmol.) were stirred 
and heated together to 90°C, then ammonium hydroxide (25mL, 642mmol.) was 
added. Three further portions of ammonium hydroxide (lOmL, 257mmol.) were 
added at 2 minute intervals. Immediately after the addition of the last portion of 
ammonium hydroxide the reflux condenser was removed and the reaction vessel 
connected to a steam distillation assembly. The reaction mixture was steam-distilled 
as rapidly as possible, collecting two 250mL fractions over a period of 15 minutes. 
The distillate was saturated with sodium chloride and cooled to O°C resulting in the 
formation of a precipitate. This was collected in a Buchner funnel to give 2-
aminobenzaldehyde as a bright yellow solid (2.82g, 58%). 
m.p. 39-40°C (lit. 38-39°C).35 
1 H NMR (CDC13) 8 6.66 (d, IH, J=8.3Hz, aryl CH), 6.76 (t, 1H, 8Hz, 
aryl CH), 7.32 (t, lH, J=7.4Hz, aryl CH), 7.49 (d, lH, J=7.8Hz, aryl CH), 9.88 
(s, I H, CHO). 
ml2 (El) 121.1 (M+), 93.1 (M-CO+). 
High Res. C7H7NO mil. calc. 121.05276; found 121.05260. 
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IR Vmax (Nujol) 2360,1651,15778,1529,1458,1377,1346 em-i. 
Preparation of 3-ethoxycarbonyl-2-methyl-quinoline 2.3036 
2-Aminobenzaldehyde C2.82g, 23mmol.) was dissolved in the minimum amount 
of ethanol and ethyl acetoacetate (2.96mL, 23mmol.) added dropwise. A sodium 
hydroxide pellet was added and the solution stined overnight. The ethanol was 
removed under reduced pressure to give an oil which was partitioned between ethyl 
acetate and water. The organic fractions were combined, dried (MgS04) and the 
ethyl acetate removed under reduced pressure to give a solid which was 
recrystallised from ethanol to give 3-ethoxycarbonyl-2-methyl-quinoline as pale 
orange needles (1.82g, 38%). 
m.p. 69-70 n C (lit. 7l-72°C). 
IH NMR (CDCl3) (5 1.46 (t, J=7.3Hz, CH3), 3.00 (s, 3H, aryl CH3), 
4.45 (q, 2H, J=7.4Hz, OCH2), 7.55 (t, IH, J=7.8Hz, aryl CH), 7.79 Ct, IH, 
J=7.3Hz, aryl CH), 7.88 Cd, 1H, J=7.8Hz, aryl CH), 8.04 (d, 1H, J=7.8Hz, aryl 
CH), 8.75 (s, IH, COCCH). 
IR Vmax 3018.4, 1720.4, 1287.7, 1236.3, 1207.4, 1197.7, 1064.6,908.4 
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Preparation of 3-ethoxycarbonyl~2-methyl-quinoline N -.oxide 2.31 
3-Ethoxycarbonyl-2-methyl-quinoline (150mg, 0.697mmoL) was dissolved in 
dichloromethane (5mL) and 3-chloroperbenzoic acid (360mg, 2.09mmmol.) was 
added. This was stirred at room temperature and monitored by TLC. After one 
hour the starting material was no longer visible by TLC. The mixture was 
partitioned between dichloromethane and saturated aqueous sodium bicarbonate 
solution. The dichloromethane fractions were combined, dried (MgS04), and the 
dichlorometbane removed under reduced pressure to give a solid. This was purified 
by radial silica chromatography to give 3-ethoxycarbonyl-2-methyl-quinoline N-
oxide as a brown solid (146mg, 91 %). 
m.p. 45-4TC. 
1 H NMR (CDC13) (5 1.47 (t, 3H, J=6.8Hz, CH3), 2.99 (s, 3H, aryl CH3), 
4.47 (q, 2H, OCH2), 7.67 (t, 1H, J=6.8Hz, aryl CH), 7.91 (m, 2H, 
aryl CH), 8.29 (s, IH, COCCH), 8.80 (d, IH, J=8.8Hz, aryl CH). 
IR Vmax 1724.2, 1321.1, 1288.4, 1240.1,1105.1, 1051.1,908.4 em-I. 
Preparation of 2-acetoxymethyl-3-ethoxycarbonyl-quinoline 2.32 
Acetic anhydride (1.09mL, 11.6mmol.) was added to 3-ethoxycarbonyl-2-
methyl-quinoline N-oxide (1. 5.75mmol.) in benzene (15mL). This was 
refJuxed for 3 hours. The reaction mixture was then distilled under reduced 
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pressure and any remaining solvent removed under reduced pressure. The solid 
formed was then dissolved in ethyl acetate and partitioned with aqueous sodium 
bicarbonate solution. The ethyl acetate fractions were combined, dried (MgS04), 
and the ethyl acetate removed under reduced pressure to give 2-acetoxymethyl-3-
ethoxycarbonyl-quinoline as a pale yellow solid (1.45g, 93%). 
m.p. 68-70°C. 
1 H NMR (CDCI3) 0 1.46 (t, 3H, J=7.3Hz, CH3), 2.23 (s, 3H, COCH3), 4.46 
(q, 2H, J=6.9Hz, OCH2CH3), 5.74 (s, 2H, OCH2), 7.61 (t, 1H, J=8.3Hz, aryl 
CH), 7.82 (t, lH, J=8.3Hz, aryl CH), 7.91 (d, 1H, J=8.2Hz, aryl CH), 8.11 (d, 
lH, J=8.3Hz, aryl CH), 8.83 (s, lH, COCCH). 
IR Vmax 3030.0, 1720.4, 1622.0, 1369.4, 1276.8, 1253.6, 1226.6, 1207.4, 
1068.5 em-I. 
Preparation of 4-aza-3H-isonaphtho[c]furan-l-one 2.33 
2-Acetoxymethyl-3-ethoxycarbonyl-quinoline (876mg, 3.21mmol.) was 
dissolved in dichloromethane (5mL) and concentrated hydrochloric acid (1.2mL, 
19.2mmol.) added. The solution was then stirred for 3 days to give a brown oily 
solution which was neutralised cautiously with saturated sodium bicarbonate 
solution and partitioned with ethyl acetate. The ethyl acetate fractions were 
combined, dried (MgS04), and the ethyl acetate removed under reduced pressure to 
give an oily solid. This was purified by dissolving the oil in methanol and drawing 
it off to give a solid which was recrystallised from ethyl acetate and petroleum ether 
to give 4-aza-3H-isonaphtho[c]furan-1-one as off white crystals (114mg, 17%). 
m.p. 186°C (decomp.). 
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1 H NMR (CDCI3) 8 5.51 (s, 2H, CH2), 7.71 (t, 1H, J=8.3Hz, aryl CH), 7.95 
(t, 1H. J=8.3Hz, aryl CH), 8.08 (d, 1H, J=8.3Hz, aryl CH), 8.21 (d, 1H, 
J=8.3Hz, aryl CH), 8.81 (s, IH, COCCH). 
13C NMR (CDCI3) 870.79, 110.67, 117.09, 119.14, 127.41, 127.68, 
129.34, 130.02, 133.12, 136.20, 163.49. 
mlz. (El) 185.0 (M+), 156.0, 128.0. 
High Res. C11H7N02 mlz calc. 185.04768, found 185.04718. 
lR Vmax 3014.5, 1770.5, 1633.6, 1585.4, 1510.2, 1326.9, 1164.9, 1035.7, 
1012.6 em-I. 
Preparation of 4-aza-3H-isonaphtho[c]furan-l-thione 2.34 
4-Aza-3H -isonaphtho [c ]furan-l-one (98mg, 0 .529mmol.) and Lawesson' s 
reagent (l07mg, 0.265mmol.) were refluxed in toluene (5mL) for 18 hours. The 
toluene was removed under reduced pressure to give a brown oil. This was 
purified by radial silica chromatography to give 4-aza-3H-isonaphtho[c]furan-l-
thione as a brown solid (3.4mg, 3%). 
m.p.110-112°C. 
1 H NMR (CDC13) 8 5.72 (s, 2H, CH2), 7.70 (t, IH, J=8.3Hz, aryl CH), 7.94 
(t, IH, J-7.3Hz, aryl CH), 8.08 (d, 1H, J=8.3Hz, aryl CH), 8.19 (d, IH, 
J=7.8Hz, aryl CH). 
mlz 201 (M+), 141. 
High Res. CI1H7NSO mlz calc. 201.02486; found 201.02501. 
lR Vrnax 1770.5, 1631.7, 1622.0, 1487.0, 1421.4, 1236.3, 1132.1 em-I. 
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7.3 Chapter 3 Experimental 
Preparation of fumaroyl dichloride 3.448 
CIOC~COCI 
Fumaric acid (lOg, 86mmol.) and phosphorus pentachloride (l7.94g, 86mmol.) 
were dissolved in dichloromethane (80mL) and stirred together. The reaction flask 
was attached to a reflux condenser followed by a calcium chloride drying tube 
followed by a gas absorption trap. The flask was heated on a water bath with 
stirring until reaction commenced and then for a further 30 minutes until the 
evolution of hydrogen chloride gas had ceased. The reaction flask was then 
attached to distillation apparatus and the water bath exchanged for an oil bath. The 
oil bath was gradually heated to 200 0 e to remove phosphorus oxychloride. Then 
the flask was allowed to cool, the water condenser was replaced by an air condenser 
and the residual liquid was distilled under reduced pressure (water pump) to give 
fumaroyl dichloride as a clear oil (12.5g, 95%). This was used immediately in the 
subsequent reactions. 
Preparation of N,N'-dibutylfumaramide 3.5 
CIOC~COCI 
Fumaroyl chloride (l2.2g, 80mmol.) was added slowly to a stirred solution of 
n-butylamine (l1.7 g, 160mmol.) in petroleum ether (90mL) which was cooled in 
an ice bath. A white mist was produced in addition to an opaque white solution. 
After the addition was complete, hydrochloric acid (lM, 60mL) was added and the 
mixture shaken in a separating funnel. The mixture was allowed to separate and 
138 
then the organic layer containing the amide was washed with water until acid free. 
The petroleum ether was removed under reduced pressure and the resulting solid 
recrystallised from ethanol to give N,N'-dibutylfumaramide as fine white crystals 
(l4.5g, 80%). 
m.p. 270-271 DC. 
1 NMR (DMSO) 0 0.97 (t, 6H, J=7.4Hz, CH3), 1.39 (m. 4H, CH2CH3), 
1.51 (m, 4H, NHCH2CH2), 3.24 (m, 4H, NHCH2), 6.89 (s, 2H, CH), 8.44 
(br.s, 2H, NH). 
l1l/z (El) 226.2 (M+), 154.1. 
High Res. C12H22N202 m/z calc. 226.16813; found 226.16787. 
Preparation of N,N'-di(N-dimethylaminoethyl)fumaramide 3.6 
Fumaroyl chloride (12.2g, 80mmol.) was added slowly to a stirred solution of 
N,N-dimethylethylenediamine (l4.1g, 17.5mL, 160mmol.) in dichloromethane 
(50mL) which was cooled in an ice bath. A white mist was produced and the 
solution turned brown. The dichloromethane was removed under reduced pressure 
to give an oily brown solid This was recrystallised from ethanol to give a pale 
brown solid, which was dissolved in distilled water and sodium hydroxide pellets 
added until pH 14. The mixture was extracted with ethyl acetate, the ethyl acetate 
fractions were combined, dried (MgS04), and the ethyl acetate removed under 
reduced pressure to give N,N'-di(N-dimethylaminoethyl)fumaramide as white 
crystals (2.4g, 12%). 
m.p. 178°C (decomp.). 
IH NMR (CDC13) 0 2.23 (s, 12H, CH3), 2.45 (m, 4H, NCH2), 3.41 (m,4H, 
NHCH2), 6.54 (br.s, 2H, NH), 6.87 (s, 2H, CH). 
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m/z (EI) 254 (M+), 71. 
High Res. C 12H24N402 m/z calc. 254.1743, found 254.1743. 
Preparation of N -phenyl maieimide50 
o 
~o 
o 
Maleanilic Acid. Maleic Anhydride (20g, 0.2mo!.) was stirred in ethyl ether 
(250mL) until all had dissolved and a solution of aniline (18.6mL, 0.2mol.) in ethyl 
ether (20mL) was run in through a dropping funnel. The resulting thick suspension 
was stirred at room temperature for 1 hour and cooled to 15-20'C in an ice bath. 
The product was obtained by suction filtration to give maleanilic acid as a fine cream 
coloured powder which was used in the next step without purification. 
m.p. 200-202'C (lit. 201-202'C). 
N-phenyl maleimide. In a conical flask were placed acetic anhydride (68.4mL, 
0.72mo!.), anhydrous sodium acetate (6.6g, 0.08mo!.), and all the maleanilic acid 
prepared above. This suspension was dissolved by swirling and heating on a steam 
bath for 30 minutes. The reaction mixture was then cooled almost to room 
temperature in a cold water bath and poured into ice water. The precipitated product 
was removed by suction filtration and washed three times with portions of ice-cold 
water (lOmL) and once with petroleum ether (lOmL). Recrystallisation from 
cyclohexane gave N-pheny I maleimide as yellow needles (17.87 g, 2 steps 51 %). 
m.p. 89-90'C (lit. 89-90'C). 
[H NMR (CDCI3) (56.85 (s, 2H, COCH), 7.33-7.40 (m, 3H, aryl CH), 7.45-
7.50 (m, 2H, aryl CH). 
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Preparation of N -(2-nitrophenyl)maJeimide 3.7 
c$ 
o 
Maleic anhydride (19.6g, 200mmol.) was stirred in ether (250mL) until 
completely dissolved. 2-Nitroaniline (27.6g, 200mmol.) in ether (250mL) was 
then added and the resulting solution was stirred for 3 weeks at room temperature 
during which time precipitation gradually occurred. This solid was refIuxed 
overnight with freshly distilled acetic anhydride (200mL, 2.12mol.). The acetic 
anhydride was removed under reduced pressure and the resulting solid partitioned 
between ethyl acetate and water. The ethyl acetate fractions were combined, dried 
(MgS04) and the ethyl acetate removed under reduced pressure to give N-(2-
nitrophenyl)maleimide as off-white crystals which were recrystallised from ethyl 
acetate and petroleum ether (26.94g, 2 steps 62 %). 
m.p. 104-lOTC. 
1H NMR (CDCl3) () 6.93 (s, 2H, COCH), 7.43 (d, IH, J=7.8Hz, aryl CH), 
7.60 (t, 1H, .8Hz, aryl CH), 7.75 (t, 1H, J=7.8Hz, aryl CH), 8.15 (d, 1H, 
J=7.8Hz, aryl CH). 
mlz (El) 218 (M+), 172.0 (M-N02+). 
High Res. ClOH6N204 mlz calc. 218.03276; found 218.03270. 
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Preparation of N -(3-NitrophenyJ)maJeimide 3.8 
~ o N02 -....-" ~N--< > 
o o 
Maleic anhydride (19.6g, 200mmol.) was stirred in ether (250mL) until 
completely dissolved. 2-Nitroaniline (27.6g, 200mmol.) in ether (250mL) was 
then added and the resulting solution was stirred overnight at room temperature 
during which time precipitation occurred. This solid was refluxed overnight with 
freshly distilled acetic anhydride (200mL, 2.12mol.) during which time the solution 
turned a dark brown colour. The acetic anhydride was removed under reduced 
pressure and the resulting solid partitioned between ethyl acetate and water. The 
ethyl acetate fractions were combined, dried (MgS04), and the ethyl acetate 
removed under reduced pressure to give N-(3-nitropheny l)maleimide as pale brown 
crystals which were recrystallised from ethyl acetate and petroleum ether (20.28g, 2 
steps 47%). 
m.p. 106-109°C. 
IH NMR (CDCl3) (5 6.94 (s, 2H, COCH), 7.66 (t, IH, J=7.8Hz, aryl CH), 
7.79 (d, IH, 
aryl CH). 
aryl CH), 8.24 (d, IH, 
mlz (El) 218.0 (M+), 172.0 (M-N02+). 
aryl CH), 8.34 (s, IH, 
High Res. ClOH6N204 calc. 2]8.03276; found 218.03291. 
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Preparation of N -acetyl 3-aminonitrobenzene 3.11 
NNH2 Y -----
N02 
3-Nitroaniline (20g, 145mmol.) was placed in a round-bottomed flask and acetic 
anhydride was added (50mL, 530mmoL). This was refluxed on an oil bath 
overnight. The following day the excess acetic anhydride was removed under 
reduced pressure and the resulting solid was recrystallised from methanol to give N-
acetyl 3-aminonitrobenzene as pale brown crystals (19g, 73%). 
m.p. 149-152°C. 
IH NMR (CDCl3) 8 2.15 (s, 3R, CH3), 7.51 (t, 1H, aryl CH), 7.83 
(dd, IH, J~ 1.0, 8.3Hz, aryl CH), 7.91 (dd, 1H, J~1.0, 8.3Hz, aryl CH), 8.58 (3, 
aryl CH). 
mlz (El) 180 (M+), 138 (M-CH3CO+), 92. 
Res. C8H8N03 mlz calc. 180.0535; found 180.0533. 
Preparation of N-acetyl 3-aminoaniline 3.12 
H 
NNI(CH3 Y 0 ----->-
N02 
N-Acetyl 3-aminonitrobenzene (5g, 27.8mmol.) was placed in around bottomed 
flask and dissolved in the minimum amount of methano1. 5% Palladium on carbon 
(3g) was added and the flask attached via a tap to a hydrogen-filled balloon. With 
the tap closed the air in the reaction vessel was evacuated under the reduced 
pressure of a water pump, also connected via a tap. The tap to the water pump was 
then closed and the tap to the hydrogen balloon opened. The reaction was stirred 
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and monitored by TLC, with the hydrogen balloon being refilled where necessary. 
Once the reaction was complete, the reaction mixture was filtered and the solvent 
removed under reduced pressure to give N-acetyl 3-aminoaniline as a white solid 
(2.Sg, 60%) 
m.p. 61-62°C. 
IH NMR (CDCI3) (5 2.0S (s, 3H, CH3), 6.46 (dd, IH, J=1.0, 8.7Hz, aryl 
CH), 6.81 (dd, lH, 1.0, 8.8Hz, aryl CH), 6.98-7.0S (m, 2H, aryl CH), 9.61 
(bLs, IH, NH). 
m/z eEl) IS0.1 (M+), 108.1 (M-COCH2+). 
High Res. C8HlON20 m/z calc. lS0.07931; found lS0.07920. 
Preparation of' N-(3-acetylaminophenyl)maleimide 3.13 
(Y~f(CH' ~ y 0 -----...... 
NH2 
N-acetyl 3-aminoaniline (4.8g, 0.032mol.) was dissolved in THF. Maleic 
anhydride (3.1g, 0.032moL) in THF was then added to the solution and it was 
stirred overnight to give a yellow precipitate. To this precipitate, sodium acetate 
(1.Sg, 0.023mol.) and acetic anhydride (lOmL, 106mmoL) were added. The flask 
was heated on a stearn bath until completely dissolved and then for a further 30 
minutes. The resulting yellow solution was then extracted with dichloromethane. 
The organic fractions were combined, dried (MgS04), and the solvent removed 
under reduced pressure to give a solid which was recrystallised from ethyl acetate to 
give N-(3-acetylaminophenyl)maleimide as yellow needles (1.36g, ] 9%). 
m.p. J88-l90°C. 
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Analysis C12HION203 calc. C, 62.60; H, 4.38; N, 12.17; found C, 62.57; H, 
4.35; N, 12.25. 
1 H NMR (CDC13) 8 2.17 (s, 3H, CH3), 6.86 (s, 2H, COCH), 7.09 (d, IH, 
J=7.8Hz, aryl CH), 7.35-7.49 (m, 2H, aryl CH), 7.59 (s, IH, aryl CH). 
mlz (El) 230.1 (M+), 188.1 (M-COCH2+). 
High Res. C12H10N203 mlz calc. 230.06914; found 230.06925. 
Preparation of N -acetyl 2-aminonitrobenzene 
2-Nitroaniline (15g, 111 mmol.) was placed in a round-bottomed flask and acetic 
anhydride was added (50mL, 530mmol.). This was refluxed on an oil bath 
overnight. The following day the excess acetic anhydride was removed under 
reduced pressure and the resulting solid was recrystallised from methanol to give N-
acetyl 2-aminonitrobenzene as yellow crystals (14.0g , 70%). 
m.p. 90-91°C. 
IH NMR (CDCI3) 8 2.18 (s, IH, CH3), 7.32 (t, lH, J=7.8Hz, aryl CH), 7.66 
(t, IH, 
CH). 
8Hz), 8.01 (d, lH, 8Hz, aryl CH), 8.06 (d, lH, J=7.8Hz, aryl 
mlz (El) 180 (M+), 138 (M-CH3CO+), 92. 
High Res. C8H8N03 111lz calc. 180.0535; found 180.0536. 
Preparation of N -acetyl 2-aminoaniline 
145 
N-Acetyl 2-aminonitrobenzene (5g, 27.8mmol.) was placed in a round bottomed 
flask and dissolved in the minimum amount of methanol. 5% Palladium on carbon 
(3 g) was then added and the flask attached via a tap to a hydrogen filled balloon. 
With the tap closed the air in the reaction vessel was evacuated under the reduced 
pressure of a water pump, also connected via a tap. The tap to the water pump was 
then closed and the tap to the hydrogen balloon opened. The reaction was stirred 
and monitored by TLC, with the hydrogen balloon being refilled where necessary. 
Once the reaction was complete, the reaction mixture was filtered and the solvent 
removed under reduced pressure to give N-acetyl 2-aminoaniline as a white solid 
(2.93g, 70%). 
m.p. 1 JO-1l2°C. 
I H NMR (CDC13) 8 2.13 (s, 3H, CH3), 6.68 (t, IH, J=7.8Hz, aryl CH), 6.82 
(d, IH, J=7.8Hz, aryl CH), 6.95-7.JO (m, 2H, aryl CH). 
111/Z. (El) 150 (M+), 132, J08 (M-COCH2+). 
High Res. C8H] ON20 m/z calc. 150.07931; found 150.07906. 
Preparation of N -(2-acetylaminophenyl)maleimide 3.14 
N-Acety12-aminonitroaniline (2.93g, 0.195mol.) was dissolved in THF. Maleic 
anhydride (1.91g, 0.195moI.) in THF was then added to the solution and it was 
stirred overnight to give a yellow precipitate. To this precipitate sodium acetate 
(1.0g, 0.151 mol.), and acetic anhydride (JOmL, 0.1 06mol.) were added. The flask 
was heated on a steam bath until completely dissolved and then for a further 30 
minutes. The resulting solution was extracted with ethyl acetate. The organic 
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fractions were combined, dried (MgS04), and the solvent concentrated under 
reduced pressure. The solution was placed in a freezer overnight resulting in 
crystallisation of a white solid which was recrystallised from ethyl acetate to give N-
(2-acetylaminophenyl)maleimide as fluffy off-white crystals (2.54g, 60%). 
m.p. 180-183°C. 
Analysis C12HlON203 calc. C, 62.60; H, 4.38; N, 12.17; found C, 62.33; H, 
4.27; N, 12.21. 
IH NMR (CDC13) 82.09 (s, 3H, CH3), 6.91 (s, 2H, COCH), 7.19-7.31 (m, 
2H, aryl CH), 7.44 (t, IH, l::7.3Hz, aryl CH), 7.84 (d, 1H, J=8.3Hz. aryl CH). 
mlz (El) 230.1 (M+), 188.1 (M-COCH2+), 170. 
High Res. C12HlON203 mlz calc. 230.06914; found 230.06925. 
Preparation of N -(N -dimethylaminoethyl)phthalimide 3.15 
o 
~o 
o 
A solution of phthalic anhydride (2.0g, 13.5mmol.) in dry toluene (l2mL) was 
brought to reflux. N,N-dimethylethylene diamine (1.63mL, 13.5mmol.) in toluene 
(8mL) was then added and the refluxing continued for two hours. The hot solution 
was filtered through anhydrous sodium sulfate and the solvent removed under 
reduced pressure. The residue was then taken up in ethyl acetate and partitioned 
with 10% sodium bicarbonate solution. The ethyl acetate fractions were combined, 
dried (MgS04), and the ethyl acetate removed under reduced pressure. The 
resultant solid was recrystallised from toluene and petroleum ether to give N-(N-
dimethylaminoethyl)phthalimide as white crystals (2.7g, 90%). 
m.p. 93-95°C. 
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1 H NMR (CDCI3) 0 2.29 (s, 6H, CH3), 2.60 (t, 2H, J=6.8Hz, 
CONCH2CH2), 3.81 (t, 8Hz, CONCH2), 7.71 (m, 2H, aryl CH), 7.84 
(m, 2H, aryl CH). 
miz (El) 218.1 (M+), 58.1. 
Res. C12H14N202miz calc. 218.10553, found 218.10509. 
lR Vmax (Nujol) 2772, 2360, 1767, 1707, 1460, 1398, 1377, 1320, 1111, 
1016,936,721 cm- 1, 
Preparation of N -(N -dimethylaminoethyl)naphthalimide 3.22 
~o------- 
o 
A solution of 2,3-naphthalic anhydride 2.19 (2g, lO.lmmol.) in dry toluene 
(12mL) was brought to reflux. N,N-dimethylethylene diamine (l.22mL, 
10.1 mmoL) in toluene (8mL) was then added and the refluxing continued for two 
hours. The hot solution was filtered through anhydrous sodium sulfate and the 
solvent removed under reduced pressure. The residue was then taken up in ethyl 
acetate and partitioned with 10% sodium bicarbonate solution. ethy 1 acetate 
fractions were combined, dried (MgS04), and the ethyl acetate removed under 
reduced pressure. Recrystallisation from toluene and petroleum ether gave N-(N-
dimethylaminoethyl)naphthalimide as long white needles (2.3g, 85%). 
m.p. 128-130Q C. 
1 H NMR (CDC13) 0 2.27 (s, 6H, CH3), 2.65 (t, 2H, J=6.8Hz, 
CONCH2CH2), 3.88 (t, 2H, J=::6.8Hz, CONCH2), 7.69 (m, 2H, aryl CH), 8.06 
(m, 2H, aryl CH), 8.33 (s, 2H, COCCH). 
miz (El) 268 (M+), 210, 154, 126, 71. 
High Res. C16H16N202 calc. 268.1212, found 268.1214. 
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lR Vmax (Nujol) 1708, 1460, 1377,1151, 1118,767 cm- I. 
Preparation of N-(2-cyanomethyl)naphthalimide 3.23 
A solution of 2,3-naphthalic anhydride 2.19 (200mg, 1.01mmol.) in dry 
toluene (5mL) was brought to reflux. Aminoacetonitrile (93.4mg, 1.01 mmol.) in 
. toluene (2.5mL) was then added and the refluxing continued for two hours. The 
hot solution was filtered through anhydrous sodium sulfate and the solvent removed 
under reduced pressure. The residue was then taken up in ethyl acetate and 
partitioned with 10% sodium bicarbonate solution. The ethyl acetate fractions were 
combined, dried (MgS04), and the ethyl acetate removed under reduced pressure. 
The resultant solid was recrystallised from toluene and petroleum ether to give N-
(2-cyanomethyl)naphthalimide as pale brown crystals (50mg, 21 %). 
m.p. 197-198°C. 
IH NMR (CDC13) 0 4.65 (s, 2H, CH2), 7.83 (m, 2H, aryl CH), 8.16 (m, 2H, 
aryl CH), 8.56 (s, 2H, COCH). 
1111z (El) 236 (M+), 192, 154, 126 
High Res. C14HgN202 111lz calc. 236.0586, found 236.0585. 
Preparation of N -(2-pyridyJ)naphthalimide 3.24 
o 
cc<':::: -D I N ~ II a a N 
o 
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A solution of 2,3-naphthalic anhydride 2.19 (200mg, 1.01111mo1.) in dry 
toluene (5mL) was brought to reflux. 2-Amino pyridine (95mg, 1.01mmo1.) in 
toluene (2.5mL) was then added and the refluxing continued for two hours. The 
hot solution was filtered through anhydrous sodium sulfate and the solvent removed 
under reduced pressure. The residue was then taken up in ethyl acetate and 
partitioned with 10% sodium bicarbonate solution. The ethyl acetate fractions were 
combined, dried (MgS04), and the ethyl acetate removed under reduced pressure. 
The resultant solid was recrystallised from toluene and petroleum ether to give N-
(2-pyridyl)naphthalimide as pale brown crystals (55mg, 20%). 
m.p. 190°C (decomp.). 
1 H NMR (CDC13) 8 7.40 (m, lH, aryl CH), 7.52 (d, IH, J=7.8Hz, aryl CH), 
7.74 (m, 2H, aryl CH), 7.94 (m, IH, aryl CH), 8.12 (m, 2H, aryl CH), 8.50 (s, 
2H, aryl CH), 8.74 (m, lH, aryl CH). 
mlz (El) 274 (M+), 246, 126. 
High Res. C17HION202 mlz calc. 274.0742, found 274.0741. 
Preparation of N -(phenyl)naphthalimide 3.25 
A solution of 2,3-naphthalic anhydride 2.19 (500mg, 2.52mmol.) in dry 
toluene (lOmL) was brought to reflux. Aniline (0.5mL, 5.49mmol.) in toluene 
(2.5mL) was then added and the refluxing continued for two hours. The solvent 
removed under reduced pressure. The residue was then taken up in ethyl acetate 
and partitioned with 10% sodium bicarbonate solution. The ethyl acetate fractions 
were combined, dried (MgS04), and the ethyl acetate removed under reduced 
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pressure. The resultant solid was recrystallised from toluene and petroleum ether to 
give N-(phenyl)naphthalimide as pale brown crystals (237mg, 34%). 
m.p. 279-282°C. 
IH NMR (CDCl3) {5 7.43-7.54 (m, 5H, aryl CH), 7.74 (m, 2H, aryl CH), 8.12 
(m, 2H, aryl CH), 8.47 (s, 2H, aryl CH). 
mlz (El) 273.1 (M+), 229.1, 126.0. 
High Res. C18HIIN02 mlz calc. 273.07898, found 273.07874. 
IR Vmax (CDCI3) 1774.4,1716.5,1500.5,1375.2 em-I. 
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Preparation of dimethyl l~methylsulfanylwll­
oxatricyclo [6.2.1.02,7] undeca -2,4, 6, 9 -tetra ene-9,1 O-dicar boxy la te 
4.17 and dimethyl 1-hydroxy-4-(methylsulfanyl)naphthaJene-2,3-
dicarboxylate 4.1864 
s 0:;0 
n-Butyl lithium (O.88mL of a l.OM solution in hexane, O.88mmol.) was added 
dropwise to a stirred solution of diisopropylamine (O.l2mL, O.88mmol.) in THF at 
O°C. The solution was stirred for ten minutes at O°C and then cooled to -78°C. A 
solution of 1 (3H)-isobenzofuranthione (l16mg, O.77mmol.) in THF was added 
and the mixture was stirred for 1 hour at -78°C. Methyl iodide (0.055mL, 
0.88mmol.) was added dropwise to the solution, whieh was then allowed to warm 
to room temperature for 2 hours. Dimethyl aeetylenedicarboxylate (0.105mL, 
O.85mmol.) in THF was added and the reaction stirred overnight. The solvent was 
removed under reduced pressure to give an oil which was partitioned between ethyl 
acetate and water. The organic layer was dried (MgS04) and the solvent removed 
under reduced pressure. Purification by radial silica chromatography gave two 
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products; dimethyl 1-methylsulfanyl-ll-oxatricyclo[6.2.1.02,7]undeca-2,4,6,9-
tetraene-9,1O-dicarboxylate 4.17 as a pale yellow oil (67.3mg, 25%) 
IH NMR (CDC13) 8 2.31 (s, 3H, SCH3), 3.77 (s, 3H, OCH3), 3.84 (s, 3H, 
OCH3), 5.97 (s, JH, OCH), 7.11 (m, 2H, aryl CH), 7.39 (m, 2H, aryl CH). 
1111z (El) 306 (1v1+), 164 (M-C6H604+). 
High Res. C15H14S05m1z calc. 306.0562; found 306.0572. 
and dimethyl I-hydroxy-4-(methylsulfanyl)naphthalene-2,3-dicarboxylate 4.18 
as a yellow oil (26.9mg, 10%). 
1 H NMR (CDC13) 8 2.31 (s, 3H, SCH3), 3.99 (s, 6H, C02CH3), 7.63 (t, tH, 
J=8.3Hz, aryl CH), 7.79 (t, lH, J=8.3Hz, aryl CH), 8.50 (d, IH, J=8.3Hz, aryl 
CH), 8,60 (d, lH, J=8.3Hz, aryl OH). 
1111z (El) 306 (M+), 290 (M-O+), 276 (M-CH20+), 259, 227,217,201,171 
High Res. C15H14S05 1111z calc. 306.0562; found 306.0556. 
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Preparation of dimethyl 9-exo-10-elldo-1-methylsulfanyl-11-
oxatricyclo [6.2.1.02,7 ]undeca-2,4,6-triene-9,1 O-dicarboxy late 4.19 
and dimethyl 9-endo-10-exo-1-methylsulfanyl-11-
oxatricyclo[ 6.2.1.02, 7]undeca-2,4,6-triene-9, 1 O-dicarboxyla te 
4.2064 
s 
eGo 
n-Butyllithium (0,48mL of a l.OM solution in hexane, 0,48mmol.) was added 
dropwise to a stirred solution of diisopropylamine (O.067mL, 0,48mmol.) in THF 
at O°C. The solution was stirred for ten minutes at O°C and then cooled to -78°e. A 
solution of 1 (3H)-isobenzofuranthione (60mg, 0,40mmol.) in THF was added and 
the mixture was stirred for 1 hour at -78°e. Methyl iodide (O.029mL, 0,48mmoL) 
was added dropwise to the solution, which was then allowed to warm to room 
temperature for 2 hours. Dimethyl fumarate (69mg, 0,48mmol.) in THF was added 
and the reaction stirred overnight. The solvent was removed under reduced 
pressure to give an oil which was partitioned between ethyl acetate and water. The 
organic layer was dried (MgS04) and the solvent removed under reduced pressure. 
This was purified by radial silica chromatography to give a mixture of dimethyl 9-
exa-l O-endo-l-methylsulfanyJ-ll-oxatricyclo[6.2.1.02,7]undeca-2,4,6-triene-
9,lO-dicarboxylate 4.19 and dimethyl 9-endo-lO-exo-l-methylsulfanyl-ll-
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oxatricyclo[6.2.1.02,7]undeca-2,4,6-triene-9, lQ-dicarboxylate 4.20 together as a 
pale yellow oil (70mg, 57%). 
4.19 (major) IH NMR (CDC13) 8 2.22 (s, 3H, SCH3), 3.21 (d, IH, J=4.4Hz, 
COCH), 3.55 (s, 3H, C02CH3), 3.79 (d, IH, J=4.4Hz, COCH), 3.80 (s, 3H, 
C02CH3), 5.68 (m, 1H, OCH), 7.27 (m, 3H, aryl CH), 7.37 (d, IH, J=7.8Hz, 
aryl CH). 
4.20 (minor) IH NMR (CDCl3) 8 2.09 (s, 3H, SCH3), 3.10 (d, IH, J=4.4Hz, 
COCH), 3.53 (s, 3H, C02CH3), 3.83 (s, 3H, C02CH3), 4.15 (d, IH, J=4,4Hz, 
COCH), 5.67 (s, lH, OCH), 7.27 (m, 3H, aryl CH), 7.37 (d, IH, J=7.8Hz, aryl 
CH). 
13C NMR (CDCI3) 12:25, 52; 19, 52.23, 52.37, 52.63, 52.67, 52.84, 80.60, 
1] 9.73, 120.70, 127.52, 127.75, 128.06, 128.23, 169.39. 
mlz (EI) 308 (M+), 164 (M-C6H604+). 
High Res. C15H16S05 mlz calc. 308.07] 8; found 308.0727. 
Preparation of 1-exo-l-hydroxy-4-methylsulfanyl-l,2-
dihydronaphthalene-2,3-dicarboxylate 4.21a and l-endo-l-hydroxy-
4-me thy lsulfanyl-l ,2-dihydronap hthalene-2,3-dicar boxylate 4.21b 
Dimethyl I-methylsulfanyl-ll-oxatricyclo[6.2.1.02,7]undeca-2,4,6-triene-9, 10-
dicarboxylate (37mg, 0.120mmoL) was stirred in dichloromethane while 
trifluoroacetic acid (14mg, 10mL, 0.240mmol.) in dichloromethane was added 
155 
Chapter 7 Experi men tal 
dropwise. The solution turned yellow straight away. The solution was stirred 
overnight. The dichloromethane was removed under reduced pressure to give 1-
exo-l-hydroxy-4-methylsulfanyl-l ,2-dihydronaphthalene-2,3-dicarboxylate 4.21a 
and l-endo-1-hydroxy-4-methylsulfanyl-l ,2-dihydronaphthalene-2,3-dicarboxylate 
4.21h together as a pale yellow oil (30mg, 82%). 
4.21a (major) I H NMR (CDCl3) 8 2.20 (s, 3H, SCH3), 3.54 (s, 3H, 
C02CH3), 3.89 (s, 3H, C02CH3), 4.15 (d, 1H, J=5.8Hz, COCH), 5.12 (d, lH, 
.9Hz, C(OH)H), 7.34-7.46 (m, 2H, aryl CH), 7.64 (d, 1H, J=6.9Hz, aryl 
CH), 7.75 (d, lH, J=7.3Hz, aryl CH). 
4.21h (minor) 1H NMR (CDCI3) 8 2.24 (s, 3H, SCH3), 3.59 (s, 3H, 
C02CH3), 3.88 (s, 3H, C02CH3), 4.19 (d, 1H, J=4.4Hz, COCH), 5.17 (d, IH, 
J=4.4Hz, C(OH)H), 7.34-7.46 (m, 2H, aryl CH), 7.63 (d, IH, J=6.9Hz, aryl 
CH), 7.90 (d, 1H, J=7.3Hz, aryl CH). 
mlz (El) 308 (M+), 290 (M-H20+). 
156 
Chapter 7 Experimental 
Preparation of 9-e ndo -13-e ndo-1-methylsulfanyl-8,11-diphenyI-
11-aza-14-oxatetracyclo [6.5.1.02 ,7.09,13] tetradeca-2,4,6-triene-
lO,12-dione 4.26 and 9-exo-13-exo-1-methylsulfanyl-8,11-diphenyl-
l1-aza-14-oxatetracyclo [6.5.1.02,7.09,13] tetradeca-2,4,6- triene-
10,12-dione 4.2967 
n-Butyllithium (2.SmL of a 1.6M solution in hexane, 4.00mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.56mL, 4.00mmol.) in THF at 
O°C. The solution was stirred for ten minutes at O°C and then cooled to -78°C. A 
solution of 3-phenyl-1 (3H)-isobenzofuranthione (7S0mg, 3.33mmol.) in THF was 
added and the mixture was stirred for 1 hour at -78°C. Methyl iodide (O.2SmL, 
4.00mmol.) was added dropwise to the solution, which was then allowed to warm 
to room temperature over a period of 2 hours. N-Phenyl maleimide (634mg, 
3.66mmol.) in THF was added and the reaction was stirred overnight. The solvent 
was removed under reduced pressure to give a brown/red oil which was partitioned 
between ethyl acetate and water. The organic layer was dried (MgS04) and the 
sol vent removed under reduced pressure. Purification by radial silica 
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chromatography and mixed solvent recrysta1lisation from ethyl acetate and 
petroleum ether gave 9-endo-l3-elldo-l-methylsulfanyl-8, 1 I-diphenyl-ll-aza-14-
oxatetracyclo[6.5 .1.02,7 .09, 13]tetradeca-2,4,6-triene-l 0, 12-dione 4.26 as white 
crystals (660mg, 48%) 
m.p. 203-205°C (lit. 202-205"C).67 
IH NMR (CDCI3) () 2.33 (s, 3H, SCH3), 3.91 (d, IH, J=8.3Hz, COCH), 
4.13 (d, IH, J=8.3Hz, COCH), 6.46 (m, 2H, aryl CH), 7.07 (d, IH, J=7.3Hz, 
aryl CH), 7.21-7.51 (m, 9H, aryl CH), 7.95 (m, 2H, aryl CH). 
13C NMR (CDCl3) () 12.49, 54.15, 54.48, 90.51, 94.6\, 121.25, 12l.47, 
126.27, 127.01, 128.50, 128.61, 128.70, 128.78, 128.89, 130.94, 135.84, 
139.96, 144.68, 171 172.96 .. 
mlz (El) 413 (M+), 365 (M-SCH3+), 240, 173. 
High Res C25H19NS03 mlz calc. 413.1086; found 413.1086. 
lR Vmax (CDCI3) 1755, 1700, 1562, 1500, 1381 em-I. 
and 9-exo-13-exo-l-methylsulfanyl-8, I1-diphenyl-ll-aza-14-oxatetracyc1o 
[6.5.1.02,7.09,13]tetradeca-2,4,6-triene-l0,12-dione 4.29 as white crystals 
(14mg, 1%). 
m.p. 202-203°C. 
1 H NMR (CDCl3) () 2.25 (s, 3H, SCH3), 3.34 (d, IH, J=6.8Hz, COCH), 
3.59 (d, lH, J=6.9Hz, COCH), 7.23-7.51 (m, 13H, aryl CH), 7.67 (d, IH, 
J=7.3Hz, aryl CH). 
mlz (El) 413 (M+), 365 (M-SCH3+), 240, ]73. 
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Preparation of 9-endo-13-e ndo -1-methylsulfanyl-8-methyl-ll-
phenyl-ll-aza-14-oxatetracyclo[6.5.1.02, 7 .09,13]tetradeca.2,4,6-
triene.lO,12-dione 4.27 
s 
eGo 
CH3 
n-Butyllithium (1.41rnL of a 1.6M solution in hexane, 2.26mmoL) was added 
dropwise to a stirred solution of diisopropylamine (0.31rnL, 2.26mmol.) in THF at 
O°C. The solution was stirred for ten minutes at ooe and then cooled to -78°C. A 
solution of 3-methyl-l(3H)-isobenzofuranthione (309mg, L88mmoL) in THF was 
added and the mixture was stirred for 1 hour at -78T. Methyl iodide (0. 14rnL, 
2.26mmol.) was added dropwise to the solution, which was allowed to warm to 
room temperature for 2 hours. N-Phenyl maleimide (326mg, 1.88mmoJ.) in THF 
was added and the reaction stirred overnight. The solvent was removed under 
reduced pressure to give an oil which was partitioned between ethyl acetate and 
water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. Radial silica chromatography followed by mixed-solvent 
recrystallisation from ethyl acetate and petroleum ether gave 9-endo-13-endo-l-
methylsulfanyl-8-methyl-ll-phenyl-II-aza-14-oxatetracyclo[6.5.1.02, 7.09,13] 
tetradeca-2,4,6-triene-1O, 12-dione as fine white needles (245mg, 37%). 
m.p. 196-19TC. 
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Analysis C20H 17NS03 calc. C, 68.36; H, 4.87; N, 3.99; found C, 68.37; H, 
4.75; N, 3.99. 
I H NMR (CDC13) 8 2.08 (s, 3H, CH3), 2.27 (s, 3H, SCH3), 3.67 (d, 1H, 
J=8.3Hz, COCH), 3.82 (d, JH, J=8.3Hz, COCH), 6.41 (m, 2H, aryl CH), 7.23-
7.38 (m, 7H, aryl CH). 
13C NMR (CDCl3) 8 172.75, 171.65, 143.77, 140.52, 130.81, 128.75, 
128.67,128.51, 128.31, 126.30, 126.14, 125.98, 121.36, 120.27, 94.80, 86.83, 
55.04, 54.25, 17.44, 12.32. 
m/z (FAB) 351 (M+), 333, 300, 178, 173, 128,91. 
High Res. C20H17NS03 calc. 351.09292; found 351.09228. 
IR Vmax (Nujol) 3032, 3020, 1717, 1499, 1460, 1385, 1279, 1182, 1117, 
1034, 908, 853,799,764 em-I. 
Preparation of 9-endo -13-endo .1-methylsulfanyl.8.ethyl-11. 
phenyl.11.aza-14.oxatetracyclo[ 6.5.1.02, 7 .09,13]tetradeca-2,4,6. 
triene.10,12-dione 4.28 
n-Butyl lithium (2.39mL of a L6M solution in hexane, 3.84mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.54mL, 3.84mmol.) in THF at 
O°c. The solution was stirred for ten minutes at O°C and then cooled to -78°C using 
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a dry ice and acetone bath. A solution of 3-ethyl-1 (3H)-isobenzofuranthione 
(570mg, 3.20mmol.) in THF was added and the mixture was stirred for 1 hour at 
-78T. Methyl iodide (0.14mL, 3.84mmo1.) was added dropwise to the solution, 
which was then allowed to warm to room temperature over a period of 2 hours. N-
Phenyl maleimide (550mg, 3.20mmo1.) in THF was added and the reaction was 
stirred overnight. The solvent was removed under reduced pressure to give an oiL 
This was partitioned between ethyl acetate and water. The organic layer was dried 
(MgS04) and the solvent removed under reduced pressure. This was purified by 
radial chromatography followed by mixed solvent recrystallisation from ethyl 
acetate and petroleum ether to give 9-endo-13-endo-l-methylsulfanyl-8-ethyl-l 
phenyl-l1-aza-14-oxatetracyclo[6.5 .1.02,7.09, 13]tetradeca-2,4,6-triene-1 0, 
dione as white crystals (55mg, 5%). 
m.p. 205-20TC. 
Analysis C21H19NS03 calc. C, 69.02; H, 5.24; N, 3.83; found C, 69.10; H, 
5.18; N, 3.79. 
IH NMR (CDC}3) 0 l.20 (t, 3R, J=7.8Hz, CH3), 2.27 (s, 3H, SCH3), 2.39-
2.65 (m, 2H, CH2), 3.72 (d, 1H, J=8.3Hz, COCH), 3.79 (d, lH, J=8.3Hz, 
COCH), 6.42 (m, 2H, aryl CH), 7.23-7.40 (m, 7H, aryl CR). 
mlz (El) 365 (M+), 347, 337, 318, 217,199. 
High Res. C21H19NS03 mlz calc. 365.10857; found 365.10821. 
IR Vmax 3028.0, 3014.5, 1716.5, 1498.6, 1379.0, 1230.5, 1222.8, 121l.2, 
1199.6, 1182.3 cm-l. 
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Preparation of N -phenyl-l-rnethylsulfanyl.4-phenyl-naphthalene-
2,3-dicarboxirnide 4.32 
SCH30 ~N-<> Vfu ~ 
Ph ~ SCH30 ~N-O 
HO Ph H 0 ~ SCH3 0 
~-o N ~/; 
Ph 0 
9-endo-13-endo-l-Methy Isulfany 1-8, Il-dipheny 1-11-aza-14-oxatetracyclo 
[6.5.1.02 ,7.09 , 13Jtetradeca-2,4,6-triene-1O, 12-dione (90mg, 0.218mmol.) was 
stirred in dichloromethane while trifluoroacetic acid (25mg, 17mL, 0.218mmo1.) in 
dichloromethane was added dropwise. A pale yellow colour was observed to form 
rapidly. The solution was stirred overnight. The dichloromethane was then 
removed under reduced pressure to give the intermediate product N-phenyl-1 
methy lsulfany lA-hydroxy -4-pheny 1-3 ,4-dihydronaphthalene-2,3-dicarboximide as 
an oiL 
1 H NMR (CDC13) 8 2.63 (s, 3H, SCH3), 4.22 (s, IH, COCH), 6.98 (m, 2H, 
aryl CH), 7.18-7.26 (m, 5H, aryl CH), 7.36-7.59 (m, 5H, aryl CH), 7.78 (d, 1H, 
J::::7.8Hz, aryl CH), 8.15 (d, 1H, J=7.8Hz, aryl CH). 
mlz (El) 395 (M-H20+), 362, 303. 
Upon a further attempt to purify N-phenyl-l-methylsulfanyl-4-hydroxy-4-
phenyl-3,4-dihydronaphthalene-2,3-dicarboximide by thin layer chromatography it 
was found to have dehydrated on the silica. This product was recrystallised from 
ethyl acetate and petroleum ether to give N-phenyl-1-methylsulfanyl-4-phenyl-
naphthalene-2,3-dicarboximide as off-white crystals (50mg, 58%). 
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m.p. 200-201 DC. 
IH NMR (CDC13) (5 1 (s, 3H, SCH3), 7.36-7.46 (m, 7H, aryl CH), 7.53-
7.55 (m, 3H, aryl CH), 7.66 (d, IH, J=S.3Hz, aryl CH), 7.S1 (m, 2H, aryl CH), 
9.10 (d, IH, J=7.SHz, aryl CH). 
/11/z (El) 395 (M+), 362, 303. 
High Res. C25H17NS02 111/Z calc. 395.0979, found 395.0973. 
Preparation of N -phenyl-l-methylsulfanyl-4-methyl-naphthalene-
2,3·dicarboximide 4.33 
9-endo-13-endo-l-Methylsulfanyl-S-methyl-l1-phenyl-ll-aza-14-oxatetracyclo 
[6.5.1.02,7 .09,13]tetradeca-2,4,6-triene-lO, 12-dione (42mg, 0.195mmol.) was 
dissolved in dichloromethane and trit1uoroacetic acid (O.OlmL, 0.215mmol.) 
added, resulting in an instant colour change of the solution to yellow. The solution 
was then stirred for 3 hours after which the solvent and excess trifluoroacetic acid 
was removed under reduced pressure, to give the intermediate product N-phenyl-l-
methylsulfanyIA-hydroxy-4-methyl-3,4-dihydronaphthalene-2,3-dicarboximide as 
an oil (33mg, 4S%). 
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I H NMR (CDC13) () 1.45 (s, 3H, CH3), 2.55 (s, 3H, SCH3), 3.92 (s, lH, 
COCH), 7.34 (d, 2H, J=8.8Hz, aryl CH), 7.43-7.54 (m, 5H, aryl CH), 7.80 (d, 
IH, J=7.9Hz, aryl CH), 8.03 (d, 1H, J=7.8Hz, aryl CH). 
To complete the aromatisation the N-phenyl-l-methylsulfanyl-4-hydroxy-4-
methyl-3,4-dihydronaphthalene-2,3-dicarboximide was dissolved in acetonitrile and 
concentrated hydrochloric acid added dropwise until a pH of 1 was reached. This 
solution was then stirred for 5 days and monitored by TLC, after which the solvent 
was removed under reduced pressure to give a solid. This was purified by a mixed 
solvent recrystallisation from ethyl acetate and petroleum ether to give N-phenyl-l-
methylsulfanyl-4-methyl-naphthalene-2,3-dicarboximide as pale yellow crystals 
(l8mg, 2 steps 28%). 
m.p. l38-l40°C. 
Analysis C20H15N02S calc. C, 72.05; H, 4.53; N, 4.20; found C, 71.98; H, 
4.32; N, 4.15. 
IH NMR (CDCI3) () 2.62 (s, 3H, CH3), 3.17 (s, 3H, SCH3), 7.43-7.56 (m, 
5H, aryl CH), 7.80 (m, 2H, aryl CH), 8.30 (m, IH, aryl CH), 9.05 (m, IH aryl 
CH). 
mlz (EI) 333.1 (M+), 300.1. 
High Res. C20H15N02S calc. 333.08235; found 333.08198. 
IR Vmax 1764.7, 1712.7, 1498.6, 1382.9, 1211.2, 1193.9, 1134.1 em-I. 
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Preparation of N -phenyl-l-methylsulfanyl.4-ethyl-naphthalene. 
2,3-dicarboximide 4.34 
9-endo-13-endo-l-Methylsulfanyl-8-ethyl-l1-phenyl-ll-aza-14-oxatetracyclo 
[6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-1O, 12-dione (6mg, 0.0164mmol.) was 
dissolved in acetonitrile and concentrated hydrochloric acid added dropwise until a 
pH of 1 was reached. This solution was then stirred for 5 days and monitored by 
TLC, after whiCh the solvent was 'removed under reduced pressure giving a clear 
oil. This was purified by radial silica chromatography to give N-phenyl-l 
methylsulfanyl-4-ethyl-naphthalene-2,3-dicarboximide as an off-white solid (4mg, 
70%). 
m.p.180-18l o C. 
Analysis C21H 17NS02 calc. C, 72.60%; 
72.81 %; H, 4.95%; N, 4.00%. 
4.93%; N, 4.03%; found C, 
1 H NMR (CDCI3) 0 1.40 (t, 3H, J=7.8Hz, CH3), 2.62 (s, 3H, SCH3), 3.74 
(q, 2H, J=7.3Hz, CH2), 7.42-7.54 (m, 5H, aryl CH), 7.80 (m, 2H, aryl CH), 
8.35 (m, lH, aryl CH), 9.09 (m, IH, aryl CH). 
m/z (El) 347 (M+, 100%),314,254,151,91. 
High Res. Cl 17N02S m/z calc. 347.09800; found 347.09837. 
IR Vmax (CDC13) 1762.8, 1710.7, 1500.5, 1384.8,1199.6,1134.1 cm-t. 
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Preparation of dimethyl 9-exo-l0-endo-l-rnethylsulfanyl·8. 
phenylsulfanyl-ll-oxatricyclo[ 6 .2.1.02,7] -undeca-2,4,6-triene-9, 1 0-
dicarboxylate 4.36 
050 - .. [~:H3l 
SPh 
~ .,\,C02CH 3 
I 0 
r:; , A C02CH 3 
SPh 
n-Butyl lithium (l.42mL of a l.OM solution in hexane, 1.42mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.2mL, 1.42mmol.) in THF at 
O°e. The solution was stirred for ten minutes at O°C and then cooled to -78°C. A 
solution of thionophthalide (97mg, 0.65mmol.) in THF was added and the mixture 
was stirred for 1 hour at -78 c e. Phenylsulfenyl chloride (0,077mL, 0.70mmol.) 
was added and the temperature kept at -78°C for a further 15 minutes, after which 
the solution was warmed to O°C for 1 hour. Methyl iodide (0.05mL, 0.80mmo1.) 
was added dropwise to the solution, which was then allowed to warm to room 
temperature for 30 minutes. Dimethyl fumarate (l02mg, 0.70mmoL) in THF was 
added and the reaction was stirred overnight. The solvent was removed under 
reduced pressure to give an orange oil which was partitioned between ethyl acetate 
and water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. This was purified twice by radial chromatography to give 
dimethyl 9-exo-l 0-endo-l-methylsulfanyl-8-phenylsulfanyl-11-oxatricyc10 
[6.2, 1.02,7]-undeca-2,4,6-triene-9, lO-dicarboxylate as a yellow oil (lmg, 0.4%). 
1 H NMR (CDCI3) 0 2.38 (s, 3H, SCH3), 3,20 (d, IH, J=3.9Hz, COCH), 
3,36 (d, IH, J=4.4Hz, COCH), 3.51 (s, 3H, C02CH3), 3.81 (8, 3H, C02CH3), 
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7.06-7.80 (m, 7H, aryl CH), 7.99 (d, IH, J=8.3Hz, aryl CH), 8.07 (d, 1H, 
J=7.3Hz, aryl CH). 
mlz (El) 416 (M+), 307 (M-SC6H5+), 272, 257, 149. 
High Res. C21H20S205 mlz calc. 416.07529; found 416.07515. 
Preparation of N,N'-dibutyl 9-exo-10-endo-l-methylsulfanyl-ll-
oxa tricyclo[ 6.2.1.02, 7]undeca-2,4,6-triene-9,1 O-dicarboxamide 4.44 
s 
cCo _" [ce:H3 J 
C4H9HNOC~CON~ 
n-Butyllithium (0.33mL of a 1.6M solution in hexane, 0.51Ommol.) was added 
dropwise to a stirred solution of diisopropylamine (0.072mL, 0.51Ommol.) in THF 
at O°C. The solution was stirred for ten minutes at O°C and then cooled to -78°C. A 
solution of thionophthalide (64.7mg, 0.431mmol.) in THF was added and the 
mixture was stirred for 1 hour at -78°C. Methyl iodide (0.033mL, 0.510mmol.) 
was added dropwise to the solution, which was then allowed to warm to room 
temperature over a period of 2 hours. N,N'-Dibutyl fumaramide (lOlmg, 
0.446mmol.) in THF was added and the reaction was stirred overnight. The 
solvent was removed under reduced pressure to give a red oil. This was paltitioned 
between ethyl acetate and water. The organic layer was dried (MgS04) and the 
sol vent removed under reduced pressure to give N,N-dibutyl 9-exo-1O-endo-l-
methylsulfanyl-ll-oxatricyclo[ 6.2.1.02, 7]undeca-2,4,6-triene-9, 10-dicarboxamide 
as a clear oil (33.5mg, 20% ). 
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IH NMR (CDC]3) d 0.84 (m, 3H, CH3), 0.92 (m, 4H, CH2CH3), 1.14-1.49 
(m, 4H, NHCH2CH2), 2.28 (s, 3H, SCH3), 2.75 (d, lH, J=4.9Hz, COCH), 
2.94 (d, 1H, J=5.4Hz, COCH), 3.03-3.36 (m, 4H, NHCH2), 5.71 (d, 1H, 
J=9.3Hz, OCH), 7.36-7.70 (m, 3H, aryl CH), 7.95 (d, 1H, J=7.3Hz, aryl CH). 
1111z (El) 389 (M+), 316, 200. 
High Res. C21H29N2S03 lnlz calc. 389.1900; found 389.1898. 
Preparation of N,N'-dibutyl 9-exo-IO-endo-l-methylsulfanyl-8-
phenyl-ll-oxatricyc1o[ 6.2.1.02, 7Jundeca-2,4,6-triene-9, 10-
dicarboxamide 4.45 
C4H9HNOC~CON~ SCHX) 
H Il 
..• \' NHC H o 4 9 
n-Butyllithium (0.67mL of a 1.6M solution in hexane, 1.068mmol.) was added 
dropwise to a stirred solution of diisopropylamine (O.l5mL, 1.068mmol.) in THF 
at O°c. The solution was stirred for ten minutes at O°C and then cooled to -78°C. 
A solution of 3-phenyl thionophthalide (200mg, 0.89mmol.) in THF was added 
and the mixture was stirred for 1 hour at -78°C. Methyl iodide (0.066mL, 
1.068mmol.) was added dropwise to the solution, which was then allowed to warm 
to room temperature over a period of 2 hours. N,N-Dibuty] fumaramide (201mg, 
0.89mmol.) in THF was added and the reaction was stirred overnight. The solvent 
was removed under reduced pressure to give a yellow oil. This was partitioned 
between ethyl acetate and water. The organic layer was dried (MgS04) and the 
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sol vent removed under reduced pressure. This was purified by radial 
chromatography. Further impurities were removed by dissolving in 
dichloromethane and filtering to give N,N'-dibutyl 10-endo-l-
methylsulfanyl-8-phenyl-11-oxatricyclo[6.2.1.02,7]undeca-2,4,6-triene-9, 10-
dicarboxamide as a yellow solid (105mg, 25%). 
m.p. 202-20YC. 
1 H NMR (CDC13) 0 0.77 (m, 3H, CH3), 0.85-0.97 (m, 
(m, 3H, CH3), 1 1.52 (m, 4H, NHCH2CH2), 2.33 (s, 
CH2CH3), 1.04 
SCH3),2.90-3.12 
(m,4H, 
COCH),7.1 
), 3.36 (d, 1H, J=4.9Hz, COCH), 3.66 (d, 1H, J=4.4Hz, 
(m, 3H, aryl CH), 7.34-7.47 (m, 4H, aryl CH), 7.59 (d, 1H, 
J=8.3Hz, aryl CH), 7.657 (d, 1H,.J=8.3Hz, aryl CH). 
m/z eEl) 466.2 (M+), 393.1,346.1, 277.1, 240.1. 
High Res. C27H34N2S03 calc. 466.22902; found 466.22896. 
Preparation of 9-endo -13-endo-l-methylsulfanyl-8-phenyl-ll-(3-
nitrophenyl)-11-aza-14-oxatetracyclo[ 6.5.1.02, 7 .09 ,13]tetradeca-
2,4,6-triene-lO,12-dione 4.48 
n-Butyl lithium (0.65mL of a 1.6M solution in hexane, 1.00mmol.) was added 
dropwise to a stirred solution of diisopropylamine (O.l4mL, 1.00mmoL) in THF at 
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O°e. The solution was stirred for ten minutes at O°C and then cooled to -78°e. A 
solution of 3-phenyl-l (3H)-isobenzofuranthione (l80mg, 0.802mmol.) in THF 
was added and the mixture was stirred for 1 hour at -78°C. Methyl iodide 
(0.065mL, 1.00mmol.) was added drop wise to the solution, which was then 
allowed to warm to room temperature over a period of 2 hours. N-(3-
Kitrophenyl)maleimide (175mg, 0.802mmo1.) in THF was added and the reaction 
was stirred overnight. The solvent was removed under reduced pressure to give a 
brown oil. This was partitioned between ethyl acetate and water. The organic layer 
was dried (MgS04) and the solvent removed under reduced pressure. Purification 
by radial silica chromatography gave 9-endo-13-endo-l-methylsulfanyl-8-phenyl-
11-(3-nitrophenyl)-11-aza-14-oxat~tracyclo[6.5.1.02,7.09, 13]tetradeca-2,4,6-
triene-1O,12-dione as a clear oil (20.3mg, 6%). 
1 H NMR (CDC13) (5 2.37 (s, 3H, SCH3), 4.00 (d, 1H, J=8.3Hz, COCH), 
4.25 (d, IH, J=8.8Hz, COCH), 6.99 (d, 1H, J=7.8Hz, aryl CH), 7.07 (d, 1H, 
J=7.4Hz, aryl CH), 7.12 (d, IH, J=6.4Hz, aryl CH), 7.29-7.81 (m, 5H, aryl 
CH), 7.93 (m, 2H, aryl CH), 8.15 (d, IH, J=7.4Hz, aryl CH), 8.23 (d, IH, 
J=7.4Hz, aryl CH), 8.55 (d, IH, J=8.3Hz, aryl CH). 
mlz (El) 458 (M+), 412 (M-N02+). 
High Res. C25H18N2S05 mlz calc. 458.0937; found 458.0962. 
Preparation of 9-endo -13-endo-1-methylsulfanyl-8-pheny 1-11-(2· 
acetamidopheny l)-11-aza-14-oxatetracyclo [6.5.1.02,7.09 ,13] 
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tetradeca-2,4,6-triene-l0,12-dione 4.49 and 9-exo-13-exo-l-
methy Isulfanyl-8-phenyl-l1-(2-acetamidophenyl)-1l-aza-14-
oxatetracyclo[6 1.02,7.09 ,13] tetradeca-2,4,6-triene-l0,12-dione 
4.51 
n-Butyl lithium (l.OmL of a 1.6M solution in hexane, 1.54mmol.) was added 
dropwise to a stirred solution of diisopropylamine (O.22mL, 1.54mmol.) in THF at 
O°C. The solution was stirred for ten minutes at O°C and then cooled to -78T. A 
solution of 3-phenyl-l (3H)-isobenzofuranthione (290mg, 1.29mmol.) in THF was 
added and the mixture was stirred for 1 hour at -78°C. Methyl iodide (O.lOmL, 
1.54mmol.) was added dropwise to the solution, which was then allowed to warm 
to room temperature over a period of2 hours. N-(2-Acetylaminophenyl)maleimide 
(296mg, 1.29mmol.) in dichloromethane was added and the reaction was stirred 
overnight. The solvent was removed under reduced pressure to give an oil which 
was partitioned between ethyl acetate and water. The organic layer was then dried 
(MgS04) and the solvent removed under reduced pressure. This was purified by 
radial silica chromatography to give 9-endo-13-endo-l-methylsulfanyl-8-phenyl-l1-
1 71 
(2-acetamidophenyl)-11-aza-14-oxatetracyclo[6.5.1.02,7.09, 13]tetradeea-2,4,6-
triene-10,l2-dione 4.49 as a white solid (80.0mg, 13.2%) 
m.p. 21 15°C. 
1 H NMR (CDC13) (5 1.95 (s, 3H, CH3), 2.33 (s, 3H, CH3), 3.98 (d, IH, 
J=8. COCH), 4.20 (d, 1H, J=8.3Hz, COCH), 5.65 (d, 1H, J=7.8Hz, aryl 
CH), 6.92 (t, 1H, J=7.8Hz, aryl CH), 7.04 (d, IH, J=7.3Hz, aryl CH), 1-7.52 
(m, 7H, aryl CH), 7.62 (d, 1H, J=8.3Hz, aryl CH), 7.90 (m, 2H, aryl CH). 
mlz (El) 470 (M+), 428 (M-COCH2+). 
High Res. C27H22N2S04 mlz calc. 470.13004; found 470.12996. 
lR vmax 3018.4, 1716.5, 1510.2, 1450.4, 1377.1,1236.3,1199.6 em-I. 
and 9-exo-1 I-methy Isulfanyl-8-phenyl-ll-(2-acetamidophenyl)-11-aza-
14-oxatetraeyclo[6.5.1.02,7 .09, 13]tetradeea-2,4,6-triene-1O, 12-dione 4.51 as a 
pale yellow solid (7.1 mg, 1.2 %). 
m.p. 215°C (decomp.). 
1 H NMR (CDCI3) (5 2.23 (s, 3H, CH3), 2.27 (s, 3H, CH3), 3.38 Cd, IH, 
J=6.4Hz, COCH), 3.68 (d, 1H, .T=6.4Hz, COCH), 7.07-7.52 (m, 11H, aryl CH), 
7.59 (d,lH, J=6.8Hz, aryl CH), 8.31 (d, lH, .T=8.3Hz, aryl CH). 
mlz (El) 470 (M+), 428 (M-COCH2+). 
High Res. C27H22N2S04 mlz calc. 470.13004; found 470.12989. 
13C NMR (CDCI3) (5 12.22, 53.67, 53.90, 54.22, 88.96, 100.08, 107.27, 
110.09, 119.96, 121.96, 
132.34. 
.73, 125.28, 127.57, 127.97, 128.11, 129.82, 
IR Vmax 3018.4, 1720.4, 1525.6, 1458.1, 1382.9, 1301.9, 1236.3, 
1195.8 em-I. 
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Preparation of 9-e ndo-13-e ndo -1-methylsulfanyl-8-methyl-11-(2-
acetamidophenyl)-11-aza-14-oxatetracyclo[ 6.5.1.02,7.09,13] 
tetradeca-2,4,6-triene-10,12-dione 4.50 and 9-exo -13-exo-1-
methylsulfanyl-8-methyl-11-(2-acetamidophenyl)-11-aza-14-
oxa tetracyclo[6.5.1.02, 7 .09,13]tetradeca-2,4,6-triene-10, 12-dione 
4.52 
n-Butyllithium (O.26mL of a 1.6M solution in hexane, OA13mmol.) was added 
dropwise to a stirred solution of diisopropy lamine (O.06mL, 0.413mmol.) in THF 
at oDe. The solution was stirred for ten minutes at ooe and then cooled to -78°C. A 
solution of 3-methyl-l(3H)-isobenzofuranthione (61.7mg, O.376mmol.) in THF 
was added and the mixture was stirred for 1 hour at -78°C. Methyl iodide 
(O.0024mL, 0.413mmol.) was added dropwise to the solution, which was then 
allowed to warm to room temperature over a period of 2 hours. N-(2-
Acetylaminophenyl)maleimide (86Amg, O.376mmol.) in dichloromethane was 
added and the reaction was stirred overnight. The solvent was removed under 
reduced pressure to give an oil which was partitioned between ethyl acetate and 
water. The organic layer was dried (MgS04) and the solvent removed under 
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reduced pressure. This was purified by radial silica ehromatography to give 9-
mdo-13-endo-l-methy Isulfanyl-S-methy 1-11-(2-acetamidophenyl)-11-aza-14-
oxatetracyclo [6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-1O, 12-dione 4.50 as fine 
white crystals (40.9mg, 26.6%) 
m.p. 279-2S0°C. 
Analysis C22H20N2S04 calc. C, 64.69; H, 4.94; N, 6.86; found C, 64.95; H, 
4.73; N, 6.80. 
1 H NMR (CDC13) 0 2.10 (s, 3H, CH3), 2.16 (s, 3H, NHCOCH3), 2.17 (s, 
3H, SCH3), 3.12 (d, IH, J=6.4Hz, COCH), 3.24 (d, lH, J=6.4Hz, COCH) , 
7.18-7.22 (m, 2H, aryl CH), 7.36-7.49 (m, 5H, aryl CH), 8.40 (d, IH, J=8.3Hz, 
aryl CH). 
mlz (El) 408 (M+), 366 (M-COCH2+). 
High Res. C22H20N2S04 mlz calc. 408.11445; found 408.11495. 
13C NMR (CDC13) 0 12.05, 14.12, 24.10, 53.87, 54.21, 94.57, 110.09, 
118.71, 119.92, 122.01, 123.86, 127.81, 127.90, 128.18, l30.02, 133.90, 
162.99. 
lR Vmax 3022.2,1718.5,1529.4,1458.1,1384.8,1190.0 em-I. 
and 9-exo-13-exo-1-methylsulfanyl-8-methyl-11-(2-acetamidophenyl)-ll-aza-
14-oxatetracyclo[6.5.1.02,7 .09, 13]tetradeca-2,4,6-triene-1O, 12-dione 4.52 as a 
white solid (1.7mg, l.1%). 
m.p. 280-28J"C. 
I H NMR (CDCI3) 0 1.96 (s, 3H, CH3), 2.07 (s, 3H, NHCOCH3), 2.26 (s, 
3H, SCH3), 3.72 (d, 1 J=7.8Hz, COCH), 3.86 (d, IH, J=7.8Hz, COCH), 
5.65 (d, IH, J=7.9Hz, aryl CH), 6.95 (t, IH, J=7.8Hz, aryl CH), 7.28 (m, 3H, 
aryl CH), 7.39 (m, 2H, aryl CH), 7.63 (d, IH, J=7.8Hz, aryl CH). 
mlz eEl) 408 (M+), 366 (M-COCH2+). 
High Res. C22H20N2S04 mlz calc. 408.11445; found 408.11501. 
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L3C NMR (CDCI3) 0 11.83, 16.94, 53.86, 54.77, 61.94, 77.54, 87.08, 
101.17,113.70,119.85,120.93,124.87,125.18, 126.69, 128.00,128.32, 
1 29.09, 15 3 047. 
IR Vmax 3024.2,1716.5,1514.0,1456.2,1375.2,1236.3, l180A em-I. 
Preparation of 9-endo-13-endo -1-methylsulfanyl-8-pheny 1-11-(3-
acetamidopheny l) -11-aza-14-oxatetracyclo[ 6.5.1.02, 7 .09 ,13] 
tetradeca-2,4,6-triene-10,12-dione 4.53 and 9-exo-13-exo-1-
methylsulfanyl-8-pheny 1-11-(3-acetamidophenyl)-11-aza-14-
oxatetracyclo[ 6.5.1.0~, 7.09,13J tetradeca-2,4,6-triene-10,12-dione 
4.55 
n-ButyI lithium (l.OmL of a 1.6M solution in hexane, 1.54mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.22mL, 1.54mmol.) in THF at 
O°c. The solution was stirred for ten minutes at OT and then cooled to -78°C using 
a dry-ice and acetone bath. A solution of 3-phenyl-l(3H)-isobenzofuranthione 
(290mg, L29mmol.) in THF was added and the mixture was stirred for 1 hour at 
-78 Q C. Methyl iodide (O.lOmL, 1.54mmoI.) was added dropwise to the solution, 
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which was then allowed to warm to room temperature over a period of 2 hours. N-
(3-Acetylaminophenyl)maleimide (296mg, 1.29mmol.) in dichloromethane was 
added and the reaction was stirred overnight The solvent was removed under 
reduced pressure to give an oil which was partitioned between ethyl acetate and 
water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. This was purified by radial silica chromatography to give both 9-
erulo-13-endo-l-methy Isulfany 1-8-pheny 1-11-(3-aeetamidopheny 1)-11-aza-14-
oxatetraeyelo[6.5.1.02 ,7 .09, 13]tetradeea-2,4,6-triene-10, 12-dione 4.53 as a 
yellow oil (78.4mg, 12.9%) 
1 H NMR (CDC13) 8 2.02 (s, IH, CH3), 2.11 (s, 1H, CH3), 2.35 (s, 1H, 
CH3), 3.96 (d, lH, J=8.3Hz, COCH), 4.20 (d, 1H, J=8.3Hz, COCH), 5.98 (d, 
1H, J=7.4Hz, aryl CH), 6.84 (s, 1H, aryl CH), 7.00-7.09 (m, 3H, aryl CH), 
7.27-7.52 (m, 4H, aryl CH), 7.61 (m, 1H aryl CH), 7.68 (m, IH, aryl CH), 7.93 
(d, 2H, aryl CH). 
mlz eEL) 470 (M+), 428 (M-COCH2+). 
High Res. C27H22N2S04 mlz calc. 470.13004; found 470.12994. 
13C NMR (CDCI3) 8 12.23, 52.27, 53.64, 54.07, 94.09, 110.70, 115.25, 
115.55, 116.89, 119.09, 120.70, 120.85, 121.10, 124.69, 126.45, 128.05, 
128.11, 128.25, 128.50, 128.66, 129.04, 135.20, 139.35. 
lR vmax 3018.4, 1716.5, 1693.4, 1608.5, 1529.4, 1490.9, 1236.3, 
1222.8 em-I. 
and 9-exo-13-exo-1-methylsulfanyl-8-phenyl-11-(3-acetamidophenyl)-11-aza-
14-oxatetraeyclo[6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-1O, 12-dione 4.55 as a 
yellow oil (2.0mg, 0.3%). 
I H NMR (CDCI3) 8 2.05 (s, IH, CH3), 2.15 (s, lH, CH3), 2.36 (s, lH, 
CH3), 4.34 (d, 1H, J=5.8Hz, COCH), 4.75 (d, IH, J=5.8Hz, COCH), 6.85 (s, 
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tH, aryl CH), 6.96 (d, IH, J=9.3Hz, aryl CH), 7.10-7.59 (m, 9H, aryl CH), 7.97 
(d, IH, J=8.3Hz, aryl CH), 8.20 (d, IH, J=9.3Hz, aryl CH). 
1I11z (El) 470 (M+), 428 (M-COCH2+). 
High Res. C27H22N2S04 111/Z calc. 470.13004; found 470.13026. 
lR Vmax 3018.4, 1720.4, 1608.5,1529.4, 1492.8, 1379.0, 1344.3, 1236.3 
Preparation of 9-endo -13-endo-1-methylsulfanyl-8-methyl-11-(3-
acetamidophenyl) -11-aza-14-oxatetracyclo [6.5.1.02,7.09,13] 
tetradeca-2,4,6-triene-10,12-dione 4.54 and 9-exo-13-exo-1-
methylsulfanyl-8-methy 1-11- (3-acetamidophenyl) -11-aza-14-
oxatetracyclo[ 6.5.1.02,7 .09,13]tetradeca-2,4,6-triene-l 0,12-dione 
4.56 
o 
H3C---{ 
n-Butyllithium (0.26mL of a 1.6M solution in hexane, 0.413mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.06mL, 0.413mmol.) in THF 
at O°c. The solution was stirred for ten minutes at O°C and then cooled to -78°C. A 
solution of 3-methyl-l(3H)-isobenzofuranthione (6L7mg, 0.376mmol.) in THF 
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was added and the mixture was stirred for 1 hour at -78°C. Methyl iodide 
(0.0024mL, 0.413mmol.) was added dropwise to the solution, which was then 
allowed to warm to room temperature over a period of 2 hours. N -(3 
Acerylaminophenyl)maleimide (86.4mg, 0.376mmol.) in dichloromethane was 
added and the reaction was stirred overnight. The solvent was removed under 
reduced pressure to give an oil which was partitioned between ethyl acetate and 
water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. This was purified by radial silica chromatography to give both 9-
endo-13-endo-l-methylsulfany 1-8-methy l-11-(3-acetamidopheny 1)-ll-aza-14-
oxatetracyc1o [6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-1O, 12-dione 4.54 as a pale 
yellow oil (77.7mg, 50.6%) 
IH NMR (CDCl3) 8 2.01 (s, IH, CH3), 2.08 (s, 1H, NHCOCH3), 2.27 (s, 
lH, SCH3), 3.67 (d, 1H, .8Hz, COCH), 3.81 (d, 1H, J=8.8Hz, COCH), 
5.92 (m, IH aryl CH), 6.92 (s, 1H, aryl CH), 7.04 (m, 2H, aryl CH), 7.28-7.44 
(m, 4H, aryl CH). 
mlz (El) 408 (M+), 366 (M-COCH2+). 
High Res. C22H20N2S04 mlz calc. 408.11445; found 408.11468. 
13C NMR (CDCl3) 8 11.86, 16.95, 23.96, 53.87, 54.65, 86.39, 94.31, 
116.85,118.98,119.77,120.81,120.91,128.01, 128.40, 128.52, 130.64, 
138.16, 139.91, 143.18, 167.58, 171.40, 172.29. 
lR Vmax 1716.5, 1529.4, 1492.8, 1444.6, 1377.1, 1236.3, 1197.7, 
1186.1 ern-I. 
and 9-exo-13-exo-l-methylsulfanyl-8-methyl-11-(3-acetamidophenyl)-11-aza-
14-oxatetracyc10 [6.5.1.02,7 .09, 13]tetradeca-2,4,6-triene-1O, 12-dione 4.56 as a 
pale yellow oil (21.5mg, 14.0%). 
1 H NMR (CDCl3) 8 2.01 (s, 3H, CH3), 2.08 (s, 3H, NHCOCID), 2.13 (s, 
3H, SCH3), 3.05 (d, IH, J=6.4Hz, COCH), 3.19 (d, IH, J=6.4Hz, COCH), 
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7.02 (d, IH, J:::7.8Hz, aryl CH), 7.27-7.43 (m, 5H, aryl CH), 7.53 (s, 1H, aryl 
CH), 7.94 (s, IH, aryl CH). 
mlz (El) 408 (M+), 366 (M-COCH2+). 
High Res. C22H20N2S04 rnlz calc. 408.11445; found 408.11499. 
I3C NMR (CDC13) 8 172.67, 171.67, 146.74, 142.84, 139.55, 128.98, 
127.85,127.57,121.43,119.91,119.38,118.47,117.01, 111.63,94.12,85.83, 
71.24,54.07, .60,24.00,14.10,11.99. 
lR Vmax 1714.6, 1606.6, 1492.8, 1444.6, 1380.9, 1197.7 cm- I . 
Preparation of N -(2-acetamidophenyl) I-methylsulfanyl.8-phenyl-
naphthalene-,2,3.dicarboximide 4.57 
1-Methylsulfany 1-8-phenyl-ll-(2-acetamidophenyl)-11-aza-14-oxatetracyclo 
[6.5.1.02,7 .09,13]tetradeca-2,4,6-triene-1O,12-dione (6.0mg, 0.0132mmol.) was 
dissolved in acetonitrile and concentrated hydrochloric acid added dropwise to a pH 
of 1. This solution was then stirred for 2 days after which the solvent was removed 
under reduced pressure to give an oil. This was purified by radial silica 
chromatography to give N-(2-acetamidophenyl) I-methylsulfanyl-8-phenyl-
naphthalene-2,3-dicarboximide as a pale yellow oil (2.0mg, 34%). 
1H NMR (CDC13) 8 2.05 (s, 3H, CH3), 2.69 (s, 3H, SCH3), 7.28-7.67 (m, 
9H, aryl CH), 7.79 (m, 3H, aryl CH), 9.07 (d, IH, J=8.3Hz, aryl CH). 
mlz (El) 452.1 (M+), 410.1 (M-COCH2+), 377.1. 
High Res. C27H20N2S03 mlz calc. 452.11947; found 452.11927. 
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Preparation of N~(2~acetamidophenyl) 1-methy)sulfany]·8-methyl-
naphthalene-2,3-dicarboximide 4.58 and N-(2-aminophenyl) 1-
methylsulfanyl-8-methyl-naphthalene-2,3-dicarboximide 4.59 
o 
SCH }-CHs 
HS 0 HN 
-{I 
~ 
I-Methy Isulfany l-S-methy 1-11-(2-acetamidopheny l)-11-aza-14-oxatetracyc10 
[6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-1 0, 12-dione (9.5mg, 0.0233mmol.) was 
dissolved in acetonitrile and concentrated hydrochloric acid added dropwise until a 
pH of 1 was reached. This solution was then stirred for 5 days and monitored by 
TLC, after which the solvent was removed under reduced pressure to give an oil. 
This was purified by radial silica chromatography to give N-(2-acetamidophenyl) 1-
methy1sulfanyl-S-methyl-naphthalene-2,3-dicarboximide 4.58 as a pale brown oil 
(4.0mg,44%) 
I H NMR (CDCl3) 0 2.0S (s, 3H, COCH3), 2.62 (s, 3H, SCH3), 3.16 (s, 3H, 
CH3), 6.93 (t, JH, J=S.3Hz, aryl CH), 7.19 (d, 1H, J=S.3Hz, aryl CH), 7.30-
7.70 (m, 6H, aryl CH). 
mlz (El) 390.1 (M+), 34S.1 (M-COCH2+). 
High Res. C22H 1SN 2S03 mlz calc. 390.1 03S2 ; found 390.1 03S2. 
IR Vmax (CDC13) 2927.7, 1762.S, 170S.S, 1515.9, 1456.2, 1379.0, 1236.3, 
1197.7,1136.0 em-I. 
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and N-(2-aminophenyl) l-methy Isulfanyl-8-methyl-naphthalene-2,3 
dicarboximide 4.59 as a yellow solid (1.1 mg 14%). 
m.p. 225-22TC. 
1 H NMR (CDC13) (3 2.62 (s, 3H, SCH3), 3.16 (s, 3H, CH3), 6.93 (m, 2H, 
aryl CH), 7.19 (d, 1H, J=6.9Hz, aryl CH), 7.28 (m, 1H, aryl CH), 7.81 (m,2H, 
aryl CH), 8.32 (d, IH, J=7.3Hz, aryl CH), 9.06 (d, IH, J=7.3Hz, aryl CH). 
mlz (El) 348.1 (M+), 297.1. 
High Res. C20H16N2S02 mlz calc. 348.09325 ; found 348.09349. 
IR Vmax (CDC13) 1760.9, 1708.8, 1504.4, 1380.9, 1234.4, 1218.9, 
1199.6 em-I, 
Preparation of N -(3-acetamidophenyl) I-methylsulfanyl-8-phenyl-
naphthalene-2,3-dicarboximide 4.60 and N-(3-aminophenyl) 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide 4.62 
SCH H3 C-f 
H3 0 NH 
o -{ > 
~ 
I-Methy Isulfanyl-8-pheny 1-11-(3-acetruuidophenyl)-11-aza-14-oxatetracyclo 
[6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-1O, 12-dione (l5.0mg, 0.0319mmol.) was 
dissolved in acetonitrile and concentrated hydrochloric acid added dropwise until a 
pH of 1 was reached. This solution was then stirred for 5 days and monitored by 
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TLC, after which the solvent was removed under reduced pressure to give an oiL 
This was purified by radial silica chromatography to give both N-(3 
acetamidopheny 1) 1-methy lsulfany 1-8-phenyl-naphthalene-2,3-dicarboximide 4.60 
as a yellow oil ( 6mg, 41 %) 
I H NMR (CDCI3) 8 2.15 (s, 3H, CH3), 2.70 (s, 3H, SCH3), 7.01 (m, 1H, 
aryl CH), 7.22 (m, 1H, aryl CH), 7.30 (d, JH, J==8.3Hz, aryl CH), 7.37-7.44 (m, 
aryl CH), 7.52-7.70 (m, 4H, aryl CH), 7.81 (t, 2H, J=7.7Hz, aryl CH), 7.99 
(d, 1H, J::::7.9Hz, aryl CH), 9.10 (d, IH, J=8.3Hz, aryl CH). 
1111z (El) 452.1 (M+), 410.1 (M-COCH2+), 377.1. 
High Res. C27H20N2S03 1111z calc. 452.11947; found 452.11902. 
and N-(3 aminophenyl) 1-methylsulfanyl-8-phenyl-naphthalene-2,3-
dicarboximide 4.62 as a yellow oil (2mg, 15%). 
1 H NMR (CDC]3) 8 2.70 (s, 3H, SCH3), 6.67 (d, 1H, J=7.8Hz, aryl CH), 
6.76 (s, 1H, aryl CH), 6.84 (d, 1H, J=7.9Hz, aryl CH), 7.22 (t, lH, J=8.3Hz, 
aryl CH), 7.39 (m, 2H, aryl CH), 7.54 (m, 3H, aryl CH), 7.64 (t, lH, J=8.3Hz, 
aryl CH), 7.80 (t, 2H, J=7.8Hz, aryl CH), 9.09 (d, 1H, J=8.3Hz aryl CH). 
mlz (El) 410.1 (M+), 377.1. 
High Res. C25H18N2S02 mlz calc. 410.10890; found 410.10967. 
IR Vmax (CDCI3) 3030.0,3018.4,1716.5,1379.0,1222.8,1215.1 em-I. 
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Preparation of N -(3-acetamidophenyl) I-methylsulfanyl-8-methyl. 
naphthalene-2,3-dicarboximide 4.61 and N -(3-aminophenyl) 1· 
methylsulfanyl-8-methyl-naphthalene-2,3-dicarboximide 4.63 
I-Methylsulfanyl-8-methyl-ll-(3-acetamidophenyl)-11-aza-14-oxatetracyc10 
[6.5.1.02,7 .09, 13Jtetradeca-2,4,6-triene-l 0,12-dione (16.4mg, 0.0402mmol.) was 
dissolved in acetonitrile and concentrated hydrochloric acid added dropwise until a 
pH 1 was reached. This solution was then stirred for 5 days and monitored by 
TLC, after which the solvent was removed under reduced pressure to give an oil. 
This was purified by radial silica chromatography to give N-(3-acetarrridophenyl) 1-
methylsulfanyl-8-methyl-naphthalene-2,3-dicarboximide 4.61 as a pale yellow 
solid (5.3mg, 34%) 
m.p. 155-156°C. 
IH NMR (CDCI3) 0 2.18 (s, 3H, COCH3), 2.61 (5, 3H, SCH3), 3.16 (s, 3H, 
CH3), 7.38 (m, 1H, aryl CH), 7.48 (t, lH, J=7.8Hz, aryl CH), 7.56 (d, IH, 
J=7.8Hz, aryl CH), 7.70 (s, lH, aryl CH), 7.80 (m, 2H, aryl CH), 8.32 (d, IH, 
J=7.8Hz, aryl CH), 9.06 (d, lH, J=7.8Hz, aryl CH). 
mlz (EI) 390.1 (M+), 348.1 (M-COCH2+), 315.1. 
High Res. C22H18N2S03 mlz calc. 390.10382; found 390.10346. 
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IR Vmax (CDCI3) 3018.4, 1762.8, 1708.8, 1606.6, 1492.8, 1419.5, 1382.9, 
1234.4, 1207.4 ern-i. 
and N -( 3- aminopheny I) I-me thy Isulfany 1-8 -methy I-naphthal ene-2,3 
dicarboximide 4.63 as a red-brown solid (0.8mg, 6%). 
m.p. 166-168°C. 
1 H NMR (CDCI3) (5 2.62 (s, 3H, SCH3), 3.17 (s, 3H, CH3), 6.74 (d, lH, 
aryl CH), 6.81 (s, IH, aryl CH), 6.87 (d, 1H, J:=7.3Hz, aryl CH), 7.30 
(t, 1 .8Hz, aryl CH), 7.80 (m, 2H, aryl CH), 8.31 (d, IH, J=6.9Hz, aryl 
CH), 9.06 Cd, 1H, J=6.9Hz, aryl CH). 
111/Z 348.1 (M+), 315.1. 
Res. C20H16N2S02 111/Z calc. 348.09325; found 348.09364. 
IR Vmax (CDCl3) 3018.4,1708.8,1234.4,1199.6 em-I. 
Preparation of 4-hydroxybenzyl alcohol 4.68 
~H HOJl) ~H ~oJl) 
4-Hydroxybenzaldehyde (lOg, 81.9mmol.) was dissolved in methanol (lOrnL) 
and added dropwise to a solution of NaBH4 in methanol (10%, lOmL). The pH 
was adjusted to 7 and the solution was stirred until the reaction was complete. The 
solvent was removed under reduced pressure giving a pink solid. This was washed 
with a little cold water and recrystallised from water to give 4-hydroxybenzyl 
alcohol as pale pink crystals (lO.17g, 100%). 
m.p. 120-122°C. 
1 NMR (CD30D) (54.47 (s, 2H, CH2), 6.73-6.75 (m,2H, aryl CH), 7.15-
7.17 (m, 2H, aryl CH). 
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Preparation of 4-chloromethylphenyl acetate 4.69 
Acetyl chloride (50mL) was stirred in an open flask, cooled in an ice-bath. 4-
Hydroxybenzyl alcohol (l1.45g, 92.2mmol.) was slowly added, causing HCI gas 
to be evolved. The mixture was left to stir overnight to allow the excess acetyl 
chloride to evaporate. The resulting solution was neutralised with NaHC03. This 
was then transferred to a separating funnel and extracted twice with ethyl acetate. 
The combined organic extracts were dried over MgS04, filtered, and the solvent 
removed under reduced pressure to give a brown oil. This was distilled under 
vacuum (15WC, 1.5mmHg) to give 4-chloromethylphenyl acetate as a clear oil 
which solidified on cooling as a white powder (6.92g, 40%). 
NMR (CDC13) 0 2.28 (s, 3H, CH3), 4.56 (s,2H, CH2), 7.07-7.10 (d, 2H, 
J=8.7Hz, aryl CH), 7.39-7.42 Cd, 2H, J=8.3Hz, aryl CH). 
m/z (El) 184 (M+), 142, 107. 
lR Vmax (KEI') 3024, 1762 em-I. 
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Preparation of 9-endo-13-endo-l-(4-
acetoxyphenyl)methylsulfanyl-8,11-diphenyl-ll-aza-14-
oxatetracycIo[ 6.5 .1.02, 7.09,13] tetradeca-2,4,6-triene-l 0, 12-dione 
4.71 
s 
cG°~ 
Ph 
n-Butyllithium (0.38mL of a 1.6M solution in hexane, 0.61mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.086mL, 0.61mmol.) in THF 
at ODe. The solution was stirred for ten minutes at O°C and then cooled to -78De. A 
solution of 3-phenyl-l(3H)-isobenzofuranthione (llSmg, 0.S1 mmol.) in THF was 
added and the mixture was stirred for 2 hours at _78°C, during which time it turned 
red. 4-Chloromethylphenyl acetate (94mg O.Slmmol.) in THF was added 
dropwise to the solution, which was then allowed to warm to room temperature 
over a period of 6 hours. N-Phenyl male imide (88mg, O.Slmmol.) in THF was 
added and the reaction was stirred overnight. The solvent was removed under 
reduced pressure to give an oil which was partitioned between ethyl acetate and 
water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. This was purified by radial chromatography to give 9-endo-13-
endo-l-( 4-acetoxyphenyl)methy Isulfany 1-8, 1 I-diphenyl-ll-aza-14-oxatetracyc10 
[6.S.l.02,7.09, 13]tetradeca-2,4,6-triene-1O, 12-dione as white needles (6mg, 2%). 
m.p. 210-211 DC. 
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1 H NMR (CD3C13) (5 2.30 (s, 3H, CH3), 3.96 (d, IH, J=8.8Hz, COCH), 4.08 
(d, J= 13.2Hz, CH2), 4.16 (d, IH, J=8.8Hz, COCH), 6.46-6.49 (m, 2H, aryl 
CH), 7.00-7.05 (m, 3H, aryl CH), 7.26-7.29 (m, 3H, aryl CH),7.31 .39 (m, 
4H, aryl CH), 7.41-7.53 (m, 
Il1lz (El) 548 (M+), 374. 
aryl CH), 7.88 (d, 2H, J=8.3Hz, aryl CH). 
High Res C33H25NS05 mlz calc. 547.1454; found 547.1464. 
lR Vmax (KBr) 1706, 1470, 1320 em-I. 
Preparation of N-phenyl I-mercapto-4-phenyl-naphthalene-2,3-
dicarboximide 4.72 
oii!~~C;H_3 ___ ....... , vXN-{ > 
Ph H 0 Ph 0 
9-endo-13-endo-l-( 4-Acetoxyphenyl)methylsulfanyl-8,11-diphenyl-11-aza-14-
oxatetracyclo [6.5.1.02 ,7.09,13 ]tetradeca-2,4,6-triene-1 0, 12-dione (3mg, 
0.0055mmol.) was added to methanol (lmL) containing sodium bicarbonate 
(O.8mg, O.0094mmol.) and refluxed for an hour and monitored by TLC, during 
which time the solution became yellow. The solvent was removed under reduced 
pressure to give a yellow solid. This was partitioned between ethyl acetate and 
water. The ethyl acetate fractions were combined, dried (MgS04), and the ethyl 
acetate removed under reduced pressure. This was purified by radial silica 
chromatography and recrystallised from dichloromethane to give N-phenyl 1-
mercapto-4-phenyl-naphthalene-2,3-dicarboximide as yellow crystals (O.9mg, 
42%). 
m.p. 150-152°C. 
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IH NMR (CDCI3) 8 7.37-7.41 (m, 3H, aryl CH), 7.43-7.47 (m, 3H, aryl CH), 
7.52-7.54 (m, 3H, aryl CH), 7.62-7.67 (m, IH, aryl CH), 7.75-7.82 (m, 3H, aryl 
CH), 8.35 (d, IH, J=7.8Hz, aryl CH). 
mlz (EI) 381 (M+). 
High Res C24H 15NS02 mlz calc. 381.0824; found 381.0816. 
IR Vmax (CDCI3) 3018.4, 1768.6, 1718.5, 1500.5, 1379.0, 1234.4, 
1199.6 em-I. 
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7.5 Chapter 5 Experimental 
Preparation of N -(2-nitropbenyl) chloroacetamide 5.2 
H 
CC~ NifCI A NO~ 
2-Nitroaniline (6g, 43.4mmol.) was dissolved in ethyl acetate (90mL). 
Chloroacetyl chloride (4.9g, 3.46mL, 43.3mmol.) was added by syringe and the 
resulting solution refluxed on an oil bath for 4 hours. The ethyl acetate was 
removed under reduced pressure to give N-(2-nitrophenyl) chloroacetamide as 
yellow needles (9.6g, 100%). 
m.p. 78-80°C, 
Analysis C8H7N203Cl calc. C, 44.77; H, 3.29; N, 13.06; found C, 44.76, H, 
3.29, N, 13.09. 
J H NMR (CDCI3) b 4.26 (s, 2H, CH2), 7.26 (t, 1H, J=7.8Hz, aryl CH) 7.67 
(t, 1H, J=7.8Hz, aryl CH), 8.22 (d, 1H, J=7.8Hz, aryl CH), 8.73 (d, IH, 
J=7.8Hz, aryl CH), 1l.30 (br.s, JH, NH). 
m/z (El) 214.0 (M+), 165.0, 138.0. 
High Res. CSH7N203CI calc. 214.01452; found 214.01446. 
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Preparation of N -(2-nitrophenyl) bromoacetamide 5.3 
H CC~ NH2 ------- CCN ..,/' .. I ~ II Br ~ N02 ~ NO~ 
2-Nitroaniline (6g, 43.4mmol.) was dissolved in ethyl acetate (90mL). 
Bromoacetyl bromide (8.76g, 3.78mL, 43,4mmol.) was added by syringe and the 
resulting solution refluxed on an oil bath for 4 hours. The ethyl acetate was 
removed under reduced pressure to give N-(2-nitrophenyl) bromoacetamide as 
yellow crystals (l1.24g, 100%). 
m.p. 60-61°C. 
lH NMR (CDC13) 84.08 (s,2H, CH2), 7.27, (t, lH, J=7,4Hz, aryl CH), 7.70 
(t, lH, J=7.4Hz, aryl CH), 8.26 (d, IH, J=7,4Hz, aryl CH), 8.74 (d, lH, 
J=7,4Hz, aryl CH), 11.28 (br.s, lH, NH). 
mlz (El) 260.0 (M+), 138.0 , 92.0. 
High Res. C8H7N20381Br calc. 259.96209; found 259.96444. 
High Res. C8H7N20379BI' calc. 257.96400; found 257.96413. 
Preparation of N -(3-nitrophenyl) chloroacetamide 5.5 
rNNH2 Y ------;0... 
N02 
3-Nitroaniline (6g, 43.4mmol.) was dissolved in ethyl acetate (90mL). 
Chloroacetyl chloride (4.9g, 3,46mL, 43,4mmol.) was added by syringe and the 
resulting solution refluxed on an oil bath for 4 hours. The ethyl acetate was 
removed under reduced pressure to give N-(3-nitrophenyl) chloroacetamide as pale 
brown crystals (9.6g, 100%). 
m.p. 200-203°C. 
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1 H NMR (CDCl3) () 4.25 (s, 2H, CH2), 7.55 (t, lH, J=8.3Hz. aryl CH), 7.96 
(d, 1 H, J=8.3Hz, aryl CH), 8.03 (d, IH, J=8.3Hz, aryl CH), 8.46 (s, 1H, aryl 
CH), 8.56 (br.s, IH, NH). 
mlz (EI) 214.0 (M+), 165.0, 138.0,92.1. 
High Res. C8H7N203Cl calc. 214.01452; found 214.01460. 
Preparation of N-(3-nitrophenyl) bromoacetamide 5.6 
NNH2 
~ ---------~ 
N02 
3-Nitroaniline (6g, 43.4mmol.) was dissolved in ethyl acetate (90mL). 
Bromoacetyl bromide (8.76g, 3.78mL, 43.3mmol.) was added by syringe and the 
resulting solution refluxed on an oil bath for 4 hours. The ethyl acetate was 
removed under reduced pressure to give N-(3-nitrophenyl) bromo acetamide as 
brown crystals (l1.24g, 100%). 
m.p. 68-69°C. 
lH NMR (CDCl3) () 4.08 (s, 2H, CH2), 7.55 Ct, lH, J=8.3Hz, aryl CH), 7.96 
(d, IH, .3Hz, aryl CH), 8.03 (d, lH, J=8.3Hz, aryl CH), 8.43 (bLs, 2H, NH 
& aryl CH). 
mlz eEI) 260.0 CVl+) , 138.0, 92.1. 
High Res. C8H7N20381 Br calc. 259.96209; found 259.96237. 
High Res. C8H7N20379Br calc. 257.96400; found 257.96339. 
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Experimental 
H 
N o Y"CI VNO~ 
Preparation of N -(2-aminophenyl) chloroacetamide 5.7 
N-(2-Nitrophenyl) chloroacetamide (2g, 9.32mmoL) was dissolved in ethyl 
acetate (20mL) and palladium on carbon (10%, 0.25g) added. Air was evacuated 
under reduced pressure and a hydrogen balloon added. Stirring under hydrogen 
was continued for 48 hours. The palladium on carbon was filtered out and washed 
with methanol. The methanol was removed under reduced pressure to give an oil. 
Purification by radial silica chromatography gave N -(2-aminophenyl) 
chloroacetamide as a pale yellow oil (586mg, 34%). 
IH NMR (CD3COD) () 4.34 (s, 2H, CH2), 7.31-7.52 (m, 4H, aryl CH). 
m/z (El) 184 (M+), 150, 108. 
Preparation of N-2-(chloroacetamldo)phenyl maleimide 5.8 
~o 
o 
" 
N-(2-Aminophenyl) chI oro acetamide (586mg, 3. 17mmol.) was dissolved in dry 
THF (3mL) and maleic anhydride (311 mg, 3.17mmol.) in dry THF (3mL) was 
added. The solution was stirred overnight resulting in a pale yellow precipitate 
which was filtered and placed in a conical flask with sodium acetate (lOOmg, 
1.2mmol.). Acetic anhydride (25mL, 265mmol.) was added and the resulting 
suspension was dissolved by heating on a steam bath and then heated for a further 
30 minutes. After cooling to room temperature the solution was partitioned between 
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ethyl acetate and water. The ethyl acetate layers were combined, dried (MgS04), 
and the ethyl acetate removed under reduced pressure to give a yellow oil. 
Purification by radial silica chromatography gave N-2-(chloroacetamido)phenyl 
maleimide as a pale yellow crystals (82.8mg, 10%). 
m.p. 114-l15°C. 
Analysis Cl2H9N203CI calc. C, 54.45; H, 3.43; N, 10.59; found C, 54.74; H, 
3.44; N, 10.48. 
1 H NMR (CDCI3) 8 4.15 (s, 2H, CH2), 6.94 (s, 2H, COCH), 7.25 (d, lH, 
J=8.3Hz, aryl CH), 7.34 (t, lH, J=8.3Hz, aryl CH), 7.48 (t, lH, J=8.3Hz, aryl 
CH), 7.93 (d, lH, J=8.3Hz, aryl CH), 8.40 (br. s, lH, NH). 
mlz (El) 264(M+), 229 (M-CI+). 
High Res. C12H9~203CI calc. 264.03019; found 264.03027. 
Preparation of 9-endo-13-endo -1-methylsulfanyl-8-phenyl-11-(2-
chloroacetarnidophenyl)-11-aza-14-oxatetracyclo [6.5.1.02,7.09,13] 
tetradeca-2,4,6-triene-lO,12-dione 5.9 
o CI 
SCH30 }-l 
~HN ~N~> 
Ph H 0 
n-Butyl lithium (0.46mL of a 1.6M solution in hexane, 0.74mmoL) was added 
dropwise to a stirred solution of diisopropyJamine (O.1OmL, 0.74mmol.) in THF at 
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O°C under dry nitrogen. The solution was stirred for ten minutes at O°C and then 
cooled to -78°C. A solution of 3-phenyl-l (3H)-isobenzofuranthione (151mg, 
0.67mmol.) in THF was added and the mixture was stirred for 1 hour at -78°C. 
Methyl iodide (0.046mL, 0.74mmol.) was added dropwise to the solution, which 
was then allowed to warm to room temperature over a period of 2 hours. N-2-
(Chloroacetamido)phenyl maleimide (177mg, 0.67mmol.) in THF was added and 
the reaction was stirred overnight under a drying tube. The solvent was removed 
under reduced pressure to give an oil which was partitioned between ethyl acetate 
and water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. This was purified by radial silica chromatography to give 9-
endo-13-endo-1 c.methy Isulfanyl-8-phenyl-ll-(2-chloroacetamidophenyl)-II-aza-
14-oxatetracyclo[6.5 .1.02,7.09, 13]tetradeca-2,4,6-triene-l 0, 12-dione as white 
crystals (50mg, 15%). 
m.p. 162-163°C. 
Analysis C27H21N2S04CI calc. C, 64.21; H, 4.19; N, 5.55; found C, 64.19; 
H, 4.50; N, 5.57. 
IH NMR (CDCl3) 8 2.33 (s, 3H, SCH3), 3.73 (s, 2H, CH2CI), 4.04 (d, IH, 
J=8.3Hz, COCH), 4.27 (d, IH, J=8.8Hz, COCH), 5.76 (d, lH, J=7.8Hz, aryl 
CH), 6.99-7.11 (m, 2H, aryl CH), 7.26-7.56 (m, 7H, aryl CH), 7.62 (m, IH, aryl 
CH), 7.91 (d, 2H, J=6.8Hz, aryl CH). 
mlz (Ell FAB) 520.1 (M+), 473.1 (M-CCl+), 256.0, 241.0. 
High Res. 111lz C27H21N2S04Cl calc. 520.06822; found 520.06905. 
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Preparation of 9-endo-13-endo-1-rnethylsulfanyl-8-rnethyl-11-(2-
chloroacetarnidophenyl)-11-aza-14-oxatetracyclo[ 6.5.1.02, 7 .09,13] 
tetradeca-2,4,6-triene-10,12-dione 5.10 
C<o--[o:Fl 
CH3 CH3 
0't-lCI 
OHN 
~N-b 
° 
o CI 
SCH30 }-! ~HN ~N~> 
CH~ 0 
n-ButyI lithium (0.19mL of a 1.6M solution in hexane, 0.301mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.04mL, 0.30Immol.) in THF 
at O°C under dry nitrogen. The solution was stirred for ten minutes at OCC and then 
cooled to -7SoC. A solution of 3-methyl-I(3H)-isobenzofuranthione (45mg, 
0.274mmol.) in THF was added and the mixture was stirred for 1 hour at -7S°C. 
Methyl iodide (0.02mL, 0.330mmoL) was added dropwise to the solution, which 
was then allowed to warm to room temperature over a period of 2 hours. N-2-
(Chloroacetamido)phenyl maleimide (73mg, 0.274mmol.) in THF was added and 
the reaction was stirred overnight under a drying tube. The solvent was removed 
under reduced pressure to give an oil which was partitioned between ethyl acetate 
and water. The organic layer was dried (MgS04) and the solvent removed under 
reduced pressure. This was purified by radial silica chromatography to give 9-
endo-13-endo-l-methylsulfanyl-S-methyl-ll-(2-chloroacetamidophenyl)-11-aza-
14-oxatetracyclo[6.5. 1.02,7.09, 13]tetradeca-2,4,6-triene-l 0, 12-dione as white 
crystals (l7mg, 14%). 
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m.p. 173-174°C. 
Analysis C22H19N2S04CI calc. C, 59.66; H, 4.32; N, 6.33; found C, 60.03, 
3.99; N, 6.11. 
1 H NMR (CDCI3) (5 2.02 (s, 3H, CH3), 2.18 (s, 3H, SCH3), 3.10 (d, 1 H, 
J=6.4Hz, COCH), 3.23 Cd, lH, J=6.4Hz, COCH), 3.83 (s, 2H, CH2), 7.18-7.27 
(m, 2H, aryl CH), 7.34-7.49 (m, 4H, aryl CH), 7.64 (s, lH, aryl CH), 8.33 (d, 
tH, J=8.3Hz, aryl CH). 
mlz (El) 442 (M+), 395 (M-CCI+), 163. 
High Res. mlz C2lH19N2S04 calc. 395.10662; found 395.10614. 
lR (CDCl3) vmax 1720.4, 1602.7, 1458.1, 1382.9, 1236.3 em-I. 
Preparation of N-(2-chloroacetamidophenyl) 1-methylsulfanyl-8-
pheny l-naphthalene-2,3-dicarboximide 5.11 
o CI 
SCH30 }-J ~HN VfuN~ > 
Ph H 0 
9-endo-13-endo-l-Methylsulfanyl-8-phenyl-l1-(2-chloroacetamidophenyl)-11-
aza-14-oxatetracyclo[6.5 .1.02,7 .09, 13]tetradeca-2,4,6-triene-lO, 12-dione (lOmg, 
0.02mmol.) and trifluoroacetic acid (lmL, 13mmol.) were stirred together in 
dichloromethane (5mL) for 18 hours. The dichloromethane and excess 
trifluoroacetic acid were removed under reduced pressure to give an oil which was 
purified by radial silica chromatography to give N-(2-chloroacetamidophenyl) 1 
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide as pale brown crystals 
(1.4mg, 14%). 
m.p. l70nC (decomp.). 
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I H NMR (CDCI3) 8 2.70 (s, 3H, SCH3), 3.69 (s, 2H, CH2CI), 7.24-7.44 (m, 
6H, aryl CH), 7.51 (m, 2H, aryl CH), 7.64 (t, 1H, J=6.8Hz, aryl CH), 7.75-7.83 
(m, 2H, aryl CH), 8.06 (m, IH, aryl CH), 9.07 (d, 1H, J=9.8Hz, aryl CH). 
mlz (El) 486 (M+), 451 (M-Cl+), 436 (M-CH3CI+), 410 (M-COCHCl+). 
High Res. mlz C26H16N2S03 calc. 436.08817; found 436.08841. 
Preparation of N.(2-chloroacetamidophenyl) l·methylsulfanyl-8-
methyl-naphthalene-2,3-dicarboximide 5.12 
o CI 
SCH30 }-I 
~HN 0fuN~ 
CH~ 0 
9-endo-13-endo-1-Methylsulfanyl-8-methy 1-11-(2-chloroacetamidopheny 1)-11-
aza-14-oxatetracyc10[6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-lO, 12-dione (l2mg, 
0.027mmoL) and trifluoroacetic acid OmL, 13mmol.) were stirred together in 
dichloromethane (5mL) for 18 hours. The dichloromethane and excess 
trifluoroacetic acid were removed under reduced pressure to give an oil which was 
purified by radial silica chromatography to give N-(2-chloroacetamidophenyl) 1-
methylsulfanyl-8-methyl-naphthalene-2,3-dicarboximide as a pale brown solid 
(3mg,26%). 
m.p. 180°C (decomp.). 
1 H NMR (CDCI3) 8 2.62 (s, 3H, SCH3), 3.16 (s, 3H, CH3), 3.75 (s, 2H, 
CH2CI), 7.38 (t, 2H, J=7.8Hz, aryl CH), 7.49 (t, JH, J=8.3Hz, aryl CH), 7.79-
7.88 (m, 3H, aryl CH), 8.08 (bLS, JH, NH), 8.30 (d, JH, J=6.8Hz, aryl CH), 
9.04 (d, lH, J=6.9Hz, aryl CH). 
mlz (El) 424 (M+), 389 (M-Cl+), 374 (M-CH3Cl+), 348 (M-COCHCl+). 
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High Res. m/z C22H17N2S03 calc. 389.09599; found 389.09538. 
Preparation of N-(3-carboxyphenyl) maleimide 5.13 
~o 
o 
3-Aminobenzoic acid (lO.Og, 73mmol.) was dissolved in dry THF (30mL) and 
maleic anhydride (7.15g, 73mmol.) in dry THF (lOmL) was added. The solution 
was stin'ed for 1 hour resulting in a yellow precipitate which was filtered and then 
mixed with sodium acetate (2g, 24mmol.) and acetic anhydride (200mL, 2. 12mol.). 
The resulting suspension was heated on a steam bath until all had dissolved and 
then for a further 30 minutes. After cooling to room temperature the solution was 
partitioned between ethyl acetate and water. The ethyl acetate layers were 
combined, dried (MgS04), and the ethyl acetate removed under reduced pressure to 
give N-(3-carboxyphenyl) maleimide as yellow crystals (14.27g, 90%). 
m.p. 223-22YC. 
Analysis CllH7N04 calc. C, 60.83; H, 3.25; N, 6.45; found C, 61.15; H, 
3.10; N, 6.46. 
1 H NMR (CDC13) 0 6.98 (s, 2H, COCH), 7.56 (m, 2H, aryl CH), 8.00 (m, 
2H, aryl CH). 
mlz eEl) 217.0 (M+), 173.0 (M-C02+). 
High Res. mlz CI1H7N04 calc. 217.03751; found 217.03762. 
IR (CDCI3) vmax 1720.4, 159l.2, 1454.2, 1384.8, 1234.4, 1147.6 em-I, 
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EXTZerimental 
Preparation of N -(3-(2-aza-4-hydroxy-l-oxobutanyl)phenyl) 
maleimide 5.14 
N-(3-Carboxyphenyl) maleimide (lg, 4.6mmo1.) was stirred in dichloromethane 
(SmL) and DMF was added dropwise until dissolution was complete. DCC 
(9S0mg, 4.6mmo1.) in dichloromethane (lmL), HOBt (622mg, 4.6mmo1.) in DMF 
(l mL), and ethanolamine (0.28mL, 4.6mmo1.) in dichloromethane (lmL) were 
added in the given order and the solution stirred for 6 hours. The resulting 
precipitate was filtered and the solvent removed under reduced pressure. The 
product from the supernatant was partitioned between water and ethyl acetate, the 
organic fractions were combined, dried (MgS04), and evaporated to give N-(3-(2-
aza-4-hydroxy-I-oxobutanyl)phenyl) maleimide as a pale yellow solid (29Smg, 
2S%). 
m.p. lOS-106°C (decomp.). 
IH NMR (CDC13/ CD30D) () 3.46 (m, 2H, NHCH2), 3.63 (m, 2H, CH20H), 
6.87 (s, 2H, COCH), 7.S1 (m, 2H, aryl CH), 7.77 (m, 2H, aryl CH). 
mlz (El) 260 (M+), 172. 
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Experimental 
Preparation of N -(3-(2-aza-4-dimethylamino-1-oxobutanyl)phenyl) 
maleimide 5.15 
t$-< r'_H ____ . ~N-JNH 
o 0 
N -(3-Carboxyphenyl) maleimide (500mg, 2.3mmol.) was st,irred in 
dichloromethane (SmL) and DMF was added dropwise until dissolved. DCC 
(475mg, 2.3mmol.) in dichloromethane (3mL), HOBt (311mg, 2.3mmol.) in DMF 
(3mL), and N,N-dimethylethylenediamine (O.25mL, 2.3mmol.) in dichloromethane 
(lmL) were added in the given order and the solution stirred for 18 hours. The 
resulting precipitate was removed by filtration. The supernatant was evaporated and 
the residue was partitioned between hydrochloric acid (1 M, 10mL) and ethyl 
acetate. The aqueous phase was neutralised with sodium bicarbonate solution until 
basic (pH paper), and extracted with ethyl acetate (10mL). The organic fractions 
from the basic solution were combined, dried (MgS04), and evaporated to give N-
(3-(2-aza-4-dimethylamino-l-oxobutanyl) phenyl)maleimide as a red solid (30mg, 
5%). 
IH NMR (CDCI3/ CD30D) 0 2.27 (s, 6H, N(CH3)2), 2.54 (t, 2H, CH2N), 
3.52 (m, 2H, NHCH2), 6.84 (s, 2H, COCH), 7.46-7.51 (m, 2H, aryl CH), 7.78 
(m, 2H, aryl CH). 
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Preparation of 3-(2-aza-4-dimethylamino-1-oxobutanyl)aniline 
5.17 
3-Aminobenzoic acid (l.OOg, 7.3mmol.) was stirred in dichloromethane (lOmL) 
and DMF was added dropwise until dissolved. DCC (1.56g, 7.3mmol.) in 
dichloromethane (5mL), HOBt (986mg, 7.3mmol.) in DMF (5mL), and N,N-
dimethylethylenediamine (0.800mL, 7.3mmol.) in dichloromethane (2mL) were 
added in the given order and the solution stirred for 16 hours. The resulting 
precipitate was filtered. The supernatant was evaporated and the residue was 
partitioned between hydrochloric acid (lM, 20mL) and ethyl acetate (20mL). The 
aqueous layer was neutralised with sodium hydroxide solution OM, 30mL) and 
extracted with ethyl acetate. The organic fractions were combined, dried (MgS04), 
and evaporated to give 3-(2-azaA-dimethylamino-1-oxobutanyl)aniline as a yellow 
oil (433mg, 29%). 
IH NMR (CDCl3/ CD30D) 0 2.26 (s, 6H, N(CH3)2), 2.52 (m, 2H, CH2), 
3.49 (m, 2H, CH2), 6.74 (m, IH, aryl CH), 6.95 (bLS, IH, CONH), 7.05-7.16 
(m, 3H, aryl CH). 
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Preparation of N -3-(3-N -(N ,N -dimethylaminoethyl) 
carhoxamidophenyl)carhoxamidophenyl maleimide 5.18 
N -(3-Carboxyphenyl) maleimide (450mg, 2.1 mmol.) was stirred in 
dichloromethane (5mL) and DMF was added dropwise until dissolved. DCC 
(428mg, 2.1mmol.) in dichloromethane (3mL), HOBt (280mg, 2.1mmol.) in DMF 
(3mL), and 3-(2-aza-4-dimethylamino-l-oxobutanyl)aniline (430mg, 2.1mmol.) in 
dichloromethane (lmL) were added in the given order and the solution stirred for 18 
hours. The resulting precipitate was removed by filtration. The supernatant was 
evaporated and the residue was partitioned between hydrochloric acid (lM, lOmL) 
and ethyl acetate (10mL). The aqueous layer neutralised with sodium bicarbonate 
solution until basic to pH paper, and extracted with ethyl acetate. The latter organic 
fractions were combined, dried (MgS04), and evaporated to give N-3-(3-N-(N,N-
dimethylaminoethyl)carboxamidophenyl)carboxamidophenyl maleimide as a red oil 
(20mg, 3%). 
1 H NMR (CDCl3/ CD30D) 0 2.44 (s, 6H, N(CH3)2), 2.75 (m, 2H, CH2), 
3.63 (m, 2H, CH2), 6.85 (s, 2H, COCH), 7.40 (d, IH, .3Hz, aryl CH), 7.52-
7.63 (111, 3H, aryl CH), 7.91-7.99 (m, 3H, aryl CH), 8.80 (bLs, IH, CONH). 
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Experimental 
Preparation of N -3-(N -(2-pyridyl»carboxamidophenyl maleimide 
5.19 
N -(3-Carboxyphenyl) maleimide (SOOmg, 2.3mmol.) was stirred in 
dichloromethane (SmL) and DMF was added drop wise until dissolved. DCC 
(474mg, 2.3mmol.) in dichloromethane (3mL), HOBt (31Omg, 2.3mmol.) in DMF 
(3mL), and 2-aminopyridine (216mg, 2.3mmol.) in a mixture of dichloromethane 
(3mL) and DMF (3mL) were added in the given order and the solution was stirred 
for 6 hours, during which time a white solid precipitated. The solution was filtered 
and the supernatant was evaporated. The product was partitioned between 
hydrochloric acid solution (lM, 20rnL) and ethyl acetate. The aqueous layer was 
neutralised with sodium hydroxide solution OM, 30rnL) and extracted with ethyl 
acetate. The organic fractions were combined, washed with water, dried (MgS04), 
and evaporated to give N-3-(N-(2-pyridyl»carboxamidophenyl maleimide as a 
brown oil (246mg, 36%). 
1 H NMR (CDC13/ CD30D) 8 6.93 (s, 2H, COCH), 7.40-7.57 (m, 4H, aryl 
CH), 7.74 (d, IH, J=7.8Hz, aryl CH), 7.84 (d, IH, J=8.3Hz, aryl CH), 8.06 (m, 
2H, aryl CH). 
mlz eEl) 293 (M+), 216 (M-C5H3N+). 
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Preparation of 9~e Ildo-13-endo-l-methylsulfanyl-8-phenyl-ll-(3-
(2-aza -4-hydroxy -l-oxo butan yl )phenyl) -ll-aza -14-oxa tetr acyclo 
[6.5.1.02,7.09 , 13]tetradeca-2,4,6-triene-lO,12-dione 5.20 
n-Butyllithium (0.76mL of a 1.6M solution in hexane, 1.2mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0. 17mL, 1.2mmol.) in THF at 
O°C under dry nitrogen. The solution was stirred for ten minutes at O°C and then 
cooled to -78°C. A solution of 3-phenyl-l(3H)-isobenzofuranthione (230mg, 
1.0mmo!.) in THF was added and the mixture was stirred for 1 hour at -78°C. 
Methyl iodide (0.076mL, 1.2mmol.) was added dropwise to the solution, which 
was then allowed to warm to room temperature over a period of 2 hours. N-(3-(2-
Aza-4-hydroxy-l-oxobutanyl)phenyl) maleimide (319mg, 1.2mmol.) in THF with 
a drop of methanol was added and the reaction was stirred overnight under a drying 
tube. The solvent was removed under reduced pressure to give an oil which was 
partitioned between ethyl acetate and water. The organic layer was dried (MgS04) 
and the solvent removed under reduced pressure. This was purified by radial silica 
chromatography to give 9-endo-13-endo-l-methylsulfanyl-8-phenyl-ll-(3-(2-aza-
4-hydroxy-l-oxobutanyl)phenyl)-11-aza-] 4-oxatetracyclo[6.5.1.02,7.09, 13] 
tetradeca-2,4,6-triene-1O, 12-dione as crystals (85mg, 18%). 
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m.p. l54-l56°C. 
Analysis C28H24N2S05 calc. C, 67.18; H, 4.83; N, 5.60; found C, 67.32, H, 
4.80, N, 5.60. 
I H NMR (CDC13) 0 2.37 (s, 3H, SCH3), 3.52 (m, 2H, NHCH2), 3.73 (m, 
2H, CH20H), 4.01 (d, IH, J=8.3Hz, COCH), 4.27 (d, lH, J=8.7Hz, COCH), 
6.55 (d, IH, J=7.8Hz, aryl CH), 6.95 (s, IH, aryl CH), 7.05 (d, IH, J=7.3Hz, 
aryl CH), 7.34-7.54 (m, 6H, aryl CH), 7.65 (m, IH, aryl CH), 7.74 (d, IH, 
J=8.3Hz, aryl CH), 7.93 (d, 2H, J=8.3Hz, aryl CH). 
mlz eEl) 500 (M+), 482 (M-H20+), 260, 240. 
High Res. C28H24N2S05 mlz calc. 500.14068; found 500.1482. 
IR (CDCl3l CD30D) vmaxlcm-1 1718.5, 1660.6, 1521.7, 1458.1, 1377.1, 
1344.3, 1276.8, 1184.2. 
Preparation of 9-e ndo-13-endo -1-methylsulfanyl-8-methyl-11-(3-
(2-aza-4-hydroxy -l-oxobutanyl)pheny l) -11-aza-14-oxatetracyclo 
[6.5.1.02,7.09 , 13]tetradeca-2,4,6-triene-10,12-dione 5.21 
n-Butyl lithium (0.54mL of a 1.6M solution in hexane, 0.87mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.12mL, 0.87mmol.) in THF at 
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O°C under dry nitrogen. The solution was stirred for ten minutes at O°C and then 
cooled to -78 c C. A solution of 3-methyl-l(3H)-isobenzofuranthione (130mg, 
0.79mmol.) in THF was added and the mixture was stirred for 1 hour at -78°C. 
Methyl iodide (0.054mL, 0.87mmol.) was added dropwise to the solution, which 
was then allowed to warm to room temperature over a period of 2 hours. N-(3-(2-
AzaA-hydroxy-l-oxobutanyl)phenyl) maleimide (206mg, 0.79mmol.) in THF with 
a drop of methanol was added and the reaction was stirred overnight under a drying 
tube. The solvent was removed under reduced pressure to give an oil which was 
partitioned between ethyl acetate and water. The organic layer was dried (MgS04) 
and the solvent removed under reduced pressure. This was purified by radial silica 
chromatography to give 9-endo-13.-endo-l-methy lsulfany 1-8-methyl-11-(3-(2-aza-
4-hydroxy-l-oxobutanyl)phenyl)-11-aza-14-oxatetracyclo[6.5.1.02,7 .09,13] 
tetradeca-2,4,6-triene-l 0, 12-dione as yellow crystals (1Smg, 4%). 
m.p. 1 129°C. 
1 H NMR (CDCI3/ CD30D) 8 2.06 (s, 3H, CH3), 2.14 (s, 3H, SCH3), 3.08 
(d, JH, 8Hz, COCH), 3.21 (d, 1H, J=6.8Hz, COCH), 3.47 (m, 2H, 
NHCH2), 3.86 (m, 2H, CH20H), 7.30-7.50 (m, SH, aryl CH), 7.7S (s, IH, aryl 
CH), 7.83 (d, lH, J=7.8Hz, aryl CH), 7.93 (m, 1H, aryl CH). 
mlz (El) 438 (M+), 420 (M-H20+), 260, 178. 
High Res. C23H 22N2S0S mlz calc. 438.12502; found 438.1250S. 
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Preparation of 9-elldo-13-endo-1-methylsulfanyl-8-phenyl-11-(3-
(N - (2 "pyridy l) carboxamidop henyl)-11-aza-14-oxa te tracy do 
[6.5.1.0 2,7.09 ,13] tetradeca-2,4,6-triene-10,12-dione 5.24 
n-Butyllithium (0.69mL of a 1.6M solution in hexane, 1.1mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.16mL, 1.1mmol.) in THF at 
O°C under dry nitrogen. The solution was stirred for ten minutes at O°C and then 
cooled to -78°C. A solution of 3-phenyl-l(3H)-isobenzofuranthione (250mg, 
1.1 mmol.) in THF was added and the mixture was stirred for 1 hour at -78°C. 
Methyl iodide (0.07mL, 1.1mmol.) was added dropwise to the solution, which was 
then allowed to warm to room temperature over a period of 2 hours. N-3-(N-(2-
Pyridyl»carboxamidophenyl maleimide (31Omg, 1.1mmol.) in THF with a drop of 
methanol was added and the reaction was stirred overnight under a drying tube. 
The solvent was removed under reduced pressure to give an oil which was 
partitioned between ethyl acetate and water. The organic layer was dried (MgS04) 
and the solvent removed under reduced pressure. This was purified by radial silica 
chromatography to give 9-endo-13-endo-l-methylsulfany J-8-phenyl-ll-(3-(N-(2-
pyridyl»carboxamidophenyl)-11-aza-14-oxatetracyclo[6.5.1.02,7 .09,13] tetradeca-
2,4,6-triene-1O,12-dione as an oil (6mg, 1 %). 
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Experimental 
I H NMR (CDCI31 CD30D) 0 2.35 (s, 3H, SCH3), 3.96 (d, lH, J=8.3Hz, 
COCH), 4.20 (d, IH, J=8.3Hz, COCH), 7.29-7.62 (m, 9H, aryl CH), 7.74 (t, 
2H, J=7.8Hz, aryl CH), 7.85 (d, 2H, J=8.3Hz, aryl CH), 7.89-7.94 (m, 3H, aryl 
CH), 8.0 1 (d, IH, .8Hz, aryl CH). 
mlz (El) 
High Res. C26H21N2S04 mlz calc. 457.12228; found 457.12260. 
IR (CDCI31 CD30D) vmax 1793.7,1720.4,1286.4,1234.4 em-I. 
Preparation of 9-endo-13-endo-1-methylsulfanyl-8-methyl-ll-(3-
(N -(2-pyridyl) )carboxamidopheny l) -11-aza-14-oxatetracyclo 
[6.5.1.02 ,7.09 ,13J tetradeca-2,4,6-triene-10,12-dione 5.25 
n-Butyl lithium (0. 19mL of a 1.6M solution in hexane, 0.30mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.04mL, 0.30mmol.) in THF at 
O°C under dry nitrogen. The solution was stirred for ten minutes at O°C and then 
cooled to -7S°C. A solution of 3-methyl-l(3H)-isobenzofuranthione (45mg, 
O.27mmol.) in THF was added and the mixture was stirred for 1 hour at -78"C. 
Methyl iodide (0.02mL, 0.33mmoL) was added dropwise to the solution, which 
was then allowed to warm to room temperature over a period of 2 hours. N-3-(N-
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(2-Pyridyl))carboxamidophenyl maleimide (73mg, 0.27mmoL) in THF with a drop 
of methanol was added and the reaction was stirred overnight under a drying tube. 
The solvent was removed under reduced pressure to give an oil which was 
partitioned between ethyl acetate and water. The organic layer was dried (MgS04) 
and the solvent removed under reduced pressure. This was purified by radial silica 
chromatography to give 9-endo-13-endo-l-methylsulfanyl-8-methyl-ll-(3-(N-(2-
pyridy 1))carboxamidophenyl)-11-aza-14-oxatetracyclo[6.S.1.02,7 .09,13] tetradeca-
2,4,6-triene-l 0, 12-dione as an oil (8mg, 6%). 
I H NMR (CDCI3/ CD30D) (3 2.2S (s, 3H, CH3), 2.S2 (s, 3H, SCH3), 3.67 
(d, IH, J=8.3Hz, COCH), 3.82 (d, 1H, J=8.3Hz, COCH), 6.61 (d, IH, 
J=8.4Hz, aryl CH), 6.87 (m, IH, aryl CH), 7.0S-7.40 (m, 6H, aryl CH), 7.S4 
(m, 2H, aryl CH), 7.91 (d, IH, J=8.3Hz, aryl CH), 8.02 (m, IH, aryl CH). 
111/Z (El) 471.S (M+), 378.1 (M-CSHSN2+). 
High Res. C21Hl6NS04 mlz calc. 378.08001; found 378.08026. 
IR (CDCI3/ CD30D) vmax 2933.S, 1720.4, 1380.9, 1278.7, 1236.3 em-I. 
Preparation of N -3-(2-aza-4-hydroxy-1-oxobutanyl)phenyl 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide 5.27 
OH OH 
SCH3o-c)° ~ ° ~ ~ NH ~JNH 0mN ",-;, ---" ~N-o 
Ph ° Ph ° 
9-endo-13-endo-l-Methylsulfanyl-8-phenyl-ll-(3-(2-aza-4-hydroxy-l-
oxobutany l)phenyl)-11-aza-14-oxatetracyclo[6.S.1.02,7.09, 13]tetradeca-2,4,6-
triene-l 0, 12-dione (30mg, 0.062mmol.) and triflllOl'Oacetic acid (1 mL, 13mmol.) 
were stirred together in dichloromethane (3mL) for 48 hours. The dichloromethane 
and excess trifluoroacetic acid were removed under reduced pressure to give an oil 
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which was purified by radial silica chromatography to give N-3-(2-aza-4-hydroxy-
l-oxobutanyl)phenyl I-methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide as 
an oil (Smg, 17%). 
I H NMR (CDC]3! CD30D) 8 2.47 (s, 3H, SCH3), 3.62 (m. 2H, NHCH2), 
4.40 (t, 2H, J=6.8Hz, CH20H), 6.93 (d, JH, J=7.3Hz, aryl CH), 7.09 (m, 4H, 
aryl CH), 7.26 (s, IH, aryl CH), 7.32-7.47 (m, 4H, aryl CH), 7.6S Cd, 
J=7.8Hz, aryl CH), 8.01 (d, IH, J=7.8Hz, aryl CH). 
m/z eEl) 482 (M+). 
High Res. C28H22N2S04m/z calc. 482.13011; found 482.1283. 
Preparation of N -3-(2-aza-4-hydroxy-1-oxobutanyl)phenyl 1-
methylsulfanyl-8-methyl-naphthalene-2,3-dicarboximide 5.28 
9-endo-13-endo-l-Methylsulfanyl-8-methyl-11-(3-(2-aza-4-hydroxy-l-
oxobutanyl)phenyl)-11-aza-14-oxatetracyclo[6.S.1.02,7.09, 13]tetradeca-2,4,6-
triene-l0,12-dione CS.Omg, 0.011mmo1.) and trifluoroacetic acid (O.SmL, 
6.Smmo1.) were stirred together in dichloromethane (SmL) for 18 hours. The 
dichloromethane and excess trifluoroacetic acid were removed under reduced 
pressure to give an oil which was purified by radial silica chromatography to give 
N -3-(2-aza-4-hydro xy -l-oxo bu tany I )phen yl 1-meth y Isulfany 1-8-methy J-
naphthalene-2,3-dicarboximide as a yellow oil (1.2mg, 25%). 
1 H NMR (CDCl3) 8 2.56 (s, 3H, CH3), 3.10 (s,3H, SCH3), 3.62 (m, 2H, 
NHCH2), 3.82 (m, 2H, CH20H), 6.98 (br. s, IH, NH), 1-7.63 (m, 2H, aryl 
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CH), 7.74-7.84 (m, 3H, aryl CH), 7.90 (s, IH, aryl CH), 8.23 (d, IH, J=7.3Hz, 
aryl CH), 8.97 (d, IH, J=8.3Hz, aryl CH). 
mlz eEl) 420 (M+). 
High Res. C23H20N2S04 mlz calc. 420.11445; found 420.11468. 
Preparation of N-3-(N-(2-pyridyl))carboxamidophenyl 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide 5.29 
NO~ NO~ 
o - 0 -
SCH30 JNH SCH30 JNH oitN-Q-/; -.----. oXN-Q 
Ph H 0 Ph 0 
9-endo-13-endo-l-Methylsulfanyl-8-phenyl-ll-(3-(N-(2-pyridyl)) 
carboxamidophenyl)-11-aza-14-oxatetracyclo[6.S.1.02,7 .09, 13Jtetradeca-2,4,6-
triene-l0,12-dione (4mg, 0.007Smmol.) and trifluoroacetic acid (O.SmL, 
6.Smmol.) were stirred together in dichloromethane (SmL) for 18 hours. The 
dichloromethane and excess trifluoroacetic acid were removed under reduced 
pressure to give an oil which was purified by radial silica chromatography to give 
N-3-(N-(2-pyridy l) )carboxamidopheny 1 I-me thy Isulfany 1-8-phenyl-naphthalene-
2,3-dicarboximide as an oil (O.Smg, 13%). 
IH NMR (CDC13! CD30D) 8 2.69 (s, 3H, SCH3), 7.18-7.43 (m, SH, aryl 
CH), 7.47-7.82 (m, 8H, aryl CH), 7.91-8.11 (m, 3H, aryl CH), 9.08 (d, IH, 
J=8.8Hz, aryl CH). 
1111z eEl) 515 (M+), 439 (M-CSH2N+), 422 (M-CSHSN2+). 
High Res. C26H19N2S03 mlz calc. 439.11171; found 439.11179. 
IR (CDCl3/ CD30D) Vmax 1768.6, l716.S, 1377.1,1286.4,1236.3 em-I. 
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Experimental 
Preparation of N -3-(N-(2-pyridyl))carboxamidophenyl 1-
methylsulfanyJ-8-methyJ-naphthalene-Z,3-dicarboximide 5.30 
9-endo-13-endo-l-Methylsulfanyl-8-methyl-l1-(3-(N-(2-pyridyl)) 
carboxamidophenyl)-II-aza-14-oxatetracyc10[6.5.1.02,7 .09, 13J tetradeca-2,4,6-
triene-I 0, 12-dione (5.5mg, 0.012rnmoL) and trifluoroacetic acid (0.5mL, 
6.5rnmol.) were stirred together in dichloromethane (5mL) for 18 hours. The 
dichloromethane and excess trifluoroacetic acid were removed under reduced 
pressure to give an oil which was purified by radial silica chromatography to give 
N-3-(N-(2-pyridyl))carboxamidophenyl 1-methylsulfanyl-8-methyl-naphthalene-
2,3-dicarboximide as an oil (1.0mg, 18%). 
1 H NMR (CDC13! CD30D) 8 2.56 (s, 3H, CH3), 3.16 (s, 3H, SCH3), 7.39-
7.62 (rn, 4H, aryl CH), 7.65-7.82 (m, 3H, aryl CH), 8.00-8.10 (m, 3H, aryl CH), 
. 8.50 (d, tH, .3Hz, aryl CH), 9.01 (d, 1 J::::7.8Hz, aryl CH), 
mlz (El) 453 (M+), 391 (M-C2H6S+), 376 (M-C5H3N+). 
High Res. C26H19N3S03 mlz calc. 453.11475; found 453.11466. 
IR (CDC]3! CD30D) vrnax 1764.7, 1712.7, 1490.4, 1450.4, 1379.0, 1276.8, 
1164.9, 1132.1, 1107.1 em-I. 
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Expe rimental 
7.6 Chapter 6 Experimental 
Preparation of 2-(benzylmercaptomethyl)benzoic acid 6.1 78 
o 
0:0 .. 
1 (3H)-Isobenzofuranone (4.00g, 30mmol.) and sodium ethoxide (2.03g, 
30mmoJ.) were added to benzyl mercaptan (3.70g, 30mmol.) and refluxed in 
ethanol (20mL) for 3 hours. The ethanol was removed under reduced pressure. Ice 
water (5mL) was added, acidified with concentrated sulfuric acid (5mL), and 
extracted with dichloromethane. The solution was concentrated under reduced 
pressure and crystallisation gave 2-(benzylmercaptomethyl)benzoic acid as white 
crystals (4.36g, 56%). 
m.p. 84-85c C (lit. 84-85"C). 
I H NMR (CDC]3) () 3.66 (s, 2H, CH2), 4.08 (s, 2H, CH2), 7.22-7.32 (m, 
6H, aryl CH), 7.35 (t, lH, J= 7.8Hz, aryl CH), 7,48 (t, IH, J=7.8Hz, aryl CH), 
8.06 (d, IH, J=7.8Hz, aryl CH). 
Preparation of 1(3H)-isobenzothiophenone 6.278 
2-Benzylmercaptomethyl benzoic acid (4.00g, 15.5mmol.) was added to 
polyphosphoric acid, formed by heating phosphorous pentoxide (27.78g, 
98mmol.) with orthophosphoric acid (l8.58mL, 98mmol.) at 100cC for 10 
minutes, and stirred at 120°C for 30 minutes. After cooling ice water (20mL) was 
added and the solution extracted with chloroform, dried (Na2S04), and the 
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chloroform removed under reduced pressure. Distillation under reduced pressure 
followed by recrystallisation from ethanol gave 1(3H)-isobenzothiophenone as 
white needles (1.25g, 54%). 
m.p. 58-60°C (58-60°C). 
I H NMR (CDCI3) 84.48 (s, 2H, CH2), 7.48 (t, IH, J=7.8Hz, aryl CH), 7.63 
(t, lH, J=7.8Hz, aryl CH), 7.84 (d, lH, J=7.4Hz, aryl CH). 
Preparation of 1(3H)-isobenzo[c]thiophene-l-thione 6.379 
o 0=;8 
1,3-Dihydro-2-benzothiophen-l-one (700mg, 4.7mmol.) and Lawesson's 
reagent (943mg, 2.4mmol.) were refluxed in toluene (lOmL) for 12 hours. The 
toluene was removed under reduced pressure, and the crude solid dissolved in ether 
and filtered to remove ether-insoluble components. Purification by radial silica 
chromatography gave 1 (3H)-isobenzo[ c Jthiophene-l-thione as orange crystals 
(180mg, 23%). 
m.p. 63-64°C (lit.63-64°C). 
I H NMR (CDCI3) 84.53 (s, 2H, CH2), 7.47 (t, IH, J=7.3Hz, aryl CH), 7.54 
(d, IH, J=6.4Hz, aryl CH), 7.60 (t, IH, J=8.3Hz, aryl CH), 8.07 Cd, IH, 
J::::7.8Hz, aryl CH). 
13C NMR (CDC13) 8 40.8, 124.4, 125.4, 128.0, 132.6, 144.1, 147.1, 228.4. 
IR Vmax (KEr) 1590. 1565, 1465, 1400, 1260, 1205, 1125, 1040, 895, 755, 
700 em-I. 
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Preparation of 3-phenyl-l(3H)-isobenzo[ c]thiophene-l-thione 
6.579 
s C0S 
Ph 
2-Benzoylbenzoic acid (6.0g, 26mmo1.) and Lawesson's reagent (21.46g, 
52111mo1.) were dissolved in toluene (lOmL) and refluxed for 8 hours followed by 
stirring for 2 days. The toluene was removed under reduced pressure and the 
residue was purified by dry flash chromatography followed by radial silica 
chromatography to give 3-phenyl-l(3H)-isobenzo[cJthiophene-l-thione as chunky 
orange crystals (2.5 g, 40%). 
m.p. 93-94°C (lit. 93-94°C). 
IH NMR (CDCI3) 0 5.97 (s, IH, SCH), 7.21-7.28 (m, 3H, aryl CH), 7.30-
7.38 (m, 3H, aryl CH), 7.49 (m, IH, aryl CH), 7.59 (m, IH, aryl CH), 8.15 (d, 
1 II, l=.7.6Hz, aryl CH). 
13C NMR (CDCI3) 060.6, 124.5, 126.0, 128.3, 128 128.6, 129.2, 133.0, 
137.5, 143.6, 151.2, 227.2. 
/11/z (El) 242.0 (M+), 210.1 (M-S+), 165.1 (M-SH2+), 121.0. 
High Res. m/z C14HIOS2 calc. 242.02220; found 242.02240. 
IR (KBr) vmax 3071, 3032, 2239,1690,1578,1497,1454,1269,1244,1217, 
1182,1049,903,745,712 em-I. 
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Preparation of 3~rnethyl-l(3H)-isobenzo[ c] thiophene-l-thione 
6.779 
s 
~S 
CH 3 
A solution of 2-acetylbenzoic acid (2.00g, 12.2mmol.) and Lawesson's reagent 
(4.93g, 12.2mmol.) in toluene (lOmL) was refluxed under nitrogen for 45 minutes. 
The toluene was removed under reduced pressure and the residue dissolved in ether 
and filtered to remove ether insoluble components. The ether was removed under 
reduced pressure and purification by radial silica chromatography gave 3-methyl-
1(3H)-isobenzo[c]thiophene-l-thione as a red oil (198mg, 9%). 
IH NMR (CDC13) (3 1.78 (d, J=6.8Hz, CH3), 4.93 (q, lH, J=6.8Hz, 
CH), 7,44-7.70 (m, 3H, aryl CH), 8.04 (d, lH, J=7.8Hz, aryl CH). 
13C NMR (CDCI3) (3 20.3, 51.1, 124.1, 128.0, 132.6, 143.1, 151.9, 227,4. 
IR Vmax (CDCI3) 1600, 1465, 1260, 1050,760, 740 em-I. 
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Preparation of dimethyl 9-exo -I O-endo -me thy Isulfany I-lI-
thia tricyclo [6.2.1.02, 7]undeca-2,4,6-triene-9,1 O-dicar boxylate 6.9 
and dimethyl 9-endo-10-exo -methylsulfanyl-11-thiatricyclo 
[6.2.1.02,7]undeca-2,4,6-triene-9,10-dicarboxylate 6.10 
n-Butyllithium (0.70mL of a l.OM solution in hexane, l.lmmol.) was added 
dropwise to a stirred solution of diisopropy lamine (0.16mL, 1.1 mmol.) in THF 
(1 mL) at ODC. The solution was stirred for ten minutes at O°C and then cooled to 
-78"C. A solution of 1 ,3-dihydro-2-benzothiophene-I-thione (l70mg, l.Ommol.) 
in THF (lmL) was added and the mixture was stirred for 1 hour at -78°C. Methyl 
iodide (0.07mL, 1.1 mmol.) was added dropwise to the solution, which was then 
allowed to warm to room temperature for 2 hours. Dimethyl fumarate (162mg, 
1.1mmol.) in THF (lmL) was added and the reaction stirred overnight The 
solvent was removed under reduced pressure to give an oil which was partitioned 
between ethyl acetate and water. The organic layer was dried (MgS04) and the 
solvent removed under reduced pressure. This was purified by radial silica 
chromatography to give a mixture of dimethyl 9-exo-lO-endo-methylsulfanyl-ll-
thiatricyclo[6.2.1.02,7]undeca-2,4,6-triene-9, lO-dicarboxylate 6.9 and dimethyl 9-
endo-l O-exo-methy Isulfany 1-11-thiatricyclo(6.2.1.02, 7]undeca-2,4,6-triene-9, 1 0-
dicarboxylate 6.10 together as a pale yellow oil (30mg, 9%). 
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6.9 (major) JH NMR (CDCl3) (52.30 (s, 3H, SCH3), 3.33 (d, JH, J=4.4Hz, 
COCH), 3.S8 (s, 3H, C02CH3), 3.83 (s, 3H, C02CH3), 4.21 (d, JH, J=4.4Hz, 
COCH), 4.42 (m, JH, SCH), 7.07-7.34 (m, 4H, aryl CH). 
6.10 (minor) (5 2.19 (s, 3H, SCH3), 3.61 (d, IH, J=4.4Hz, COCH), 3.SS (s, 
3H, C02CH3), 3.81 (s, 3H, C02CH3), 4.81 (d, IH, J=4.4Hz, COCH), 4.92 (m, 
IH, SCH), 7.07-7.34 (m, 4H, aryl CH). 
ml" (El) 324 (M+), 180 (M-C6H604+). 
High Res. C15H16S204 mlz calc. 324.04906; found 324.04915. 
Preparation of 9-eJldo-13~endo -1-methylsulfanyl-11-phenyl-11-
aza-14·thiatetracyclo [6.5.1.02 ,7.09, 13]tetradeca-2,4,6 .triene·10, 12-
dione 6.11 
n-Butyl lithium (0.041 mL of a l.OM solution in hexane, 0.066mmol.) was 
added dropwise to a stirred solution of diisopropylamine (0.0093mL, 0.066mmol.) 
in THF at O°C. The solution was stirred for ten minutes at OnC and then cooled to 
-78°C. A solution of 1 (3H)-isobenzo[cJthiophene-l-thione (11mg, O.066mmol.) in 
THF was added and the mixture was stirred for J hour at _78°C. Methyl iodide 
(O.0045mL, 0.073mmol.) was added dropwise to the solution, which was then 
allowed to warm to room temperature for 1.5 hours. N-Phenyl maleimide 
(12.5mg, O.073mmol.) in THF was added and the reaction stirred overnight. The 
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solvent was removed under reduced pressure to give an oil which was partitioned 
between ethyl acetate and water. The organic layer was dried (MgS04) and the 
solvent removed under reduced pressure. This was purified by radial silica 
chromatography to give 9-endo-13-endo-l-methylsulfanyl-ll-phenyl-l1-aza-14-
th iatetracyclo[6.5 .1.02,7.09, 13]tetradeca-2,4,6-triene-l 0, 12-dione as a brown oil 
(1.5mg, 6%). 
1 H NMR (CDC13) (3 2.25 (s, 3H, SCH3), 3.25 (d, IH, J=6.8Hz, COCH), 3.57 
(d, IH, J=6.8Hz, COCH), 4.97 (s, IH, SCH), 7.08-7.48 (m, 9H, aryl CH). 
mlz (Ell FAB) 353 (M+), 180, 173. 
High Res. C19HI5NS202111/Z calc. 353.05448; found 353.05500. 
Preparation of 9-endo-13-endo -l-methylsulfanyl- 8-methyl-11-
phenyl-l1-aza-14-thiatetracyclo[6.5.1.02 , 7.09,13]tetradeca-2,4,6-
triene-10,12-dione 6.13 and 9-exo-13-exo-l-methylsulfanyl-8-
methy 1-11-pheny 1-11-aza-14-thiatetracyclo[ 6.5 .1.02, 7.09,13] 
tetradeca-2,4,6-triene.10,12.dione 6.14 
n-Butyl lithium (0.14mL of a 1.0M solution in hexane, 0.22mmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.031mL, 0.22mmol.) in THF 
at O°c. The solution was stirred for ten minutes at O°C and then cooled to -7WC. A 
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solution of 3-methy 1-1 ,3-dihydro-2-benzothiophene-] -thione (37.9mg, 0.22mmol.) 
in THF was added and the mixture was stirred for 1 hour at -78°C. Methyl iodide 
(0.014mL, 0.22mmol.) was added dropwise to the solution, which was then 
allowed to warm to room temperature for 2 hours. N-Phenyl maleimide (38.4mg, 
0.22mmol.) in THF was added and the reaction stirred overnight. The solvent was 
removed under reduced pressure to give an oil which was partitioned between ethyl 
acetate and water. The organic layer was dried (MgS04) and the solvent removed 
under reduced pressure. This was purified by radial silica chromatography to give 
both 9-endo 13-endo-1-methylsulfanyl 8-methyl-ll-phenyl-11-aza-14-
thiatetracyc10[6.5.1.02,7 .09 , 13]tetradeca-2,4,6-triene-1O, 12-dione 6.14 and 9-
. exo-13-exo-1-methylsulfanyl-8-methyl-1] -phenyl-l1-aza-14-thiatetracyc10 
[6.5.1.02,7 .09, 13]tetradeca-2,4,6-triene-l 0, 12-dione 6.13 together as a yellow oil 
(6mg,7%). 
6.14 (maioI') 1H NMR (CDCI3) () 2.16 (s, 3H, CH3), 2.32 (s, 3H, SCH3), 
4.07 (d, IH, J=8.3Hz, COCH), 4.23 (d, 1H, J=8.3Hz, COCH), 6.40 (m, IH, 
aryl CH), 7.16-7.47 (m, 8H, aryl CH). 
6.13 (minor) () 2.13 (s, 3H, CH3), 2.24 (s, 3H, SCH3), 3.21 (d, IH, 
J=6.3Hz, COCH), 3.34 (d, 1H, J=6.3Hz, COCH), 6.40 (m, IH, aryl CH), 7.16-
7.47 (m, 8H, aryl CH). 
mlz eEl) 367 (M+), 333 (M-SH2+), 194, 173. 
High Res. C20H17NS202 m/z calc. 367.07008; found 367.06980. 
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Preparation of dimethyl 1-mercapto-4-methylsulfanyl-l,2-
dihydronaphthalene-2,3-dicarboxylate 6.18 
SCHs SCHs oif~ C02CHs C¢~ C02CHs I~s ---'I~ 
"'CO CH C02CHS H 2 s 
SH 
Dimethyl methylsulfanyl-ll-thiatricyclo[6.2.1.02,7]undeca-2,4,6-triene-9, 10-
dicarboxylate (lOmg, 0.03mmol.) and mercuric acetate (9.6mg, O.03mmol.) were 
dissolved in methanol (lmL) and stirred for 5 days. The methanol was removed 
under reduced pressure and the product partitioned between dichloromethane and 
water. The dichloromethane fractions were combined, dried (MgS04), and the 
dichloromethane removed under reduced pressure. The product was purified by 
radial silica chromatography to give dimethyl I-mercapto-4-methylsulfanyl-l,2-
dihydronaphthalene-2,3-dicarboxylate as a yellow oil (2.6mg, 26%). 
IH NMR (CDCI3) 0 1 (s, 3H, SCH3), 3.56 (s, 3H, C02CH3), 3.88 (s, 3H, 
C02CH3), 4.30 Cd, lH, J=6.0Hz, COCH), 5.08 (d, lH, J=6.0Hz, C(SH)H), 
7.30-7.60 (m, 3H, aryl CH), 7.74 (d, 1H, J=7.3Hz, aryl CH). 
m/z (El) 324 (M+), 306 (M-H20+), 180 (M-C6H604+). 
Preparation of N-phenyl I-mercapto-4-methylsulfanyl-l,2-
dihydronaphthalene-2,3-dicarboximide 6.19 
SCH30 ~N-{> 
H 0 
9-endo-13-endo-l-Methylsulfanyl-ll-phenyl-l1-aza-14-thiatetracyclo 
[6.5. I .02,7.09, 13]tetradeca-2,4,6-triene-l 0, 12-dione (t.Omg, 0.0028mmol.) and 
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mercuric acetate (0.9mg, 0.0028mmo!.) were dissolved in methanol (lmL) and 
stirred for 5 days. The methanol was removed under reduced pressure and the 
product partitioned between dichloromethane and water. The dichloromethane 
fractions were combined, dried (MgS04), and the dichloromethane removed under 
reduced pressure. The product was purified by radial silica chromatography to give 
N-phenyl I-mercapto-4-methylsulfany 1-1 ,2-dihydronaphthalene-2,3-dicarboximide 
as an oil (Oo4mg, 40%). 
IH NMR (CDCI3) 0 2041 (s, 3H, SCH3), 3.90 (s, 1H, C(SH)H), 7.64-7.81 
(m, 5H, aryl CH), 7.98 (m, 1H, aryl CH), 8.07 (d, 1H, J=5.9Hz, aryl CH), 8.70 
(d, IH, J=7.8Hz, aryl CH), 8.99 (d, 1H, J=7.8Hz, aryl CH). 
mlz (EIIFAB) 353 (M+), 317 (M-SH2+). 
High Res. C19H15NS202 mlz calc. 353.05448; found 353.05398. 
Preparation of N -phenyl 1-methylsulfanyl·8-methyl-naphthalene-
2,3-dicarboximide 4.33 
I-methylsulfanyl-8-methyl-l1-phenyl-11-aza-14-thiatetracyclo 
[6.5.1.02,7.09, 13]tetradeca-2,4,6-triene-l 0, 12-dione (4mg, 0.01 mmol.) and 
mercuric acetate (3.2mg, 0.01 mmo!.) were dissolved in methanol (1 rnL) and stirred 
for 1 week. The methanol was removed under reduced pressure to give an oil 
which was purified by radial silica chromatography to give N -phenyl 1-
methylsulfanyl-8-methyl-naphthalene-2,3-dicarboximide as a white solid (2.8mg, 
84%). 
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IH NMR (CDC13) () 2.62 (s, 3H, CH3), 3.17 (s, 3H, SCH3), 7.43-7.56 (m, 
5H, aryl CH), 7.80 (m, 2H, aryl CH), 8.30 (m, lH, aryl CH), 9.05 (m, IH aryl 
CH). 
Preparation of I-methyIsulfanyl-3-phenyI-isobenzo[c]thiophene 
6.2080 
s 
~s 
Ph Ph 
n-Butyllithium (6.16mL of a 1.6M solution in hexane, lOmmol.) was added 
dropwise to a stirred solution of diisopropylamine (0.92mL, 10mmol.) in THF at 
O°C under dry nitrogen. The solution was stirred for ten minutes at O°C and then 
cooled to _78°C. A solution of 3-phenyl-l(3H)-isobenzo[cJthiophene-l-thione 
(l.Og. 4mmol.) in THF was added and the mixture was stilTed for 1 hour at -78 c C, 
Methyl iodide (0.66mL, lOmmol.) was added dropwise to the solution, which was 
then allowed to warm to room temperature over a period of 2 hours. The THF was 
removed under reduced pressure and the product purified by radial silica 
chromatography to give I-methylsulfanyl-3-phenyl-isobenzo[c]thiophene as a 
yellow oil (0.9g, 88%). 
1H NMR (CDC13) () 2.51 (s, 3H, SCH3), 10 (m, lH, aryl CH), 7.17 (m, 
lH, aryl CH), 7.38 (m, IH, aryl CH), 7.48 (m, 2H, aryl CH), 7.50 (m, 2H, aryl 
CH), 7.80 (m, 2H, aryl CH). 
13C NMR (CDCI3) () 22.4, 118.0, 120.2, 120.6, 123.7, 123.8, 127.2, 128.5, 
128.7,133.4,1 1,144.2. 
mlz (El) 256.0 (M+), 241.0, (M-CH3+), 208.0, 143.0. 
High Res. mlz C I5H 12S2 calc. 256.03784; found 256.03805. 
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IR (KEr) vmax 3693.4, 3064.7, 2923.9, 1600.8, 1504.4, 1485.1, 1444.6, 
1365.5,1334.6,1313.4,1203.5,1078.1 em-I. 
Preparation of 9 R endo-13 R e ndo-1-methylsulfanyl-g-phenyl-11- (3-
(2-aza-4-hydroxy -1-oxo butanyl)pheny 1) -11-aza-14 -thiatetracyclo 
[6.5.1. 02, 7 .09, 13]tetradeca-2,4,6-triene-1 0, 12-dione 6.21 
I-Methylsulfanyl-3-phenyl-isobenzo[c]thiophene (64mg, 0.25mmol.) and N-(3-
(2-aza-4-hydroxy-l-oxobutanyl)phenyl) male imide (65mg, 0.25mmoL) were 
dissolved in toluene (lOmL) and ref1uxed at 120°C for 48 hours. The toluene was 
removed under reduced pressure and the resulting oil purified by radial silica 
chromatography to give a solid. Recrystallisation from ethyl acetate and pet ether 
gave 9-endo-13-endo-l-methy lsulfany 1-8-phenyl-ll-(3-(2-aza-4-hydroxy-l-
oxobutanyl)phenyl)-11-aza-14-thiatetracyclo[6,5.1.02,7.09, 13] tetradeca-2,4,6-
triene-IO,12-dione as white crystals (9mg, 7%). 
m.p. 167-168°C. 
Analysis C2SH24N2S204 calc. C, 65.09; H, 4.68; N, 5.42; found C, 65.24, 
H, 4.28, N, 5,61. 
I H NMR (CDC13) 0 2.41 (s, 3H, SCH3), 3.54 (m, 2H, NHCH2), 3.73 (m, 
2H, CH20H), 4.45 (d, IH, J=8.3Hz, COCH), 4.98 (d, IH, J=8.3Hz, COCH), 
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6.55 Cd, IH, J=7.3Hz, aryl CH), 6.83 (d, IH, J=7.3Hz, aryl CH), 6.92 (s, IH, 
aryl CH), 7.21 (d, IH, J=7.8Hz, aryl CH), 7.31-7.51 (m, 6H, aryl CH), 7.72 (d, 
IH, J=7.8Hz, aryl CH), 7.88 (d, 2H, J=7.8Hz, aryl CH). 
1111:::; (El) 516 (M+), 498 (M-H20+), 260, 256. 
High Res. C28H24N2S204 mlz calc. 516.11784; found 516.11810. 
Preparation of 9-endo-13-endo-1-methylsulfanyl-8-phenyl-11-(3-
(2-aza-4-dimethy lamino-1-oxobutanyl)phenyl) -11-aza-14-
thiatetracyclo[ 6.5.1.02, 7 .09,13] tetradeca-2,4,6- triene-1 0,12-dione 
6.22 
I-Methy Isulfany 1-3-phenyl-isobenzo[ c ]thiophene (25mg, O.lOmmol.) and N-(3-
(2-aza-4-dimethylamino-l-oxobutanyl)phenyl) maleimide (28mg, O.lOmmol.) were 
dissolved in toluene (lOmL) and refluxed at 120°C for 4 days. The toluene was 
removed under reduced pressure and the resulting oil purified by radial silica 
chromatography to give 9-endo-13-endo-l-methylsulfanyl-8-phenyl-ll-(3-(2-aza-
4-dimethylamino-l-oxobutanyl)phenyl)-1 I -aza-14-thiatetracyclo[6.5.1.02,7 .09,13] 
tetradeca-2,4,6-triene-l 0, 12-dione as an oil (2.0mg, 4%). 
1 H NMR (CDCI3/ CD30D) () 2.32 (s, 3H, SCH3), 2.62 (s, 6H, N(CH3)2), 
3.20 (m, 2H, CH2), 3.78 (m, 2H, CH2), 4.36 (d, IH, J=8.3Hz, COCH), 4.88 
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(d, IH, .3Hz, COCH), 6.35 (d, IH, J=8.8Hz, aryl CH), 6.74 (d, IH, 
J=7.4Hz, aryl CH), 7.10-7.29 (m, 3H, aryl CH), 7.31-7.44 (m, 4H, aryl CH), 
7.71 (d, IH, J=8.3Hz, aryl CH), 7.82 (d, 2H, J=8.3Hz, aryl CH), 8.46 (br.s, 
IH, NH). 
Ill/I. (El) 543 (M+), 429 (M-C5HtON20+), 256, 241. 
High Res. C30H29N3S203 m/z calc. 543.16515; found 543.16549. 
lR (CDCI3/ CD30D) vmax 2970.2, 1716.5, 1660.6, 1602.7, 1456.2, 1379.0, 
1236.3,1188.1 ern-i. 
Preparation of 9-endo-13-e ndo-1-methylsulfanyl-8-phenyl-11-(3-
(N -(Z-pyridy 1) )car boxamidopheny I)-ll-aza -14- thiatetracyclo 
[6.5.1. OZ, 7.09, 13]tetradeca-Z,4,6-triene-l O,lZ-dione 6.Z3 
o N; > 
° JNH (ZN-G ~ O~ 
SCH3o-c>0 N_ 
° 
H NH ~N :-4 
Ph 
I-Methylsulfanyl-3-phenyl-isobenzo[c]thiophene (52mg, 0.20mmol.) and N-3-
(N-(2-pyridyl))carboxamidophenyl maleimide (66mg, 0.20mmol.) were dissolved 
in toluene (1 OmL) and refluxed at 120°C for 3 days. The toluene was removed 
under reduced pressure and the resulting oil purified by radial silica chromatography 
to give 9-endo-13-endo-l-methylsulfanyl-8-phenyl 11-(3-(N-(2-pyridyl)) 
carboxamidophenyl)-11-aza-14-thiatetracyclo[6.5.1.02,7.09, 13]tetradeca-2/t,6-
triene-lO, 12-dione as an oil (4.4mg, 4%). 
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1 H NMR (CDC13/ CD30D) 0 2.27 (s, 3H, SCH3), 4.35 (d, IH, J=8.3Hz, 
COCH), 4.89 (d, 1H, J=8.3Hz, COCH), 5.60 (d, lH, J=8.3Hz, aryl CH), 6.72 
(d, IH, .3Hz, aryl CH), 6.89 (t, JH, J=7.3Hz, aryl CH), 7.10 (t, IH, 
J=7.3Hz, aryl CH), 7.18 (m, 3H, aryl CH), 7.27-7.38 (m, 6H, aryl CH), 7.55 (d, 
IH. J=7.8Hz, myl CH), 7.61 (m, lH, aryl CH), 7.74 (d, 2H, J=7.3Hz, aryl CH). 
Illiz (F AB) 550.1 (M+), 460.1. 
High Res.C31H23N3S203 mlz calc. 550.12591; found 550.12575. 
IR (CDCI3/ CD30D) vmax 1716.5, 1600.8, 1458.1, 1377.1, 1236.3 ern-I. 
Preparation of 9-endo -13-endo -1-methylsulfanyl-8-phenyl-ll-(2-
chloroacetamidophenyl)-11-,aza-14-thiatetracyclo[ 6.5.1.02,7.09 ,13] 
tetradeca-2,4,6-triene-10,12-dione 6.25 
I-Methylsulfanyl-3-phenyl-isobenzo[c]thiophene (51.6mg, 0.2mmoL) and N-(2-
chloroacetamidophenyl) maleimide (50mg, 0.2mmol.) were dissolved in toluene 
(10mL) and refluxed at 120°C for 48 hours. The toluene was removed under 
reduced pressure and the resulting oil purified by radial silica chromatography to 
give 9-endo-13-endo-I-methylsulfanyl-8-phenyl-ll-(2-chloroacetamidophenyl)-11-
aza-14-thiatetracyclo[6.5.1.02,7 .09,13] tetradeca-2,4,6-triene-l 0, 12-dione as white 
crystals (8mg, 8%). 
m.p. 252-254°C. 
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Analysis C27H21N2S203CI calc. C, 62.24; H, 4.06; N, 5.38; found C, 62.20, 
H, 3.97; N, 5.40. 
IH NMR (CDCI3) 0 2.38 (s, 3H, SCH3), 4.l3 (s, 2H, CH2CI), 4.45 (d, IH, 
J:::8.3Hz, COCH), 4.96 (d, lH, J:::8.3Hz, COCH), 5.75 (d, tH, .8Hz, aryl 
CH), 6.83 (d, IH, J=8.3Hz, aryl CH), 6.99 (t, 1H, J=7.8Hz, aryl CH), 7.17-7.32 
(m, 3H, aryl CH), 7.39-7.49 (m, 4H, aryl CH), 7.71 (d, IH, 
7.85 (d, 2H, J=8.3Hz, aryl CH), 8.17 (bLS, 1H, NH). 
mlz (El) 520 (M+), 485 (M-CI+), 444, 256. 
.3Hz, aryl CH), 
High Res. C27H21N2S203CI mlz calc. 520.06829; found 520.0649. 
lR (CDCI3) vmax 1716.5, 1521.7, 1458.1, 1375.2, 1186.1, 1157.2 em-I. 
Preparation of' N -3- (2-aza -4-hydroxy -1-oxobutanyl)pheny I 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide 5.27 
9-endo-13-endo-1-Methylsulfanyl-8-phenyl-11-(3-(2-aza-4-hydroxy-l-
oxobutanyl)phenyl)-11-aza-14-thiatetracyclo[ 6.5.1.02,7.09, 13Jtetradeca-2,4,6-
triene-1O,12-dione (3mg, 0.006mmol.) and mercuric acetate (L9mg, 0.006mmol.) 
were dissolved in methanol (1 mL) and stirred for 1 week. The methanol was 
removed under reduced pressure to give an oil which was purified by radial silica 
chromatography to give N-3-(2-aza-4-hydroxy-l-oxobutanyl)phenyl 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide as an oil (O.4mg, 14%). 
1 H NMR (CDCI3/ CD30D) 0 2.47 (s, 3H, SCH3), 3.62 (m, 2H, NHCH2), 
4.40 (t, 2H, J=6.8Hz, CH20H), 6.93 (d, lH, J=7.3Hz, aryl CH), 7.09 (m, 4H, 
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Experimental 
IR (CDCI3/ CD30D) vmax 2360.7, 2343.4,1718.5,1236.3 em-I. 
Preparation of N -3-CN-(2-pyridyl))carboxamidophenyl 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide 5.29 
9-endo-13-endo-l-Methy lsulfany 1-8-phenyl-ll-(3-(N-(2-pyridy 1)) 
carboxamidophenyl)-11-aza-14-thlatetracyc!0[6S1.02,7 .09, 13] tetradeca-2,4, 6-
triene-l 0, 12-dione (3mg, 0.0055mmol.) and mercuric acetate (l.7mg, 
0.0055mmol.) were dissolved in methanol (1 mL) and stirred for 1 week. The 
methanol was removed under reduced pressure to give an oil which was purified by 
radial silica chromatography to give N-3-(N-(2-pyridyl))carboxamidophenyl 1-
methylsulfanyl-S-phenyl-naphthalene-2,3-dicarboximide as an oil (0.3mg, 11 %). 
III NMR (CDCI3/ CD30D) (3 2.69 (s, 3ll, SCll3), 7.1S-7.43 (m, 5ll, aryl 
Cll), 7.47-7.S2 (m, Sll, aryl Cll), 7.91-8.11 (m, 3ll, aryl Cll), 9.0S Cd, Ill, 
J=8.8llz, aryl Cll). 
Preparation of N -2-( chloroacetamido )phenyl 1-methylsulfanyl-8-
phenyl-naphthalene-2,3-dicarboximide 5.11 
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9-elldo-13-endo-l-Methylsulfanyl-8-phenyl-ll-(2-chloroacetamidophenyl)-ll-
aza-14-thiatetracyclo[6.5 .1.02,7.09, 13Jtetradeca-2,4,6-triene-1O, 12-dione (3mg, 
0.0057mmol.) and mercuric acetate (1.8mg, 0.0057mmol.) were dissolved in 
methanol (lmL) and stirred for I week. The methanol was removed under reduced 
pressure and the product partitioned between dichloromethane and water. The 
dichloromethane fractions were combined, dried (MgS04), and the 
dichloromethane removed under reduced pressure. The product was purified by 
radial silica chromatography to give N -2-( chloroacetamido )phenyl 1-
methylsulfanyl-8-phenyl-naphthalene-2,3-dicarboximide as white crystals (0.8mg, 
29%). 
1 H NMR (CDCl3) 8 2.70 (s, 3H, SCH3), 3.69 (s, 2H, CH2Cl), 7.24-7 (m, 
6H, aryl CR), 7.51 (m, 2H, aryl CH), 7.64 (t, IR, J=6.8Rz, aryl CH), 7.75-7.83 
(m, 2H, aryl CH), 8.06 (m, IR, aryl CH), 9.07 (d, IR, J=9.8Rz, aryl CR). 
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Al Biological Testing: 
The P388 Anti-cancer Assay 
Many of the compounds prepared in this thesis were tested for biological 
activity, in particular anti-cancer activity, via the P388 assay. This assay uses the 
P388 cell line of murine leukemia cells. It is a cytotoxic based assay against this 
specific cell type and is up to one hundred times more sensitive to cytotoxic 
effects than the anti-viral BSC-J line. The result obtained is in the form of an 
ID50, which represents the concentration of the test compound at which the 
number of viable P388 cells is reduced to 50% relative to the control, and is 
expressed here in micrograms per millilitre Q.Lg/mL). Although the P388 cell line 
represents a rapidly dividing cell type, a compound found active by this assay may 
also display selective activity against the slow growing tumours and is worthy of 
further consideration.82 
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P388 Assay Results 
Compound Number ID 50 (flglmL) 
2.19 51.00 
2.33 >25.00 
3.15 >62.50 
3.22 >62.50 
3.23 62.50 
3.24 >31.25 
3.25 4.39 
4.19,4.20 >62.50 
4.26 >62.50 
4.27 >25.00 
4.28 >25.00 
4.29 >62.50 
4.32 >12.50 
4.33 >14.58 
4.34 >20.00 
4.44 >62.50 
4.45 >62.50 
4.48 >62.50 
4.49 >17.50 
4.50 >27.50 
4.51 >26.25 
4.52 >12.50 
4.53 5.85 
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Compound Number IDSO (~g1mL) 
4.54 >26.25 
4.55 9.67 
4.56 >31 
4.57 > 12.50 
4.58 >12.50 
4.59 >23.75 
4.60 >10.00 
4.61 >10.00 
4.62 >7.50 
4.63 >15.00 
4.71 >25.00 
4.72 >31.00 
5.9 1.26 
5.10 0.43 
5.11 3.03 
5.12 2.53 
5.20 2.27 
5.21 8.15 
5.24 10.99 
5.25 4.99 
5.27 34.60 
5.28 51.00 
5.29 >6.25 
5.30 8.11 
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Compound Number IDSO (J.lg/mL) 
6.9,6.10 >62.50 
6.11 51.00 
6.13,6.14 >20.00 
6.18 >50.00 
6.19 51.00 
6.21 0.24 
6.22 7.98 
6.23 2.23 
6.25 38.34 
6.26 2.86 
A2 X .. Ray Crystal Structure of 4.27 
A2.1 Method of Data Collection and Structure Refinement 
A unique data set was measured at 293 (2)K within 28max = 5T limit. Of the 
2703 reflections obtained, 2623 were unique (Rint = 0.1557) and were used in the 
full-matrix least-squares refinement [ SHELXL-93 (Sheldrick, 1993) ] after being 
corrected for absorption by using the psi-scan method.83 The intensities of 3 
standard reflections, measured every 97 reflections throughout the data collection, 
showed no decay. The structure was solved by direct methods [SHELXL-86 
(Sheldrick, 1990)].84 Hydrogen atoms were fixed in idealised positions. All non-
hydrogen atoms were refined with anisotropic atomic displacement parameters. 
Neutral scattering factors and anomalous dispersion corrections for non-hydrogen 
atoms were taken from Ibers and Hamilton. 85 
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A2.2 Structure of 4.27 
A2.2 9-endo-13-endo-l-Methylsulfanyl-8-methyl-ll-phenyl-l1-aza-
14-oxatetracyclo[6.5.1.02,7 .09,13] tetradeca-2,4,6-triene-l0, 12-dione 
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Appendix 
A2.3 Data Tables 
Table 1 Crystal data and structure refinement for 4.27 
Crystal data 
Identification code 
Empirical fonnula 
Formula weight 
Crystal description 
Crystal colour 
Crystal size 
Crystal system 
Space group 
Unit cell dimensions 
RefIns to determine unit cell 
F (000) 
Volume 
z 
Density (calculated) 
Radiation 
Linear absorption coefficient 
Temperature of measurement 
Data collection 
Diffractometer 
Temperature of data collection 
Diffraction measurement method 
Reflections collected 
Independent reflections 
Gq range for data collection 
Range of h, k and I 
jmdrt 
C20H17N03S 
351.41 
needles 
white 
0.9 x 0.45 x 0.14mm 
monoclinic 
C2 
a= 23.451 (l4)A a = 90" 
b= 8.090 (4)A ~ =116.96(5)" 
c=21.84 (2)A 
25 
1472 
3693 (4) A3 
8 
1.264 Mg/m3 
MoK\a 0.71073A 
"(=90" 
fine-focus sealed tube, graphite 
monochromator 
0.193 mm-1 
293(2) 
Siemens P4 
-U5"C 
0) scans 
2703 
2623 (Rint= 0.1557) 
2.09 to 22.50° 
0;:; h ;:; 25, 0 ;:; k ;:; 8, -23 ;:; l ;:; 20 
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Check reflections 
Rejlnement 
Refinement method 
Data / restraints / parameters 
Method of refining H atoms 
Goodness-of-fit on F2 
Final R indices [I>2cr(I)] 
R indices (all data) 
Largest diff. peak and hole 
Extinction method 
Computer processing 
3 every 97 reflections 
Full-matrix least-squares on F2 
2623/1/457 
Riding hydrogens 
1.118 
R1 = 0.1129, wR2 = 0.2845 
R1 = 0.1943, wR2 = 0.3498 
1.518 and -0.445 eA-3 
none 
Structure solution SHELXS-86 (Sheldrick, 1990) 
Structure refinement SHELXL-93 (Sheldrick, 1993) 
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Table 2 Atomic coordinates and equivalent isotropic displacement 
parameters for 4.27 
----------------------------------------------------------------------------------------------
atom x y z U(eq) 
---------------------------------------------------------------------------------------------
S 9658(3) 7540(10) 4054(2) 35(2) 
N 8351(7) 5260(20) 1849(7) 24(4) 
0(2) 10138(6) 5370(20) 3506(7) 30(4) 
0(1) 8105(7) 6990(20) 526(7) 36(4) 
0(8) 8825(7) 3350(20) 469(7) 39(4) 
C(1) 8470(10) 5920(30) 2480(10) 33(6) 
C(2) 9040(10) 5270(30) 3020(10) 24(5) 
C(3) 9620(10) 6510(30) 3330(10) 26(5) 
C(4) 9646(8) 7390(30) 760(10) 28(6) 
C(5) 9853(8) 6260(30) 430(10) 21(5) 
C(6) 9960(10) 4670(30) 2830(10) 29(5) 
C(7) 9290(10) 4020(30) 2680(10) 27(5) 
C(8) 8790(10) 4130(30) 1920(10) 24(5) 
C(9) 10410(10) 3490(30) 2820(10) 36(6) 
C(10) 10340(10) 8740(40) 4310(10) 49(7) 
C(11) 9430(10) 8990(30) 2470(10) 25(5) 
C(12) 9470(10) 9480(30) 1890(10) 28(5) 
C(13) 9720(10) 8260(40) 1590(10) 44(7) 
C(14) 9880(10) 6690(40) 1840(10) 40(7) 
C(21) 7830(10) 5620(30) 1200(10) 35(6) 
C(22) 7230(10) 4950(30) 1060(10) 34(6) 
C(23) 6720(10) 5230(30) 440(10) 8(5) 
C(24) 6820(10) 6280(30) -40(10) 4(7) 
C(25) 7390(10) ··6980(40) 100(10) 1(7) 
C(26) 7890(10) 6590(30) 720(10) 0(6) 
------------------------------------~----------------------------
U(eq) is defined as 113 the trace of the Uij tensor. 
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Table 3 Bond lengths (A) and angles (deg) for 4.27 
S-C(10) 1.73(2) S-C(3) 1.75(2) 
N-C(8) 1.34(3) N-C(1) 1.38(3) 
N-C(2l) 1.42(3) O(2)-C(3) 1.44(3) 
O(2)-C(6) 1.45(2) O(l)-C(l) 1.25(3) 
O(8)-C(8) 1.21(2) C(1)-C(2) 1.42(3) 
C(2)-C(7) 1.52(3) C(2)-C(3) 1.58(3) 
C(3)-C(4) 1.46(3) C(4)-C(5) 1.39(3) 
C(4)-C(l1) 1.42(3) C(5)-C(14) 1.35(3) 
C(5)-C(6) 1.52(3) C(6)-C(9) 1.44(3) 
C(6)-C(7) 1.53(3) C(7)-C(8) 1.53(3) 
C(11)-C(l2) 1.40(3) C(12)-C(13) 1.44(3) 
C(13)-C(14) 1.37(4) C(2l )-C(26) 1.36(3) 
C(21 )-C(22) 1.42(3) C(22)-C(23) 1.36(3) 
C(23)-C(24) 1.44(3) C(24)-C(25) 1.36(3) 
C(25)-C(26) 1.37(3) 
C( 10)-S-C(3) 103(1) C(8)-N-C(1) 110(2) 
C(8)-N-C(21) 122(2) C(1)-N-C(21) 128(2) 
C(3)-O(2)-C(6) 99(1) O( 1 )-C(1)-N 121(2) 
O(1)-C(1)-C(2) 127(2) N-C(1)-C(2) 112(2) 
C( 1 )-C(2)-C(7) 106(2) C(1)-C(2)-C(3) 115(2) 
C(7)-C(2)-C(3 ) 100(2) O(2)-C(3)-C(4) 100(2) 
O(2)-C(3 )-C(2) 100(2) C( 4 )-C(3)-C(2) 108(2) 
O(2)-C(3)-S 112(1) C( 4 )-C(3 )-S 122(2) 
C(2)-C(3)-S 112(1) C(5)-C(4)-C(11) 120(2) 
C(5)-C(4)-C(3) 107(2) C(11)-C( 4)-C(3) 132(2) 
C(14)-C(5)-C( 4) 120(2) C( 14 )-C( 5)-C( 6) 135(2) 
C(4)-C(5)-C(6) 105(2) C(9)-C(6)-O(2) 113(2) 
C(9)-C(6)-C(5) 118(2) O(2)-C(6)-C(5) 99(2) 
C(9)-C(6)-C(7) 118(2) O(2)-C(6)-C(7) 99(1) 
C( 5)-C( 6)-C(7) 107(2) C(2)-C(7)-C(8) 102(2) 
C(2)-C(7)-C(6) 105(2) C(8)-C(7)-C( 6) 124(2) 
N-C(8)-C(7) ] 10(2) C(12)-C(l1 )-C( 4) 120(2) 
C(l1)-C(l2)-C(13) 115(2) C(l4)-C( 13)-C(l2) 124(2) 
C(5)-C(14)-C(13) 120(3) C(26)-C(21 )-C(22) 120(2) 
C(26)-C(21)-N 123(2) C(22)-C(21)-N 117(2) 
C(23)-C(22)-C(21 ) 119(2) C(22)-C(23 )-C(24) 118(2) 
C(25)-C(24)-C(23) 124(2) C(24 )-C(25)-C(26) 116(2) 
C(21 )-C(26)-C(25) 124(2) C(3')-S'-C(10') 104(1) 
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Table 4 Anisotropic displacement parameters for 4.27 
----------------------------------------------------------------------------------------------
atom U11 U22 U33 U23 U13 U12 
--------------------------------------------------------------------------------------------------
S 39(3) 42(4) 24(3) -7(3) 15(2) 2(3) 
N 13(8) 40(10) 22(9) -14(9) 8(7) 1(9) 
0(2) 28(8) 40(10) 25(7) - 10(8) 10(6) 7(8) 
0(1) 29(8) 50(10) 30(8) 4(9) 28(8) -20(9) 
C(1) 20(10) 40(20) 40(10) 10(10) 20(10) 10(10) 
C(2) 30(10) 20(10) 30(10) 10(10) 20(10) 0(10) 
C(3) 20(10) 40(20) 4(9) 0(10) 0(8) 10(10) 
C(4) 3(9) 30(20) 50(10) -10(10) 12(9) -20(10) 
C(5) 10(10) 10(10) 40(10) -10(10) 3(9) -9(9) 
C(6) 40(10) 30(10) 30(10) 10(10) 30(10) 0(10) 
C(7) 40(10) 30(lO) 10(10) 0(10) 10(10) -10(10) 
C(8) 50(10) 20(10) 0(10) - 20(10) 10(10) 10(10) 
C(9) 40(10) 20(10) 50(10) -20(10) 30(10) -10(10) 
C(lO) 70(20) 50(20) 40(10) -10(10) 40(10) -10(20) 
C(ll) 40(10) 20(10) 20(10) -10(10) 10(10) 0(10) 
C(12) 50(10) 10(10) 40(10) -10(10) 30(10) 10(10) 
C(13) 60(20) 40(20) 40(10) 10(10) 40(10) -10(20) 
C(14) 40(20) 50(20) 40(10) -10(10) 30(10) -10(10) 
C(21) 40(10) 30(20) 40(10) 10(10) 20(10) 20(10) 
C(22) 20(10) 50(20) 30(10) 20(10) 10(10) 0(10) 
C(23) 30(10) 10(10) 30(10) 0(10) 10(10) 0(10) 
C(24) 40(20) 40(20) 30(10) 10(10) 0(10) 20(10) 
C(25) 20(10) 60(20) 40(10) 0(10) 20(10) 0(10) 
C(26) 40(10) 30(10) 50(20) 10(10) 20(10) 0(10) 
---------------------------------------------------------------------------
The anisotropic displacement factor exponent takes the form 
2 pi"'2 [h"2aM 2U(11) + ... + 2hka*b*U(12)] 
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Table 5 Hydrogen coordinates and equivalent isotropic displacement 
parameters for 4.27 
--------------------------------------------------------------------------------------------------
atom x y z U(eq) 
-------~------------------------------------------------------------------------------------------
H(2A) 10487(6) 5150(20) 3927(7) 36 
H(2B) 8950(10) 4750(30) 3380(10) 29 
H(7A) 310(10) 2910(30) 2860(10) 32 
H(9A) 10820(20) 030(50) 2950(70) 54 
H(9B) 10260(30) 000(100) 2370(20) 54 
H(9C) 10470(50) 620(90) 3140(50) 54 
H(lOA) 10420(50) 9300(200) 4730(50) 73 
H(lOB) 10280(30) 9500(100) 3960(40) 73 
H(10C) 10700(20) 8040(40) 4390(80) 73 
H(11A) 9250(10) 700(30) 2680(10) 30 
H(12A) 9350(10) 0540(30) 1700(10) 34 
H(13A) . 9760(10) .550(40) 1200(10) 53 
H(14A) 10010(10) 5930(40) 1610(10) 48 
H(22A) 7180(10) 330(30) 1390(10) 41 
H(23A) 6320(10) 760(30) 320(10) 33 
H(24A) 6470(10) 490(30) -460(10) 53 
H(25A) 7440(10) 690(40) -210(10) 49 
H(26A) 8290(10) 000(30) 820(10) 47 
H(lOD) 9500(30) 400(200) 5240(70) 100 
H(10E) 8980(90) 300(60) 5310(60) 100 
H(10F) 8770(70) 700(100) 4770(10) 100 
H(l2B) 6760(10) 610(40) 3120(10) 48 
H(13B) 6050(10) 940(30) 3250(10) 44 
H(14B) 6370(10) 210(30) 3670(10) 39 
H(22B) 7300(10) 750(30) 1300(10) 51 
H(23B) 6570(10) 270(40) 210(10) 61 
H(24B) 5710(10) 500(50) -40(10) 80 
H(25B) 5580(10) 710(40) 870(10) 57 
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249 
No-one knows this calm 
Like the trees 
Arching over swollen water, 
Like the subtle pools which are 
Your eyes. 
See the stones splashed silent, 
Waiting for a smile to awaken, 
Or gentle laughter to stir 
Greenly amongst the leaves above, 
But soft rain is the only sound 
Today 
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